# CE2006193EN.01012301.xml

| 17.8.2006 | EN | Official Journal of the European Union | CE 193/123 |
| --- | --- | --- | --- |

17.8.2006

EN

Official Journal of the European Union

CE 193/123

---

MINUTES

(2006/C 193 E/03)

PROCEEDINGS OF THE SITTING

IN THE CHAIR: Josep BORRELL FONTELLES

President

1.   Opening of sitting

The sitting opened at 09.05.

2.   Liberty and security (debate)

(debate)

Council and Commission statements: Liberty and security (Responding to the threat of terrorism whilst protecting the rights of citizens)

Charles Clarke (President-in-Office of the Council) and Franco Frattini (Vice-President of the Commission) made the statements.

The following spoke: Hans-Gert Poettering, on behalf of the PPE-DE Group, Martin Schulz, on behalf of the PSE Group, Graham Watson, on behalf of the ALDE Group, Jean Lambert, on behalf of the Verts/ALE Group, Francis Wurtz, on behalf of the GUE/NGL Group, Nigel Farage, on behalf of the IND/DEM Group, Brian Crowley, on behalf of the UEN Group, Philip Claeys, Non-attached Member, and Timothy Kirkhope.

IN THE CHAIR: Antonios TRAKATELLIS

Vice-President

The following spoke: Magda Kósáné Kovács, Jean-Marie Cavada, Hélène Flautre, Giusto Catania, Mario Borghezio, Ryszard Czarnecki, Jaime Mayor Oreja, Martine Roure, Antoine Duquesne, Johannes Voggenhuber, Johannes Blokland, Ewa Klamt, Stavros Lambrinidis, Sophia in 't Veld, Carl Schlyter, Carlos Coelho, Jan Marinus Wiersma, Antonio Di Pietro, Elmar Brok, Enrique Barón Crespo, Sajjad Karim, Camiel Eurlings, Giovanni Claudio Fava, Cecilia Malmström, Antonio Tajani, Rosa Díez González, Geoffrey Van Orden, Michael Cashman, Othmar Karas, Edith Mastenbroek, Agustín Díaz de Mera García Consuegra, Libor Rouček, Herbert Reul, Emilio Menéndez del Valle, Charles Clarke, Franco Frattini and Martin Schulz, who made a clarification in respect of his previous remarks.

The debate closed.

IN THE CHAIR: Edward McMILLAN-SCOTT

Vice-President

The following spoke: Jürgen Zimmerling, to point out that he had been present at Monday's sitting; Robert Atkins, who asked that the vote should start at the scheduled time (the President replied that he would forward the request to the Conference of Presidents) and Véronique De Keyser, who informed the House that the Tunisian League for Human Rights was at that moment surrounded by the army (the President noted her remarks).

3.   Membership of committees and delegations

At the request of the IND/DEM Group, Parliament ratified the appointment of Andrzej Tomasz Zapałowski as a member of the AGRI Committee and the Delegation to the EU-Ukraine Parliamentary Cooperation Committee.

4.   Voting time

Details of voting (amendments, separate and split votes, etc.) appear in Annex I to the Minutes.

4.1.   Mobilisation of the flexibility instrument (Tsunami) (vote)

(vote)

Report on the proposal for a decision of the European Parliament and of the Council relating to the mobilisation of the flexibility instrument in favour of assistance for the rehabilitation and reconstruction for those countries affected by the Tsunami according to point 24 of the Interinstitutional Agreement of 6 May 1999 [SEC(2005)0548 — C6-0127/2005 — 2005/2083(ACI)] — Committee on Budgets.

Rapporteur: Reimer Böge (A6-0254/2005)

(Qualified majority)

(Qualified majority)

(Voting record: Annex I, Item 1)

(Voting record: Annex I, Item 1)

MOTION FOR A RESOLUTION

Adopted (P6_TA(2005)0323)

(P6_TA(2005)0323)

4.2.   Mobilisation of the European Union Solidarity Fund (Rule 131) (vote)

(Rule 131) (vote)

Report on the proposal for a decision of the European Parliament and of the Council on the mobilisation of the European Union Solidarity Fund according to point 3 of the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure [COM 2005)0247 — C6-0183/2005 — 2005/2127(ACI)] — Committee on Budgets.

Rapporteur: Reimer Böge (A6-0229/2005)

(Qualified majority)

(Qualified majority)

(Voting record: Annex I, Item 2)

(Voting record: Annex I, Item 2)

MOTION FOR A RESOLUTION

Adopted by single vote (P6_TA(2005)0324)

(P6_TA(2005)0324)

4.3.   Revision of the financial perspective 2000-2006 (Rule 131) (vote)

(Rule 131) (vote)

Report on the proposal for a decision of the European Parliament and of the Council on the revision of the financial perspective 2000-2006 [COM(2004)0666 — C6-0219/2004 — 2004/2222(ACI)] — Committee on Budgets.

Rapporteur: Reimer Böge (A6-0252/2005)

(Qualified majority)

(Qualified majority)

(Voting record: Annex I, Item 3)

(Voting record: Annex I, Item 3)

MOTION FOR A RESOLUTION

Adopted by single vote (P6_TA(2005)0325)

(P6_TA(2005)0325)

4.4.   Draft amending budget No 4/2005 (vote)

(vote)

Report on Draft amending budget No 4/2005 of the European Union for the financial year 2005

Section III — Commission [11220/2005 — C6-0239/2005 — 2005/2079(BUD)] — Committee on Budgets.

Rapporteur: Salvador Garriga Polledo (A6-0255/2005)

(Simple majority)/(Qualified majority on paragraph 6)

(Simple majority)/(Qualified majority on paragraph 6)

(Voting record: Annex I, Item 4)

(Voting record: Annex I, Item 4)

MOTION FOR A RESOLUTION

Adopted (P6_TA(2005)0326)

(P6_TA(2005)0326)

4.5.   Draft amending budget No 3/2005 (Rule 131) (vote)

(Rule 131) (vote)

Report on Draft amending budget No 3/2005 of the European Union for the financial year 2005

Section III — Commission [9760/2005 — C6 0214/2005 — 2005/2102(BUD)] — Committee on Budgets.

Rapporteur: Salvador Garriga Polledo (A6-0248/2005)

(Qualified majority)

(Qualified majority)

(Voting record: Annex I, Item 5)

(Voting record: Annex I, Item 5)

MOTION FOR A RESOLUTION

Adopted by single vote (P6_TA(2005)0327)

(P6_TA(2005)0327)

4.6.   Draft amending budget No 5/2005 (Rule 131) (vote)

(Rule 131) (vote)

Report on Draft amending budget No 5/2005 of the European Union for the financial year 2005

Section III — Commission [11221/2005 — C6-0240/2005 — 2005/2126(BUD)] — Committee on Budgets.

Rapporteur: Salvador Garriga Polledo (A6-0253/2005)

(Qualified majority)

(Qualified majority)

(Voting record: Annex I, Item 6)

(Voting record: Annex I, Item 6)

MOTION FOR A RESOLUTION

Adopted by single vote (P6_TA(2005)0328)

(P6_TA(2005)0328)

4.7.   Health and safety at work: Exposure to optical radiation ***II (vote)

(vote)

Recommendation for second reading on the common position adopted by the Council with a view to the adoption of a directive of the European Parliament and of the Council on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (optical radiation) (19th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) [05571/6/2005 — C6-0129/2005 — 1992/0449B((COD)] — Committee on Employment and Social Affairs.

Rapporteur: Csaba Őry (A6-0249/2005)

(Qualified majority)

(Qualified majority)

(Voting record: Annex I, Item 7)

(Voting record: Annex I, Item 7)

COMMON POSITION OF THE COUNCIL

Declared approved as amended (P6_TA(2005)0329)

(P6_TA(2005)0329)

The following spoke on the vote:

The following spoke on the vote:

| — | Marios Matsakis, on the conduct of the vote. |
| --- | --- |

—

Marios Matsakis, on the conduct of the vote.

4.8.   Competitiveness of audiovisual and information services: protection of minors and human dignity ***I (vote)

(vote)

Report on the proposal for a recommendation of the European Parliament and of the Council on the protection of minors and human dignity and the right of reply in relation to the competitiveness of the European audiovisual and information services industry [COM(2004)0341 — C6-0029/2004 — 2004/0117 (COD)] — Committee on Culture and Education.

Rapporteur: Marielle De Sarnez (A6-0244/2005)

(Simple majority)

(Simple majority)

(Voting record: Annex I, Item 8)

(Voting record: Annex I, Item 8)

COMMISSION PROPOSAL

Approved as amended (P6_TA(2005)0330)

(P6_TA(2005)0330)

DRAFT LEGISLATIVE RESOLUTION

Adopted (P6_TA(2005)0330)

(P6_TA(2005)0330)

4.9.   Medicinal products for paediatric use ***I (vote)

(vote)

Report on the proposal for a regulation of the European Parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 [COM(2004)0599 — C6-0159/2004 — 2004/0217(COD)] — Committee on the Environment, Public Health and Food Safety.

Rapporteur: Françoise Grossetête (A6-0247/2005)

(Simple majority)

(Simple majority)

(Voting record: Annex I, Item 9)

(Voting record: Annex I, Item 9)

COMMISSION PROPOSAL

Approved as amended (P6_TA(2005)0331)

(P6_TA(2005)0331)

DRAFT LEGISLATIVE RESOLUTION

Adopted (P6_TA(2005)0331)

(P6_TA(2005)0331)

4.10.   VAT: Simplifying obligations/VAT: One-stop scheme * (vote)

(vote)

Report

| 1. | on the proposal for a Council directive amending Directive 77/388/EEC with a view to simplifying value added tax obligations [COM(2004)0728 — C6-0024/2005 — 2004/0261(CNS)] |
| --- | --- |

1.

on the proposal for a Council directive amending Directive 77/388/EEC with a view to simplifying value added tax obligations [COM(2004)0728 — C6-0024/2005 — 2004/0261(CNS)]

| 2. | on the proposal for a Council regulation amending Regulation (EC) No 1798/2003 as regards the introduction of administrative cooperation arrangements in the context of the one-stop scheme and the refund procedure for value added tax [COM(2004)0728 — C6-0025/2005 — 2004/0262(CNS)] — Committee on Economic and Monetary Affairs |
| --- | --- |

2.

on the proposal for a Council regulation amending Regulation (EC) No 1798/2003 as regards the introduction of administrative cooperation arrangements in the context of the one-stop scheme and the refund procedure for value added tax [COM(2004)0728 — C6-0025/2005 — 2004/0262(CNS)] — Committee on Economic and Monetary Affairs

Rapporteur: Zsolt László Becsey (A6-0228/2005)

(Simple majority)

(Simple majority)

(Voting record: Annex I, Item 10)

(Voting record: Annex I, Item 10)

1. COMMISSION PROPOSAL

Approved as amended (P6_TA(2005)0332)

(P6_TA(2005)0332)

DRAFT LEGISLATIVE RESOLUTION

Adopted (P6_TA(2005)0332

(P6_TA(2005)0332

2. COMMISSION PROPOSAL

Approved (P6_TA(2005)0333)

(P6_TA(2005)0333)

DRAFT LEGISLATIVE RESOLUTION

Adopted (P6_TA(2005)0333)

(P6_TA(2005)0333)

5.   Explanations of vote

Written explanations of vote:

Written explanations of vote:

Explanations of vote submitted in writing under Rule 163(3) appear in the verbatim report of proceedings for the sitting.

Oral explanations of vote:

Oral explanations of vote:

| — | Report: Reimer Böge — A6-0229/2005
  Zita Pleštinská |
| --- | --- |

—

Report: Reimer Böge — A6-0229/2005

Zita Pleštinská

| — | Report: Csaba Őry — A6-0249/2005
  Andreas Schwab, Albert Deß |
| --- | --- |

—

Report: Csaba Őry — A6-0249/2005

Andreas Schwab, Albert Deß

| — | Report: Salvador Garriga Polledo — A6-0255/2005
  Zita Pleštinská |
| --- | --- |

—

Report: Salvador Garriga Polledo — A6-0255/2005

Zita Pleštinská

6.   Corrections to votes

Corrections to votes appear on the ‘Séance en direct’ website under ‘Votes’/‘Results of votes’/‘Roll-call votes’. They are published in hard copy in Annex II to the Minutes, ‘Result of roll-call votes’.

Séance en direct

The electronic version on Europarl will be regularly updated for a maximum of two weeks after the day of the vote concerned.

After the two-week deadline has passed, the list of corrections to votes will be finalised so that it can be translated and published in the Official Journal.

(The sitting was suspended at 13.05 and resumed at 15.05.)

(The sitting was suspended at 13.05 and resumed at 15.05.)

IN THE CHAIR: Gérard ONESTA

Vice-President

7.   Approval of Minutes of previous sitting

Iles Braghetto and Andrzej Tomasz Zapałowski had informed the Chair that they had been present at the sittings of 05.09.2005 and 06.09.2005, but that their names were not on the attendance register.

The Minutes of the previous sitting were approved.

8.   Situation in the Middle East (debate)

(debate)

Council and Commission statements: Situation in the Middle East

Douglas Alexander (President-in-Office of the Council) and Günther Verheugen (Vice-President of the Commission) made the statements.

The following spoke: José Ignacio Salafranca Sánchez-Neyra, on behalf of the PPE-DE Group, Pasqualina Napoletano, on behalf of the PSE Group, Cecilia Malmström, on behalf of the ALDE Group, David Hammerstein Mintz, on behalf of the Verts/ALE Group, Adamos Adamou, on behalf of the GUE/NGL Group, Bastiaan Belder, on behalf of the IND/DEM Group, Andreas Mölzer, Non-attached Member, Edward McMillan-Scott, Véronique De Keyser, Frédérique Ries, Miguel Portas, Jana Hybášková, Richard Howitt, Sajjad Karim, Ioannis Kasoulides, Hannes Swoboda and Gunnar Hökmark.

IN THE CHAIR: Janusz ONYSZKIEWICZ

Vice-President

The following spoke: Józef Pinior, Charles Tannock, Panagiotis Beglitis and Douglas Alexander.

The debate closed.

9.   Basic guidelines for sustainable European tourism (debate)

(debate)

Report on the basic guidelines for sustainable European tourism [2004/2229(INI)] — Committee on Transport and Tourism.

Rapporteur: Luís Queiró (A6-0235/2005)

Luís Queiró introduced the report.

Günther Verheugen (Vice-President of the Commission) spoke.

The following spoke: Margie Sudre (draftsman of the opinion of the REGI Committee), Zdzisław Zbigniew Podkański (draftsman of the opinion of the CULT Committee), Georg Jarzembowski, on behalf of the PPEDE Group, Marta Vincenzi, on behalf of the PSE Group, Josu Ortuondo Larrea, on behalf of the ALDE Group, Sepp Kusstatscher, on behalf of the Verts/ALE Group, Georgios Toussas, on behalf of the GUE/NGL Group, Seán Ó Neachtain, on behalf of the UEN Group, Andreas Mölzer, Non-attached Member, Simon Busuttil, Inés Ayala Sender, Marian Harkin, Michael Cramer, Pedro Guerreiro, Zita Pleštinská, Herbert Bösch, Alfonso Andria, Alyn Smith, Armando Dionisi, Zita Gurmai, José Manuel García-Margallo y Marfil, Stavros Arnaoutakis, Stanisław Jałowiecki, Emanuel Jardim Fernandes, Andreas Schwab, Luis Yañez-Barnuevo García, Alexander Stubb, Justas Vincas Paleckis, Bogusław Sonik, Teresa Riera Madurell, Rodi Kratsa-Tsagaropoulou, Corien Wortmann-Kool, Reinhard Rack, Paul Rübig and Günther Verheugen.

The debate closed.

Vote: Minutes of 08.09.2005, Item 7.2

Minutes of 08.09.2005, Item 7.2

IN THE CHAIR: Pierre MOSCOVICI

Vice-President

10.   Question Time (Council)

(Council)

Parliament considered a number of questions to the Council (B6-0330/2005).

Question 1 (Sajjad Karim): EU's revised services offer in the Doha negotiations — mobility of natural persons.

Douglas Alexander (President-in-Office of the Council) answered the question and supplementaries by Sajjad Karim, Paul Rübig and David Martin.

Question 2 (Sarah Ludford): Data protection.

Douglas Alexander answered the question and supplementaries by Bill Newton Dunn (deputising for the author) and Agnes Schierhuber.

Question 3 (Chris Davies): Transparency and openness.

Douglas Alexander answered the question and supplementaries by Chris Davies, Justas Vincas Paleckis and Catherine Stihler.

Question 4 had been withdrawn.

Question 5 (Dimitrios Papadimoulis): Statements by Mr Gül concerning the Patriarchate and the Halki School of Theology.

Douglas Alexander answered the question and supplementaries by Dimitrios Papadimoulis, Michl Ebner and Agnes Schierhuber.

Question 6 (Bernd Posselt): Preparations for Croatia's accession.

Douglas Alexander answered the question and supplementaries by Bernd Posselt, Paul Rübig and David Martin.

Under Annex II(A)(4) to the Rules of Procedure, Michl Ebner requested a second supplementary question (the President referred him to the procedure outlined in Annex II, part B (‘Recommendations’) and stated that he would ask for the services to provide an interpretation of the provision cited by Michl Ebner).

Question 7 (Claude Moraes): Transparency of Europol.

Douglas Alexander answered the question and a supplementary by Claude Moraes.

Question 8 (Sahra Wagenknecht): Impunity law for paramilitaries in Colombia.

Douglas Alexander answered the question and supplementaries by Vittorio Agnoletto (deputising for the author), José Ignacio Salafranca Sánchez-Neyra and James Hugh Allister.

Question 9 (Struan Stevenson): Postal sector and regulatory asymmetry.

Douglas Alexander answered the question and supplementaries by Struan Stevenson and Gary Titley.

Question 10 (Liam Aylward): Zimbabwe update.

Douglas Alexander answered the question and a supplementary by Liam Aylward.

Question 11 (Brian Crowley): Constraints on all political leaders in Myanmar.

Douglas Alexander answered the question and a supplementary by Brian Crowley.

Question 12 (Seán Ó Neachtain): Rape as a weapon of war.

Douglas Alexander answered the question and a supplementary by Seán Ó Neachtain.

Questions which had not been answered for lack of time would receive written answers.

Council Question Time closed.

(The sitting was suspended at 19.00 and resumed at 21.00.)

(The sitting was suspended at 19.00 and resumed at 21.00.)

IN THE CHAIR: Gérard ONESTA

Vice-President

11.   Gender discrimination in health systems (debate)

(debate)

Report on gender discrimination in health systems [2004/2218(INI)] — Committee on Women's Rights and Gender Equality.

Rapporteur: Eva-Britt Svensson (A6-0250/2005)

Eva-Britt Svensson introduced the report.

Markos Kyprianou (Member of the Commission) spoke.

The following spoke: Anna Záborská, on behalf of the PPE-DE Group, Karin Jöns, on behalf of the PSE Group, Anneli Jäätteenmäki, on behalf of the ALDE Group, Hiltrud Breyer, on behalf of the Verts/ALE Group, Kartika Tamara Liotard, on behalf of the GUE/NGL Group, Urszula Krupa, on behalf of the IND/DEM Group, Marcin Libicki, on behalf of the UEN Group, Lydia Schenardi, Non-attached Member, Rodi Kratsa-Tsagaropoulou, Marta Vincenzi, Diana Wallis, Raül Romeva i Rueda, Bairbre de Brún, Johannes Blokland, Angelika Niebler, Edite Estrela, Ilda Figueiredo, Marie Panayotopoulos-Cassiotou, Anna Hedh, Lívia Járóka, Teresa Riera Madurell, Romana Jordan Cizelj, María Elena Valenciano Martínez-Orozco, Katalin Lévai and Markos Kyprianou.

The debate closed.

Vote: Minutes of 08.09.2005, Item 7.3

Minutes of 08.09.2005, Item 7.3

12.   European schools (debate)

(debate)

Report on the consultation concerning the options for developing the system of European schools [2004/2237(INI)] — Committee on Culture and Education.

Rapporteur: Mary Honeyball (A6-0200/2005)

Mary Honeyball introduced the report.

Siim Kallas (Vice-President of the Commission) spoke.

The following spoke: Herbert Bösch (draftsman of the opinion of the BUDG Committee), Erna Hennicot-Schoepges, on behalf of the PPE-DE Group, Bernat Joan i Marí, on behalf of the Verts/ALE Group, Thomas Wise, on behalf of the IND/DEM Group, Hans-Peter Martin, Non-attached Member, Ljudmila Novak, Proinsias De Rossa, Tomáš Zatloukal, Manolis Mavrommatis, Daniel Caspary, Othmar Karas, Siim Kallas and Proinsias De Rossa, who asked Siim Kallas to provide some additional information in writing.

The debate closed.

Vote: Minutes of 08.09.2005, Item 7.4

Minutes of 08.09.2005, Item 7.4

13.   Agenda for next sitting

The agenda for the next sitting had been established (‘Agenda’ 360.636/OJJE).

14.   Closure of sitting

The sitting closed at 22.55.

Julian Priestley

Secretary-General

Gérard Onesta

Vice-President

---

ATTENDANCE REGISTER

The following signed:

Adamou, Agnoletto, Albertini, Allister, Alvaro, Andersson, Andrejevs, Andria, Andrikienė, Angelilli, Antoniozzi, Arif, Arnaoutakis, Ashworth, Atkins, Attard-Montalto, Attwooll, Aubert, Audy, Auken, Ayala Sender, Aylward, Ayuso González, Bachelot-Narquin, Baco, Badia I Cutchet, Barón Crespo, Barsi-Pataky, Batten, Battilocchio, Batzeli, Bauer, Beaupuy, Beazley, Becsey, Beer, Beglitis, Belder, Belet, Belohorská, Bennahmias, Beňová, Berend, Berès, van den Berg, Berger, Berlato, Berlinguer, Berman, Bertinotti, Bielan, Birutis, Blokland, Bloom, Bobošíková, Böge, Bösch, Bonde, Bono, Bonsignore, Booth, Borghezio, Borrell Fontelles, Bourlanges, Bourzai, Bowis, Bowles, Bozkurt, Bradbourn, Braghetto, Mihael Brejc, Brepoels, Breyer, Březina, Brie, Brok, Brunetta, Budreikaitė, Buitenweg, Bullmann, van den Burg, Bushill-Matthews, Busk, Busquin, Busuttil, Buzek, Cabrnoch, Calabuig Rull, Callanan, Camre, Capoulas Santos, Carlotti, Carlshamre, Carnero González, Carollo, Casa, Cashman, Caspary, Castex, Castiglione, del Castillo Vera, Catania, Cavada, Cederschiöld, Cercas, Cesa, Chatzimarkakis, Chichester, Chiesa, Chmielewski, Christensen, Chruszcz, Cirino Pomicino, Claeys, Clark, Cocilovo, Coelho, Cohn-Bendit, Corbett, Cornillet, Correia, Costa, Cottigny, Coûteaux, Coveney, Cramer, Crowley, Marek Aleksander Czarnecki, Ryszard Czarnecki, D'Alema, Davies, de Brún, Degutis, De Keyser, Demetriou, De Michelis, Deprez, De Rossa, De Sarnez, Descamps, Désir, Deß, Deva, De Veyrac, De Vits, Díaz de Mera García Consuegra, Didžiokas, Díez González, Dillen, Dimitrakopoulos, Dionisi, Di Pietro, Dobolyi, Dombrovskis, Doorn, Douay, Dover, Doyle, Drčar Murko, Duchoň, Dührkop Dührkop, Duff, Duka-Zólyomi, Duquesne, Ebner, Ehler, Ek, El Khadraoui, Elles, Esteves, Estrela, Ettl, Eurlings, Jillian Evans, Jonathan Evans, Robert Evans, Fajmon, Falbr, Farage, Fatuzzo, Fava, Fazakas, Ferber, Fernandes, Fernández Martín, Anne Ferreira, Elisa Ferreira, Figueiredo, Fjellner, Flasarová, Flautre, Florenz, Foglietta, Fontaine, Ford, Fotyga, Fourtou, Fraga Estévez, Frassoni, Freitas, Friedrich, Fruteau, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, García Pérez, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gebhardt, Gentvilas, Geremek, Geringer de Oedenberg, Gibault, Gierek, Giertych, Gklavakis, Glante, Glattfelder, Goebbels, Goepel, Golik, Gollnisch, Gomes, Gomolka, Goudin, Genowefa Grabowska, Grabowski, Graça Moura, Graefe zu Baringdorf, Gräßle, de Grandes Pascual, Grech, Griesbeck, Gröner, de Groen-Kouwenhoven, Grosch, Grossetête, Gruber, Guardans Cambó, Guellec, Guerreiro, Guidoni, Gurmai, Guy-Quint, Gyürk, Hänsch, Hall, Hammerstein Mintz, Hamon, Handzlik, Hannan, Harangozó, Harbour, Harkin, Harms, Hasse Ferreira, Hassi, Hatzidakis, Haug, Hazan, Heaton-Harris, Hedh, Hedkvist Petersen, Hegyi, Helmer, Henin, Hennicot-Schoepges, Hennis-Plasschaert, Herczog, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Honeyball, Hoppenstedt, Horáček, Howitt, Hudacký, Hudghton, Hughes, Hutchinson, Hybášková, Ibrisagic, Ilves, in 't Veld, Isler Béguin, Itälä, Iturgaiz Angulo, Jäätteenmäki, Jałowiecki, Janowski, Járóka, Jarzembowski, Jeggle, Jensen, Joan i Marí, Jöns, Jørgensen, Jonckheer, Jordan Cizelj, Juknevičienė, Jelko Kacin, Kaczmarek, Kallenbach, Kamall, Kamiński, Karas, Karatzaferis, Karim, Kasoulides, Kaufmann, Tunne Kelam, Kindermann, Kinnock, Kirkhope, Klamt, Klaß, Klich, Klinz, Knapman, Koch, Kohlíček, Konrad, Korhola, Kósáné Kovács, Koterec, Kozlík, Krahmer, Krarup, Krasts, Kratsa-Tsagaropoulou, Krehl, Kreissl-Dörfler, Kristensen, Kristovskis, Krupa, Kuc, Kudrycka, Kuhne, Kušķis, Kusstatscher, Kuźmiuk, Lagendijk, Laignel, Lamassoure, Lambert, Lambrinidis, Landsbergis, Lang, Langen, Langendries, Laperrouze, La Russa, Lauk, Lavarra, Lax, Lechner, Le Foll, Lehideux, Lehne, Lehtinen, Leichtfried, Leinen, Marine Le Pen, Lévai, Janusz Lewandowski, Liberadzki, Libicki, Lichtenberger, Lienemann, Liese, Liotard, Lipietz, Locatelli, Lombardo, Louis, Lucas, Lulling, Lundgren, Lynne, Maat, Maaten, McAvan, McGuinness, McMillan-Scott, Madeira, Malmström, Manders, Maňka, Erika Mann, Thomas Mann, Mantovani, Markov, Marques, Martens, David Martin, Hans-Peter Martin, Martinez, Martínez Martínez, Masiel, Masip Hidalgo, Maštálka, Mastenbroek, Mathieu, Mato Adrover, Matsakis, Matsis, Matsouka, Mauro, Mavrommatis, Mayer, Mayor Oreja, Medina Ortega, Meijer, Méndez de Vigo, Menéndez del Valle, Meyer Pleite, Miguélez Ramos, Mikko, Mikolášik, Millán Mon, Mitchell, Mölzer, Montoro Romero, Moraes, Moreno Sánchez, Morgan, Morgantini, Morillon, Moscovici, Mote, Mulder, Musacchio, Muscat, Musotto, Mussolini, Musumeci, Myller, Napoletano, Nassauer, Nattrass, Navarro, Newton Dunn, Annemie Neyts-Uyttebroeck, Nicholson, Nicholson of Winterbourne, Niebler, van Nistelrooij, Novak, Obiols i Germà, Öger, Özdemir, Olajos, Olbrycht, Ó Neachtain, Onesta, Onyszkiewicz, Oomen-Ruijten, Ortuondo Larrea, Őry, Ouzký, Oviir, Paasilinna, Pack, Borut Pahor, Paleckis, Pálfi, Panayotopoulos-Cassiotou, Panzeri, Papadimoulis, Papastamkos, Patrie, Peillon, Pęk, Alojz Peterle, Pflüger, Piecyk, Pieper, Pīks, Pinheiro, Pinior, Piotrowski, Pirilli, Piskorski, Pistelli, Pittella, Pleguezuelos Aguilar, Pleštinská, Podestà, Podkański, Poettering, Poignant, Polfer, Pomés Ruiz, Portas, Posselt, Prets, Prodi, Purvis, Queiró, Rack, Radwan, Rapkay, Rasmussen, Remek, Resetarits, Reul, Reynaud, Ribeiro e Castro, Riera Madurell, Ries, Riis-Jørgensen, Rivera, Rizzo, Rogalski, Roithová, Romagnoli, Romeva i Rueda, Roszkowski, Roth-Behrendt, Rothe, Rouček, Roure, Rudi Ubeda, Rübig, Rühle, Rutowicz, Ryan, Sacconi, Saïfi, Sakalas, Salafranca Sánchez-Neyra, Salinas García, Salvini, Samaras, Samuelsen, Sánchez Presedo, Sartori, Saryusz-Wolski, Savary, Savi, Sbarbati, Scheele, Schenardi, Schierhuber, Schlyter, Schmidt, Pál Schmitt, Schnellhardt, Schöpflin, Schröder, Schroedter, Schulz, Schuth, Schwab, Seeber, Seeberg, Segelström, Seppänen, Siekierski, Sifunakis, Silva Peneda, Sinnott, Siwiec, Sjöstedt, Skinner, Škottová, Smith, Sommer, Sonik, Sornosa Martínez, Sousa Pinto, Spautz, Speroni, Staes, Staniszewska, Starkevičiūtė, Stenzel, Sterckx, Stevenson, Stihler, Stockmann, Strejček, Strož, Stubb, Sturdy, Sudre, Sumberg, Surján, Svensson, Swoboda, Szájer, Szejna, Szent-Iványi, Szymański, Tabajdi, Tajani, Takkula, Tannock, Tarabella, Tarand, Tatarella, Thomsen, Thyssen, Titford, Titley, Toia, Tomczak, Toubon, Toussas, Trakatellis, Trautmann, Triantaphyllides, Trüpel, Turmes, Tzampazi, Uca, Ulmer, Väyrynen, Vaidere, Vakalis, Valenciano Martínez-Orozco, Vanhecke, Van Hecke, Van Lancker, Van Orden, Varela Suanzes-Carpegna, Vatanen, Vaugrenard, Ventre, Vergnaud, Vernola, Vidal-Quadras Roca, de Villiers, Vincenzi, Virrankoski, Vlasák, Vlasto, Voggenhuber, Wallis, Walter, Watson, Henri Weber, Manfred Weber, Weiler, Weisgerber, Westlund, Whitehead, Whittaker, Wieland, Wiersma, Wijkman, Wise, von Wogau, Wohlin, Janusz Wojciechowski, Wortmann-Kool, Wuermeling, Wurtz, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Záborská, Zahradil, Zaleski, Zani, Zapałowski, Zappalà, Zatloukal, Ždanoka, Železný, Zieleniec, Zīle, Zimmer, Zimmerling, Zingaretti, Zvěřina, Zwiefka

---

ANNEX I

RESULTS OF VOTES

Abbreviations and symbols

| + | adopted |
| --- | --- |
| - | rejected |
| ↓ | lapsed |
| W | withdrawn |
| RCV (..., ..., ...) | roll-call vote (for, against, abstentions) |
| EV (..., ..., ...) | electronic vote (for, against, abstentions) |
| split | split vote |
| sep | separate vote |
| am | amendment |
| CA | compromise amendment |
| CP | corresponding part |
| D | deleting amendment |
| = | identical amendments |
| § | paragraph |
| art | article |
| rec | recital |
| MOT | motion for a resolution |
| JT MOT | joint motion for a resolution |
| SEC | secret ballot |

+

adopted

-

rejected

↓

lapsed

W

withdrawn

RCV (..., ..., ...)

roll-call vote (for, against, abstentions)

EV (..., ..., ...)

electronic vote (for, against, abstentions)

split

split vote

sep

separate vote

am

amendment

CA

compromise amendment

CP

corresponding part

D

deleting amendment

=

identical amendments

§

paragraph

art

article

rec

recital

MOT

motion for a resolution

JT MOT

joint motion for a resolution

SEC

secret ballot

1.   Mobilisation of the flexibility instrument (Tsunami)

Report: Reimer BÖGE (A6-0254/2005)

| Subject | Amendment No | Author | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- | --- | --- |
| after § 3 | 1 | Verts/ALE | | + | |
| vote: resolution (as a whole) | | + | qualified majority |

Subject

Amendment No

Author

RCV, etc.

Vote

RCV/EV — remarks

after § 3

1

Verts/ALE

+

vote: resolution (as a whole)

+

qualified majority

2.   Mobilisation of the European Union Solidarity Fund

Report: Reimer BÖGE (A6-0229/2005)

| Subject | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- |
| single vote | | + | qualified majority |

Subject

RCV, etc.

Vote

RCV/EV — remarks

single vote

+

qualified majority

3.   Revision of the financial perspective 2000-2006

Report: Reimer BÖGE (A6-0252/2005)

| Subject | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- |
| single vote | | + | qualified majority |

Subject

RCV, etc.

Vote

RCV/EV — remarks

single vote

+

qualified majority

4.   Draft amending budget No 4/2005

Report: Salvador GARRIGA POLLEDO (A6-0255/2005)

| Subject | Amendment No | Author | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- | --- | --- |
| after § 4 | 1 | Verts/ALE | | + | |
| after § 5 | 2 | Verts/ALE | | + | |
| § 6 | § | original text | | + | qualified majority |
| vote: resolution (as a whole) | | + | |

Subject

Amendment No

Author

RCV, etc.

Vote

RCV/EV — remarks

after § 4

1

Verts/ALE

+

after § 5

2

Verts/ALE

+

§ 6

§

original text

+

qualified majority

vote: resolution (as a whole)

+

5.   Draft amending budget No 3/2005

Report: Salvador GARRIGA POLLEDO (A6-0248/2005)

| Subject | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- |
| single vote | RCV | + | 606, 16, 44


  qualified majority |

Subject

RCV, etc.

Vote

RCV/EV — remarks

single vote

RCV

+

606, 16, 44

qualified majority

Request for roll-call vote

IND/DEM

6.   Draft amending budget No 5/2005

Report: Salvador GARRIGA POLLEDO (A6-0253/2005)

| Subject | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- |
| single vote | | + | qualified majority |

Subject

RCV, etc.

Vote

RCV/EV — remarks

single vote

+

qualified majority

7.   Health and safety at work: Exposure to optical radiation ***II

Recommendation for second reading: Csaba ŐRY (A6-0249/2005) — qualified majority

| Subject | Amendment No | Author | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- | --- | --- |
| Rejection of the common position | 18/rev | Nassauer et al | RCV | - | 305, 348, 18 |
| Amendments by the committee responsible — block vote | 2-4
  6
  8-10
  12
  13 | committee | | + | |
| art 4, § 2 | 19=
  27= | Weisgerber et al
  ALDE | RCV | - | 361, 296, 14 |
| 5 | committee | RCV | + | 397, 260, 9 |
| 14 | PSE | | ↓ | |
| 16=
  34= | Verts/ALE
  GUE/NGL | | W
  ↓ | |
| art 4, § 3 | 20=
  28= | Weisgerber et al
  ALDE | RCV | + | 374, 282, 10 |
| art 4, § 4 | 21 | Weisgerber et al | RCV | - | 305, 351, 16 |
| 29 | ALDE | RCV | + | 371, 286, 12 |
| art 5, § 1 | 22=
  30= | Weisgerber et al
  ALDE | RCV | + | 384, 281, 9 |
| art 5, § 3 | 23=
  31= | Weisgerber et al
  ALDE | RCV | + | 377, 279, 15 |
| 15 | PSE | | ↓ | |
| 37 | PPE-DE | | ↓ | |
| 7 | committee | RCV | ↓ | |
| 17 | Verts/ALE | | W | |
| 35 | GUE/NGL | | ↓ | |
| art 5, § 6 | 24 | Weisgerber et al | RCV | - | 306, 339, 12 |
| art 6 | 25=
  32= | Weisgerber et al
  ALDE | RCV | + | 382, 277, 6 |
| art 8, § 3 | 11 | committee | | + | |
| 26 | Weisgerber et al | RCV | + | 372, 291, 7 |
| 33 | ALDE | | ↓ | |
| after rec
  - 4 | 1 | committee | | + | |
| 36 | PPE-DE | | ↓ | |

Subject

Amendment No

Author

RCV, etc.

Vote

RCV/EV — remarks

Rejection of the common position

18/rev

Nassauer et al

RCV

-

305, 348, 18

Amendments by the committee responsible — block vote

2-4

6

8-10

12

13

committee

+

art 4, § 2

19=

27=

Weisgerber et al

ALDE

RCV

-

361, 296, 14

5

committee

RCV

+

397, 260, 9

14

PSE

↓

16=

34=

Verts/ALE

GUE/NGL

W

↓

art 4, § 3

20=

28=

Weisgerber et al

ALDE

RCV

+

374, 282, 10

art 4, § 4

21

Weisgerber et al

RCV

-

305, 351, 16

29

ALDE

RCV

+

371, 286, 12

art 5, § 1

22=

30=

Weisgerber et al

ALDE

RCV

+

384, 281, 9

art 5, § 3

23=

31=

Weisgerber et al

ALDE

RCV

+

377, 279, 15

15

PSE

↓

37

PPE-DE

↓

7

committee

RCV

↓

17

Verts/ALE

W

35

GUE/NGL

↓

art 5, § 6

24

Weisgerber et al

RCV

-

306, 339, 12

art 6

25=

32=

Weisgerber et al

ALDE

RCV

+

382, 277, 6

art 8, § 3

11

committee

+

26

Weisgerber et al

RCV

+

372, 291, 7

33

ALDE

↓

after rec

- 4

1

committee

+

36

PPE-DE

↓

Requests for roll-call votes

Mr RADWAN et al: ams 18/rev, 19, 20, 21, 22, 23, 24, 25, 26

GUE/NGL: am 5

ALDE: ams 27, 28, 29, 30, 31, 32, 26, 5, 7

PPE-DE: ams 5, 7

Miscellaneous

The Verts/ALE Group had withdrawn its amendments 16 and 17.

8.   Competitiveness of audiovisual and information services: Protection of minors and human dignity ***I

Report: Marielle DE SARNEZ (A6-0244/2005)

| Subject | Amendment No | Author | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- | --- | --- |
| Amendments by the committee responsible — block vote | 1
  4
  6-11
  13-16
  18-31
  33-38 | committee | | + | |
| Amendments by the committee responsible — separate vote | 2 | committee | split | | |
| 1 | + | |
| 2 | + | |
| 3 | committee | sep | + | |
| 5 | committee | sep | + | |
| 12 | committee | split | | |
| 1 | + | |
| 2 | + | |
| 32 | committee | split | | |
| 1 | + | |
| 2 | + | |
| annex | 39 | PSE | | W | |
| vote: amended proposal | | + | |
| vote: legislative resolution | | + | |

Subject

Amendment No

Author

RCV, etc.

Vote

RCV/EV — remarks

Amendments by the committee responsible — block vote

1

4

6-11

13-16

18-31

33-38

committee

+

Amendments by the committee responsible — separate vote

2

committee

split

1

+

2

+

3

committee

sep

+

5

committee

sep

+

12

committee

split

1

+

2

+

32

committee

split

1

+

2

+

annex

39

PSE

W

vote: amended proposal

+

vote: legislative resolution

+

Requests for separate votes

IND/DEM: am 5

UEN: am 3

Requests for split votes

IND/DEM

am 2

1st part: up to ‘protected.’

2nd part: remainder

UEN

am 12

1st part: Text as a whole without the words ‘as laid down in the Treaty establishing a Constitution for Europe’

2nd part: those words

am 32

1st part: Text as a whole without the words ‘as defined in Article II-81 of the Treaty establishing a Constitution for Europe’

2nd part: those words

Miscellaneous

The PSE Group had withdrawn its amendment 39.

9.   Medicinal products for paediatric use ***I

Report: Françoise GROSSETETE (A6-0247/2005)

| Subject | Amendment No | Author | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- | --- | --- |
| Amendments by the committee responsible — block vote | 1-5
  7-10
  12-13
  15-18
  20
  22-24
  30-31
  33-35
  39-42
  44
  46-50
  53
  55-58
  62-67
  69
  71 | committee | | + | |
| Amendments by the committee responsible — separate vote | 11 | committee | sep | + | |
| 19 | committee | split | | |
| 1 | + | |
| 2/EV | - | 314, 343, 6 |
| 21 | committee | split | | |
| 1 | + | |
| 2 | - | |
| 25 | committee | sep | + | |
| 26 | committee | sep | + | |
| 27 | committee | sep | + | |
| 32 | committee | sep | + | |
| 36 | committee | sep | + | |
| 37 | committee | sep | + | |
| 38 | committee | sep | + | |
| 43 | committee | split | | |
| 1 | + | |
| 2 | + | |
| 3 | + | |
| 4 | - | |
| 45 | committee | sep | + | |
| 54 | committee | sep | + | |
| 59 | committee | sep | - | |
| 60 | committee | sep | - | |
| 61 | committee | sep | - | |
| 68 | committee | sep/EV | + | 338, 319, 7 |
| 70 | committee | sep | + | |
| art 7, § 1, point (d) | 79/rev | Verts/ALE +
  Ferreira | RCV | - | 141, 512, 15 |
| art 7, § 2 | 80/rev | Verts/ALE +
  Ferreira | RCV | - | 149, 505, 11 |
| 28 | committee | | + | |
| art 8, § 1, after point (a) | 81/rev | Verts/ALE +
  Ferreira | | - | |
| art 29, § 1, sub-§ 1 | 82/rev | Verts/ALE +
  Ferreira | RCV | - | 151, 502, 15 |
| art 35, after § 2 | 83/rev | Verts/ALE +
  Ferreira | RCV | + | 362, 294, 13 |
| art 36, § 1, sub-§ 1 | 91=
  89cp= | IND/DEM
  McAvan et al | RCV | - | 215, 444, 9 |
| 84/rev | Verts/ALE | RCV | - | 202, 450, 15 |
| 72 | ALDE | RCV | - | 238, 417, 15 |
| art 36, § 1, sub-§ 2 | 85/rev | Verts/ALE +
  Ferreira | RCV | - | 149, 497, 15 |
| art 36, § 3 | 89/revcp
  92= | McAvan et al
  IND/DEM | RCV | - | 214, 444, 13 |
| 86/rev | Verts/ALE | RCV | - | 166, 481, 22 |
| 73 | ALDE | RCV | - | 229, 419, 15 |
| 51 | committee | | + | |
| art 36, § 4 | 88/rev | Corbey et al | | - | |
| 87/rev | Verts/ALE | | - | |
| 75 | GUE/NGL | | - | |
| 52 | committee | | + | |
| art 52, point 5 | 93 | IND/DEM | | - | |
| rec 8 | 6 | committee | split | | |
| 1 | + | |
| 2/EV | + | 371, 268, 8 |
| 3 | - | |
| 76/rev | Verts/ALE +
  Ferreira | | ↓ | |
| rec 9 | 77/rev | Verts/ALE +
  Ferreira | | - | |
| rec 24 | 78/rev | Verts/ALE | | - | |
| 74 | ALDE | RCV | - | 198, 441, 17 |
| 14 | committee | | + | |
| vote: amended proposal | | + | |
| vote: legislative resolution | | + | |

Subject

Amendment No

Author

RCV, etc.

Vote

RCV/EV — remarks

Amendments by the committee responsible — block vote

1-5

7-10

12-13

15-18

20

22-24

30-31

33-35

39-42

44

46-50

53

55-58

62-67

69

71

committee

+

Amendments by the committee responsible — separate vote

11

committee

sep

+

19

committee

split

1

+

2/EV

-

314, 343, 6

21

committee

split

1

+

2

-

25

committee

sep

+

26

committee

sep

+

27

committee

sep

+

32

committee

sep

+

36

committee

sep

+

37

committee

sep

+

38

committee

sep

+

43

committee

split

1

+

2

+

3

+

4

-

45

committee

sep

+

54

committee

sep

+

59

committee

sep

-

60

committee

sep

-

61

committee

sep

-

68

committee

sep/EV

+

338, 319, 7

70

committee

sep

+

art 7, § 1, point (d)

79/rev

Verts/ALE +

Ferreira

RCV

-

141, 512, 15

art 7, § 2

80/rev

Verts/ALE +

Ferreira

RCV

-

149, 505, 11

28

committee

+

art 8, § 1, after point (a)

81/rev

Verts/ALE +

Ferreira

-

art 29, § 1, sub-§ 1

82/rev

Verts/ALE +

Ferreira

RCV

-

151, 502, 15

art 35, after § 2

83/rev

Verts/ALE +

Ferreira

RCV

+

362, 294, 13

art 36, § 1, sub-§ 1

91=

89cp=

IND/DEM

McAvan et al

RCV

-

215, 444, 9

84/rev

Verts/ALE

RCV

-

202, 450, 15

72

ALDE

RCV

-

238, 417, 15

art 36, § 1, sub-§ 2

85/rev

Verts/ALE +

Ferreira

RCV

-

149, 497, 15

art 36, § 3

89/revcp

92=

McAvan et al

IND/DEM

RCV

-

214, 444, 13

86/rev

Verts/ALE

RCV

-

166, 481, 22

73

ALDE

RCV

-

229, 419, 15

51

committee

+

art 36, § 4

88/rev

Corbey et al

-

87/rev

Verts/ALE

-

75

GUE/NGL

-

52

committee

+

art 52, point 5

93

IND/DEM

-

rec 8

6

committee

split

1

+

2/EV

+

371, 268, 8

3

-

76/rev

Verts/ALE +

Ferreira

↓

rec 9

77/rev

Verts/ALE +

Ferreira

-

rec 24

78/rev

Verts/ALE

-

74

ALDE

RCV

-

198, 441, 17

14

committee

+

vote: amended proposal

+

vote: legislative resolution

+

Amendment 90 had been cancelled as it was identical to amendment 75.

Amendment 29 had been merged with amendment 26.

Requests for roll-call votes

PPE-DE: ams 72, 84, 85, 86, 89 and 92

Verts/ALE: ams 79, 80, 82, 83, 84 and 85

ALDE: ams 72, 73 and 74

Requests for separate votes

Verts/ALE: am 68

UEN: am 68

PSE: ams 11, 19, 25, 26, 27, 32, 36, 37, 38, 45, 54, 59, 60, 61, 68 and 70

Requests for split votes

PPE-DE

am 19

1st part: Text as a whole without Article 2c(1)

2nd part: Article 2c(1)

am 21

1st part: up to ‘parents’ associations'

2nd part: remainder

Verts/ALE, PPE-DE

am 6

1st part: up to ‘in this Regulation’

2nd part:‘In all its work ... studies in children’ excluding the words ‘involved in the studies’

3rd part: remainder

PSE, PPE-DE

am 43

1st part: up to ‘the medicinal product’

2nd part:‘provided that ... indications concerned were approved’

3rd part:‘In such cases ... and those that have not’

4th part: remainder

10.   VAT: Simplifying obligations/VAT: One-stop scheme *

Report: Zsolt László BECSEY (A6-0228/2005)

| Subject | Amendment No | Author | RCV, etc. | Vote | RCV/EV — remarks |
| --- | --- | --- | --- | --- | --- |
| Proposal for a directive — Simplifying obligations |
| Amendments by the committee responsible — block vote | 1-8
  10 | committee | | + | |
| Amendment by the committee responsible — separate vote | 9 | committee | sep/EV | + | 343, 228, 48 |
| vote: amended proposal | | + | |
| vote: legislative resolution | | + | |
| Proposal for a regulation — One-stop scheme |
| vote: legislative proposal | | + | |
| vote: legislative resolution | | + | |

Subject

Amendment No

Author

RCV, etc.

Vote

RCV/EV — remarks

Proposal for a directive — Simplifying obligations

Amendments by the committee responsible — block vote

1-8

10

committee

+

Amendment by the committee responsible — separate vote

9

committee

sep/EV

+

343, 228, 48

vote: amended proposal

+

vote: legislative resolution

+

Proposal for a regulation — One-stop scheme

vote: legislative proposal

+

vote: legislative resolution

+

Requests for separate votes

PSE: am 9

---

ANNEX II

RESULT OF ROLL-CALL VOTES

1.   Report: Garriga Polledo A6-0248/2005

For: 606

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Borghezio, Chruszcz, Coûteaux, Giertych, Grabowski, Karatzaferis, Krupa, Louis, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Zapałowski

NI: Baco, Battilocchio, Belohorská, Bobošíková, Czarnecki Marek Aleksander, Czarnecki Ryszard, De Michelis, Kozlík, Masiel, Rivera, Rutowicz

PPE-DE: Albertini, Andrikienė, Antoniozzi, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Becsey, Belet, Berend, Böge, Bonsignore, Bowis, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Busuttil, Buzek, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Eurlings, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hatzidakis, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Karas, Kasoulides, Kelam, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Őry, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Sommer, Spautz, Stenzel, Stubb, Sudre, Surján, Szájer, Tajani, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Gurmai, Guy-Quint, Hänsch, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 16

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Goudin, Knapman, Lundgren, Nattrass, Titford, Whittaker, Wise, Wohlin

NI: Allister, Martin Hans-Peter, Mote

Abstention: 44

IND/DEM: Bonde, Železný

NI: Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Mussolini, Romagnoli, Schenardi, Vanhecke

PPE-DE: Ashworth, Atkins, Beazley, Bradbourn, Bushill-Matthews, Cabrnoch, Callanan, Chichester, Deva, Dover, Evans Jonathan, Fajmon, Hannan, Harbour, Heaton-Harris, Kamall, Kirkhope, McMillan-Scott, Nicholson, Ouzký, Purvis, Škottová, Stevenson, Strejček, Sturdy, Sumberg, Tannock, Zahradil

Verts/ALE: Schlyter

2.   Recommendation: Őry A6-0249/2005

For: 305

IND/DEM: Batten, Belder, Blokland, Bloom, Booth, Borghezio, Chruszcz, Clark, Coûteaux, Farage, Giertych, Grabowski, Karatzaferis, Knapman, Krupa, Louis, Nattrass, Pęk, Rogalski, Salvini, Sinnott, Speroni, Titford, Tomczak, Whittaker, Wise, Zapałowski, Železný

NI: Allister, Bobošíková, Claeys, Czarnecki Marek Aleksander, Czarnecki Ryszard, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martin Hans-Peter, Martinez, Masiel, Mölzer, Mote, Rivera, Romagnoli, Rutowicz, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Buzek, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels

UEN: Angelilli, Berlato, Bielan, Camre, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Pirilli, Roszkowski, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Schlyter

Against: 348

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Goudin, Lundgren, Wohlin

NI: Battilocchio, De Michelis

PPE-DE: Brejc, Busuttil, Casa, Fatuzzo, Őry, Sumberg

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Gurmai, Guy-Quint, Hänsch, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Aylward, Crowley, Ó Neachtain, Ryan

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 18

ALDE: Maaten

GUE/NGL: Toussas

IND/DEM: Bonde, Piotrowski

NI: Baco, Belohorská, Kozlík, Mussolini

PPE-DE: Bauer, Becsey, Duka-Zólyomi, Gál, Járóka, Olajos, Schmitt Pál, Schöpflin, Szájer

PSE: Kindermann

3.   Recommendation: Őry A6-0249/2005

For: 361

ALDE: Alvaro, Andrejevs, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cornillet, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Coûteaux, Goudin, Karatzaferis, Louis, Lundgren, Salvini, Sinnott, Speroni, Wohlin

NI: Allister, Bobošíková, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martin Hans-Peter, Martinez, Mölzer, Mote, Rivera, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Buzek, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zwiefka

PSE: Goebbels, Hänsch, Kreissl-Dörfler, Patrie

UEN: Aylward, Bielan, Camre, Crowley, Janowski, Krasts, Kristovskis, La Russa, Libicki, Ó Neachtain, Roszkowski, Ryan, Szymański, Vaidere, Zīle

Verts/ALE: Buitenweg, Hudghton, Lagendijk, Rühle, Schlyter, Smith

Against: 296

ALDE: Andria, Cocilovo, Costa, Pistelli

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Chruszcz, Clark, Farage, Giertych, Grabowski, Knapman, Krupa, Nattrass, Pęk, Piotrowski, Rogalski, Titford, Tomczak, Whittaker, Wise, Zapałowski, Železný

NI: Baco, Battilocchio, Czarnecki Ryszard, De Michelis, Masiel, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Busuttil, Casa, Duka-Zólyomi, Járóka, Olajos, Őry, Schöpflin, Surján, Szájer

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Gurmai, Guy-Quint, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kristensen, Kuc, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Berlato, Didžiokas, Foglietta, Musumeci, Pirilli, Tatarella

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, de Groen-Kouwenhoven, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 14

NI: Belohorská, Czarnecki Marek Aleksander, Kozlík, Mussolini

PPE-DE: Brejc, Fraga Estévez, Glattfelder, Herranz García, Herrero-Tejedor, Mato Adrover, Zvěřina

PSE: Kuhne, Leinen

UEN: Fotyga

Corrections to vote

Abstention:
  Elspeth Attwooll

4.   Recommendation: Őry A6-0249/2005

For: 397

ALDE: Alvaro, Andrejevs, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Belder, Blokland, Bloom, Bonde, Booth, Borghezio, Chruszcz, Clark, Coûteaux, Farage, Giertych, Goudin, Grabowski, Karatzaferis, Knapman, Krupa, Louis, Lundgren, Nattrass, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Titford, Tomczak, Whittaker, Wise, Wohlin, Zapałowski, Železný

NI: Allister, Czarnecki Ryszard, Helmer, Martin Hans-Peter, Masiel, Mote, Rivera, Romagnoli, Rutowicz

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Berend, Böge, Bowis, Bradbourn, Braghetto, Brejc, Březina, Brok, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Őry, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Dobolyi, Glante, Goebbels, Gurmai, Hänsch, Kreissl-Dörfler, Le Foll

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Buitenweg, Hudghton, Lagendijk, Rühle, Schlyter, Smith

Against: 260

ALDE: Andria

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

NI: Battilocchio, Claeys, De Michelis, Dillen, Gollnisch, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Schenardi, Vanhecke

PPE-DE: Brepoels, Busuttil, Casa, Fatuzzo

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Reynaud, Riera Madurell, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 9

NI: Baco, Belohorská, Bobošíková, Czarnecki Marek Aleksander, Kozlík, Mussolini

PSE: Mann Erika, Roth-Behrendt

Verts/ALE: Kallenbach

5.   Recommendation: Őry A6-0249/2005

For: 374

ALDE: Alvaro, Andrejevs, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cornillet, Davies, Degutis, Deprez, De Sarnez, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Coûteaux, Giertych, Goudin, Grabowski, Karatzaferis, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Wohlin, Zapałowski

NI: Allister, Belohorská, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mote, Rivera, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels, Thomsen

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Buitenweg, Hudghton, Lagendijk, Rühle, Schlyter, Smith

Against: 282

ALDE: Andria, Cocilovo, Costa, Pistelli

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Knapman, Nattrass, Titford, Whittaker, Wise, Železný

NI: Battilocchio, Czarnecki Marek Aleksander, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Bachelot-Narquin, Barsi-Pataky, Bauer, Becsey, Demetriou, Duka-Zólyomi, Gál, Járóka, Olajos, Őry, Roithová, Rudi Ubeda, Schöpflin

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 10

IND/DEM: Krupa

NI: Baco, Bobošíková, Kozlík, Martin Hans-Peter, Mussolini

PPE-DE: Brejc

PSE: Gurmai, Hänsch, Leinen

6.   Recommendation: Őry A6-0249/2005

For: 305

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Coûteaux, Giertych, Goudin, Grabowski, Karatzaferis, Krupa, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Wohlin, Zapałowski

NI: Allister, Belohorská, Bobošíková, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mote, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels

UEN: Angelilli, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, Hudghton, Lagendijk, Rühle, Smith

Against: 351

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Knapman, Nattrass, Titford, Whittaker, Wise, Železný

NI: Battilocchio, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Duka-Zólyomi, Fatuzzo, Gál, Járóka, Olajos, Őry

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hänsch, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schlyter, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 16

ALDE: Chatzimarkakis, Klinz, Krahmer, Schuth

NI: Baco, Czarnecki Marek Aleksander, Kozlík, Martin Hans-Peter, Mussolini, Rivera, Romagnoli

PPE-DE: Brejc, Schöpflin

PSE: Gurmai

UEN: Aylward, Fotyga

7.   Recommendation: Őry A6-0249/2005

For: 371

ALDE: Alvaro, Andrejevs, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cornillet, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Coûteaux, Karatzaferis, Louis, Lundgren, Salvini, Sinnott, Speroni, Wohlin

NI: Allister, Belohorská, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mussolini, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels, Gurmai, Hänsch

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Didžiokas, Foglietta, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, Hudghton, Lagendijk, Rühle, Schlyter, Smith

Against: 286

ALDE: Andria, Cocilovo, Costa, Pistelli

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Chruszcz, Clark, Farage, Giertych, Grabowski, Knapman, Krupa, Nattrass, Piotrowski, Titford, Tomczak, Whittaker, Wise, Zapałowski, Železný

NI: Battilocchio, Bobošíková, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Bauer, Becsey, Duka-Zólyomi, Fatuzzo, Gál, Járóka, Olajos, Őry

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Crowley, Ó Neachtain

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 12

IND/DEM: Goudin, Pęk, Rogalski

NI: Baco, Czarnecki Marek Aleksander, Kozlík, Martin Hans-Peter, Mote, Rivera

PPE-DE: Brejc, Schöpflin

UEN: Fotyga

8.   Recommendation: Őry A6-0249/2005

For: 384

ALDE: Alvaro, Andrejevs, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cornillet, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Coûteaux, Giertych, Goudin, Grabowski, Karatzaferis, Krupa, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Wohlin, Zapałowski

NI: Allister, Belohorská, Bobošíková, Claeys, Czarnecki Marek Aleksander, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mote, Mussolini, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels

UEN: Angelilli, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, Hudghton, Lagendijk, Rühle, Schlyter, Smith

Against: 281

ALDE: Andria, Cocilovo, Costa, Pistelli

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Knapman, Nattrass, Titford, Whittaker, Wise, Železný

NI: Battilocchio, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Duka-Zólyomi, Fatuzzo, Járóka, Olajos, Őry, Schmitt Pál

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Aylward, Ryan

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 9

NI: Baco, Kozlík, Martin Hans-Peter, Rivera

PPE-DE: Brejc, Gál, Schöpflin

PSE: Gurmai, Hänsch

9.   Recommendation: Őry A6-0249/2005

For: 377

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Coûteaux, Goudin, Karatzaferis, Louis, Lundgren, Salvini, Sinnott, Speroni, Wohlin

NI: Allister, Belohorská, Bobošíková, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mote, Mussolini, Rivera, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Buzek, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Mitchell, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Hänsch, Kreissl-Dörfler, Kuhne

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, Hammerstein Mintz, Harms, Hudghton, Lagendijk, Özdemir, Rühle, Schlyter, Smith

Against: 279

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Chruszcz, Clark, Farage, Giertych, Grabowski, Knapman, Nattrass, Pęk, Piotrowski, Rogalski, Titford, Tomczak, Whittaker, Wise, Zapałowski, Železný

NI: Battilocchio, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Busuttil, Casa, Duka-Zólyomi, Fatuzzo, Gál, Járóka, Olajos, Őry, Schmitt Pál

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kristensen, Kuc, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kusstatscher, Lambert, Lucas, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 15

NI: Baco, Czarnecki Marek Aleksander, Kozlík, Martin Hans-Peter

PPE-DE: Brejc, Fraga Estévez, Herranz García, Herrero-Tejedor, Iturgaiz Angulo, Mato Adrover, Millán Mon, Montoro Romero, Schöpflin

PSE: Gurmai

Verts/ALE: Kallenbach

10.   Recommendation: Őry A6-0249/2005

For: 306

ALDE: Andria, Chatzimarkakis, Jäätteenmäki, Klinz, Krahmer

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Coûteaux, Giertych, Goudin, Grabowski, Karatzaferis, Krupa, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Wohlin, Zapałowski

NI: Allister, Belohorská, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Marine, Martin Hans-Peter, Martinez, Masiel, Mölzer, Mote, Schenardi, Vanhecke

PPE-DE: Albertini, Antoniozzi, Ashworth, Atkins, Audy, Bachelot-Narquin, Barsi-Pataky, Beazley, Becsey, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Garriga Polledo, Gaubert, Gawronski, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Őry, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Krehl

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Crowley, Foglietta, Fotyga, Janowski, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, de Groen-Kouwenhoven, Hudghton, Isler Béguin, Lagendijk, Smith

Against: 339

ALDE: Alvaro, Andrejevs, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jensen, Juknevičienė, Kacin, Karim, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Knapman, Nattrass, Titford, Whittaker, Wise, Železný

NI: Battilocchio, Czarnecki Marek Aleksander, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Bauer, Fatuzzo, Gál, Mikolášik, Millán Mon

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hänsch, Hamon, Harangozó, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, Hammerstein Mintz, Harms, Hassi, Horáček, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schlyter, Schmidt, Schroedter, Staes, Trüpel, Turmes, Ždanoka

Abstention: 12

ALDE: Schuth

NI: Baco, Bobošíková, Kozlík, Mussolini, Rivera, Romagnoli

PPE-DE: Schöpflin

PSE: Gurmai

UEN: Didžiokas, Krasts

Verts/ALE: Rühle

11.   Recommendation: Őry A6-0249/2005

For: 382

ALDE: Alvaro, Andrejevs, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cornillet, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Coûteaux, Giertych, Goudin, Grabowski, Karatzaferis, Louis, Lundgren, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Wohlin, Zapałowski

NI: Allister, Baco, Belohorská, Bobošíková, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martin Hans-Peter, Martinez, Masiel, Mölzer, Mote, Mussolini, Romagnoli, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels

UEN: Angelilli, Aylward, Berlato, Bielan, Camre, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, Hudghton, Lagendijk, Rühle, Schlyter, Smith

Against: 277

ALDE: Andria, Cocilovo, Costa, Pistelli

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Knapman, Nattrass, Titford, Whittaker, Wise, Železný

NI: Battilocchio, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Bauer, Becsey, Duka-Zólyomi, Fatuzzo, Gál, Glattfelder, Járóka, Schmitt Pál, Schöpflin, Szájer, Ventre

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hänsch, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 6

NI: Czarnecki Marek Aleksander, Kozlík, Rivera

PSE: Gurmai, Mann Erika

Verts/ALE: Kallenbach

12.   Recommendation: Őry A6-0249/2005

For: 372

ALDE: Alvaro, Andrejevs, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Cornillet, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Neyts-Uyttebroeck, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Giertych, Grabowski, Krupa, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Wohlin, Zapałowski

NI: Allister, Baco, Belohorská, Bobošíková, Claeys, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martin Hans-Peter, Martinez, Masiel, Mölzer, Mote, Mussolini, Rivera, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Cirino Pomicino, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olbrycht, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Goebbels

UEN: Angelilli, Berlato, Bielan, Camre, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Pirilli, Roszkowski, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Breyer, Buitenweg, Hudghton, Lagendijk, Smith

Against: 291

ALDE: Andria, Chiesa, Cocilovo, Costa, Pistelli

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Goudin, Knapman, Nattrass, Titford, Whittaker, Wise, Železný

NI: Battilocchio, Czarnecki Ryszard, De Michelis, Rutowicz

PPE-DE: Bauer, Becsey, Duka-Zólyomi, Fatuzzo, Gál, Glattfelder, Járóka, Olajos, Őry, Schmitt Pál, Schöpflin, Surján, Szájer

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fava, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Guy-Quint, Hänsch, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Aylward, Crowley, Ó Neachtain, Ryan

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Schlyter, Schmidt, Schroedter, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Abstention: 7

IND/DEM: Coûteaux, Karatzaferis

NI: Czarnecki Marek Aleksander

PPE-DE: Brejc

PSE: Gurmai, Mann Erika

Verts/ALE: Rühle

13.   Report: Grossetête A6-0247/2005

For: 141

ALDE: Szent-Iványi, Toia

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Goudin, Grabowski, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Wohlin, Zapałowski

NI: Bobošíková, Martin Hans-Peter

PPE-DE: Dombrovskis, Pieper

PSE: Andersson, Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Carlotti, Casaca, Castex, Corbey, Cottigny, De Keyser, Désir, De Vits, Dobolyi, Douay, El Khadraoui, Fazakas, Ferreira Anne, Fruteau, Grabowska, Guy-Quint, Hamon, Harangozó, Hegyi, Kósáné Kovács, Laignel, Lavarra, Le Foll, Lienemann, Mastenbroek, Moscovici, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Tabajdi, Trautmann, Van Lancker, Vaugrenard, Vergnaud

UEN: Camre

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 512

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Takkula, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Knapman, Krupa, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise

NI: Battilocchio, Belohorská, Czarnecki Marek Aleksander, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mussolini, Romagnoli, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Berend, Böge, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Őry, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Berger, Berlinguer, Bösch, Busquin, Calabuig Rull, Capoulas Santos, Carnero González, Cashman, Christensen, Corbett, Correia, D'Alema, De Rossa, Díez González, Dührkop Dührkop, Estrela, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ferreira Elisa, Ford, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Golik, Gomes, Grech, Gröner, Gruber, Gurmai, Hänsch, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Lambrinidis, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Bielan, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Verts/ALE: Staes

Abstention: 15

IND/DEM: Coûteaux, Karatzaferis, Železný

NI: Allister, Baco, Claeys, Czarnecki Ryszard, Dillen, Kozlík, Mote, Rivera, Rutowicz, Vanhecke

PSE: Wiersma

UEN: Musumeci

Corrections to vote

| For: | Bart Staes |
| --- | --- |
| Against: | Jan Andersson |

For:

Bart Staes

Against:

Jan Andersson

14.   Report: Grossetête A6-0247/2005

For: 149

ALDE: Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Goudin, Grabowski, Krupa, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Wohlin, Zapałowski

NI: Bobošíková, Czarnecki Marek Aleksander, Martin Hans-Peter

PPE-DE: Glattfelder

PSE: Andersson, Arif, Berès, van den Berg, Berger, Berman, Bono, Bourzai, Bozkurt, van den Burg, Capoulas Santos, Carlotti, Casaca, Castex, Corbett, Corbey, Cottigny, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Fazakas, Ferreira Anne, Fruteau, Grabowska, Guy-Quint, Hamon, Harangozó, Hazan, Hegyi, Kósáné Kovács, Laignel, Lambrinidis, Le Foll, Leichtfried, Lévai, Lienemann, Mastenbroek, Moscovici, Peillon, Poignant, Reynaud, Roure, Savary, Siwiec, Tabajdi, Trautmann, Vaugrenard, Vergnaud

UEN: Camre

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 505

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Takkula, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Knapman, Salvini, Speroni, Titford, Whittaker, Wise

NI: Battilocchio, Belohorská, Czarnecki Ryszard, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mussolini, Romagnoli, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Berend, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Őry, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berlinguer, Bösch, Bullmann, Busquin, Calabuig Rull, Carnero González, Cashman, Christensen, Correia, D'Alema, De Rossa, Díez González, Dobolyi, Dührkop Dührkop, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ferreira Elisa, Ford, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Golik, Grech, Gröner, Gruber, Gurmai, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Lavarra, Lehtinen, Leinen, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani

UEN: Angelilli, Aylward, Berlato, Bielan, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Abstention: 11

IND/DEM: Coûteaux, Karatzaferis, Železný

NI: Baco, Claeys, Dillen, Kozlík, Mote, Rutowicz, Vanhecke

PSE: Wiersma

Corrections to vote

| Against: | Jan Andersson |
| --- | --- |

Against:

Jan Andersson

15.   Report: Grossetête A6-0247/2005

For: 151

ALDE: Cavada, Griesbeck, Sbarbati, Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Grabowski, Krupa, Louis, Lundgren, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Wohlin, Zapałowski

NI: Bobošíková, Czarnecki Ryszard, Martin Hans-Peter, Rutowicz

PPE-DE: Lauk, Pack

PSE: Andersson, Arif, Berès, van den Berg, Berman, Bono, Bozkurt, van den Burg, Carlotti, Casaca, Castex, Corbett, Corbey, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Fazakas, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, Golik, Grabowska, Guy-Quint, Hamon, Harangozó, Hazan, Hegyi, Kósáné Kovács, Laignel, Lavarra, Le Foll, Lévai, Lienemann, Mastenbroek, Moscovici, Patrie, Peillon, Poignant, Reynaud, Roure, Siwiec, Tabajdi, Trautmann, Van Lancker, Vaugrenard, Vergnaud

UEN: Camre

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 502

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Takkula, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Knapman, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise

NI: Battilocchio, Belohorská, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mussolini, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Lamassoure, Landsbergis, Langen, Langendries, Lechner, Lehne, Lewandowski, Liese, Lombardo, Lulling, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Bösch, Bourzai, Bullmann, Busquin, Calabuig Rull, Capoulas Santos, Carnero González, Cashman, Christensen, Correia, Cottigny, D'Alema, De Rossa, Díez González, Dobolyi, Dührkop Dührkop, Ettl, Evans Robert, Falbr, Fava, Fernandes, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Gomes, Grech, Gröner, Gruber, Gurmai, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Lambrinidis, Lehtinen, Leinen, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Bielan, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Abstention: 15

IND/DEM: Coûteaux, Goudin, Karatzaferis, Železný

NI: Allister, Baco, Claeys, Czarnecki Marek Aleksander, Dillen, Kozlík, Mote, Rivera, Vanhecke

PSE: Leichtfried, Wiersma

Corrections to vote

| Against: | Jan Andersson, Richard Corbett |
| --- | --- |

Against:

Jan Andersson, Richard Corbett

16.   Report: Grossetête A6-0247/2005

For: 362

ALDE: Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cornillet, Costa, Davies, Degutis, Deprez, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Szent-Iványi, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Coûteaux, Giertych, Goudin, Grabowski, Krupa, Louis, Lundgren, Pęk, Piotrowski, Sinnott, Tomczak, Zapałowski

NI: Bobošíková, Czarnecki Marek Aleksander, Czarnecki Ryszard, Martin Hans-Peter, Rutowicz

PSE: Andersson, Arif, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, van den Berg, Berger, Berlinguer, Berman, Bösch, Bono, Bourzai, Bozkurt, Bullmann, van den Burg, Busquin, Calabuig Rull, Capoulas Santos, Carlotti, Carnero González, Casaca, Cashman, Castex, Christensen, Corbett, Corbey, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Estrela, Ettl, Evans Robert, Falbr, Fazakas, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Golik, Gomes, Grabowska, Grech, Gröner, Gruber, Gurmai, Guy-Quint, Hänsch, Hamon, Harangozó, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Mastenbroek, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Moscovici, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Tabajdi, Tarabella, Tarand, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wiersma, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García

UEN: Berlato, Bielan, Camre, Didžiokas, Foglietta, Fotyga, Janowski, Libicki, Musumeci, Pirilli, Roszkowski

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 294

ALDE: Cocilovo, De Sarnez, Takkula

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Knapman, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Mussolini, Romagnoli, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Böge, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Őry, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Fava, Szejna, Zani, Zingaretti

UEN: Angelilli, Aylward, Crowley, Kristovskis, La Russa, Ó Neachtain, Ryan, Szymański, Vaidere, Zīle

Abstention: 13

ALDE: Alvaro

IND/DEM: Karatzaferis, Rogalski, Železný

NI: Allister, Baco, Claeys, Dillen, Kozlík, Mote, Rivera, Vanhecke

PPE-DE: Berend

Corrections to vote

| Against: | Jan Andersson |
| --- | --- |

Against:

Jan Andersson

17.   Report: Grossetête A6-0247/2005

For: 215

ALDE: Drčar Murko, Geremek, Onyszkiewicz, Staniszewska, Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Coûteaux, Giertych, Grabowski, Krupa, Louis, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Zapałowski

NI: Allister, Bobošíková, Czarnecki Marek Aleksander, Czarnecki Ryszard, Masiel, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Busuttil, Buzek, Casa, Chmielewski, Dombrovskis, Gál, Glattfelder, Gyürk, Handzlik, Jałowiecki, Járóka, Kaczmarek, Klich, Kudrycka, Kušķis, Kuźmiuk, Landsbergis, Lewandowski, Olajos, Olbrycht, Őry, Peterle, Piskorski, Podkański, Saryusz-Wolski, Schmitt Pál, Schöpflin, Surján, Szájer, Zaleski, Zwiefka

PSE: Andersson, Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Capoulas Santos, Carlotti, Casaca, Castex, Corbett, Corbey, Cottigny, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Evans Robert, Fazakas, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, Geringer de Oedenberg, Gierek, Golik, Grabowska, Guy-Quint, Hamon, Harangozó, Hazan, Hegyi, Honeyball, Howitt, Hughes, Kinnock, Kuc, Laignel, Le Foll, Lienemann, McAvan, Martin David, Mastenbroek, Morgan, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Siwiec, Skinner, Sousa Pinto, Stihler, Tabajdi, Titley, Trautmann, Van Lancker, Vaugrenard, Vergnaud, Whitehead, Wynn

UEN: Bielan, Camre, Fotyga, Janowski, Krasts, Kristovskis, Libicki, Roszkowski, Szymański, Vaidere, Zīle

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Voggenhuber, Ždanoka

Against: 444

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Duff, Duquesne, Ek, Fourtou, Gentvilas, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Starkevičiūtė, Sterckx, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Goudin, Knapman, Lundgren, Nattrass, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, Claeys, De Michelis, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Mussolini, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Lamassoure, Langen, Langendries, Lauk, Lechner, Lehne, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Pieper, Pīks, Pinheiro, Pleštinská, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Berlinguer, Bösch, Busquin, Calabuig Rull, Carnero González, Cashman, Christensen, Correia, D'Alema, De Rossa, Díez González, Dobolyi, Dührkop Dührkop, Ettl, Falbr, Fava, Fernandes, García Pérez, Gebhardt, Glante, Goebbels, Gomes, Grech, Gröner, Gruber, Gurmai, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Lambrinidis, Lavarra, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, Madeira, Maňka, Mann Erika, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Sornosa Martínez, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Crowley, Didžiokas, Foglietta, La Russa, Musumeci, Ó Neachtain, Pirilli, Ryan, Tatarella

Abstention: 9

IND/DEM: Karatzaferis, Železný

NI: Baco, Kozlík, Martin Hans-Peter, Mote, Rivera

PSE: Moscovici, Wiersma

Corrections to vote

| Against: | Jan Andersson |
| --- | --- |

Against:

Jan Andersson

18.   Report: Grossetête A6-0247/2005

For: 202

ALDE: Drčar Murko, Geremek, Lax, Maaten, Manders, Mulder, Onyszkiewicz, Staniszewska, Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Grabowski, Krupa, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Zapałowski

NI: Allister, Bobošíková, Czarnecki Ryszard, Masiel, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Busuttil, Buzek, Casa, Chmielewski, Dombrovskis, Freitas, Glattfelder, Gyürk, Handzlik, Jałowiecki, Járóka, Kaczmarek, Klich, Kudrycka, Kušķis, Kuźmiuk, Lewandowski, Olajos, Olbrycht, Őry, Peterle, Piskorski, Podkański, Saryusz-Wolski, Schmitt Pál, Schöpflin, Spautz, Surján, Szájer, Vatanen, Wojciechowski, Zaleski, Zwiefka

PSE: Andersson, Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Capoulas Santos, Carlotti, Casaca, Castex, Corbey, Cottigny, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Fazakas, Ferreira Anne, Ferreira Elisa, Fruteau, Geringer de Oedenberg, Gierek, Golik, Grabowska, Guy-Quint, Hamon, Harangozó, Hazan, Hegyi, Kósáné Kovács, Koterec, Kuc, Laignel, Le Foll, Lienemann, Mastenbroek, Moscovici, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Siwiec, Tabajdi, Trautmann, Van Lancker, Vaugrenard, Vergnaud

UEN: Bielan, Camre, Fotyga, Janowski, Krasts, Kristovskis, Libicki, Roszkowski, Szymański, Vaidere, Zīle

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 450

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Duff, Duquesne, Ek, Fourtou, Gentvilas, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lehideux, Lynne, Malmström, Matsakis, Morillon, Newton Dunn, Nicholson of Winterbourne, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Starkevičiūtė, Sterckx, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Goudin, Knapman, Lundgren, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, Claeys, De Michelis, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Mussolini, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fraga Estévez, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Oomen-Ruijten, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Pieper, Pīks, Pinheiro, Pleštinská, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Bösch, Bullmann, Busquin, Calabuig Rull, Carnero González, Cashman, Christensen, Corbett, Correia, D'Alema, De Rossa, Díez González, Dobolyi, Dührkop Dührkop, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ford, García Pérez, Gebhardt, Glante, Goebbels, Grech, Gröner, Gruber, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Lambrinidis, Lavarra, Lehtinen, Leinen, Lévai, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Crowley, Didžiokas, Foglietta, La Russa, Musumeci, Ó Neachtain, Pirilli, Ryan, Tatarella

Abstention: 15

ALDE: Hennis-Plasschaert

IND/DEM: Coûteaux, Karatzaferis, Louis, Železný

NI: Baco, Czarnecki Marek Aleksander, Kozlík, Martin Hans-Peter, Mote, Rivera

PPE-DE: Belet

PSE: Gurmai, Leichtfried, Wiersma

Corrections to vote

| Against: | Jan Andersson, Ari Vatanen |
| --- | --- |

Against:

Jan Andersson, Ari Vatanen

19.   Report: Grossetête A6-0247/2005

For: 238

ALDE: Andrejevs, Attwooll, Bowles, Budreikaitė, Busk, Carlshamre, Chatzimarkakis, Chiesa, Costa, Davies, Degutis, Di Pietro, Drčar Murko, Duff, Ek, Gentvilas, Geremek, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Lax, Lynne, Maaten, Malmström, Manders, Matsakis, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Resetarits, Samuelsen, Savi, Staniszewska, Starkevičiūtė, Szent-Iványi, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Giertych, Grabowski, Krupa, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Zapałowski

NI: Czarnecki Marek Aleksander, Czarnecki Ryszard, Masiel, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Busuttil, Buzek, Casa, Chmielewski, Dombrovskis, Gál, Glattfelder, Gyürk, Handzlik, Jałowiecki, Járóka, Kaczmarek, Klich, Kudrycka, Kušķis, Kuźmiuk, Lewandowski, Olajos, Olbrycht, Pálfi, Piskorski, Podkański, Saryusz-Wolski, Schmitt Pál, Schöpflin, Surján, Szájer, Wojciechowski, Zaleski, Zwiefka

PSE: Andersson, Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Capoulas Santos, Carlotti, Casaca, Castex, Corbey, Cottigny, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Fazakas, Ferreira Anne, Ferreira Elisa, Fruteau, Golik, Grabowska, Guy-Quint, Hamon, Harangozó, Hazan, Hegyi, Kósáné Kovács, Kuc, Laignel, Le Foll, Lienemann, Mastenbroek, Moraes, Moscovici, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Siwiec, Tabajdi, Trautmann, Van Lancker, Vaugrenard, Vergnaud

UEN: Bielan, Camre, Fotyga, Janowski, Krasts, Kristovskis, La Russa, Libicki, Roszkowski, Szymański, Zīle

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 417

ALDE: Andria, Beaupuy, Birutis, Bourlanges, Cavada, Cornillet, Deprez, De Sarnez, Duquesne, Fourtou, Gibault, Griesbeck, Guardans Cambó, Klinz, Krahmer, Laperrouze, Lehideux, Morillon, Pistelli, Prodi, Ries, Sbarbati, Schuth, Sterckx, Takkula

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Goudin, Knapman, Lundgren, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, Claeys, De Michelis, Dillen, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Mussolini, Romagnoli, Schenardi, Vanhecke

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Liese, Lombardo, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Oomen-Ruijten, Ouzký, Pack, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Pleštinská, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Berlinguer, Bösch, Bullmann, Busquin, Calabuig Rull, Carnero González, Cashman, Christensen, Corbett, Correia, D'Alema, De Rossa, Díez González, Dobolyi, Dührkop Dührkop, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ford, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Gomes, Grech, Gröner, Gruber, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Lambrinidis, Lavarra, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moreno Sánchez, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Crowley, Didžiokas, Foglietta, Musumeci, Ó Neachtain, Pirilli, Ryan, Tatarella, Vaidere

Abstention: 15

ALDE: Alvaro

IND/DEM: Coûteaux, Karatzaferis, Louis, Železný

NI: Allister, Baco, Bobošíková, Kozlík, Martin Hans-Peter, Mote, Rivera

PPE-DE: Lulling

PSE: Gurmai, Wiersma

Corrections to vote

| Against: | Jan Andersson, Jorgo Chatzimarkakis |
| --- | --- |

Against:

Jan Andersson, Jorgo Chatzimarkakis

20.   Report: Grossetête A6-0247/2005

For: 149

ALDE: Guardans Cambó, Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Goudin, Grabowski, Krupa, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Zapałowski

NI: Allister, Martin Hans-Peter, Mussolini, Romagnoli

PSE: Andersson, Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Capoulas Santos, Carlotti, Casaca, Castex, Corbey, Cottigny, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Fazakas, Ferreira Anne, Ferreira Elisa, Fruteau, Grabowska, Guy-Quint, Hamon, Harangozó, Hazan, Hegyi, Laignel, Le Foll, Lienemann, Mastenbroek, Moraes, Moscovici, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Tabajdi, Trautmann, Van Lancker, Vaugrenard, Vergnaud

UEN: Camre, Krasts, Kristovskis, Vaidere, Zīle

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 497

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Geremek, Gibault, Griesbeck, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Matsakis, Morillon, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Staniszewska, Starkevičiūtė, Sterckx, Takkula, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Karatzaferis, Knapman, Lundgren, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise, Wohlin, Železný

NI: Battilocchio, Belohorská, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Masiel, Mölzer, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Busuttil, Buzek, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Chmielewski, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Handzlik, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jałowiecki, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kaczmarek, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Klich, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kudrycka, Kušķis, Kuźmiuk, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Lewandowski, Liese, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Olbrycht, Oomen-Ruijten, Őry, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Peterle, Pieper, Pīks, Pinheiro, Piskorski, Pleštinská, Podestà, Podkański, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Saryusz-Wolski, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Siekierski, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Surján, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wojciechowski, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zaleski, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina, Zwiefka

PSE: Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Berlinguer, Bösch, Busquin, Calabuig Rull, Carnero González, Cashman, Christensen, Correia, D'Alema, De Rossa, Díez González, Dührkop Dührkop, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ford, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Golik, Gomes, Gröner, Gruber, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Kósáné Kovács, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuc, Kuhne, Lambrinidis, Lavarra, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Siwiec, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Bielan, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański

Abstention: 15

IND/DEM: Coûteaux, Louis

NI: Baco, Bobošíková, Claeys, Czarnecki Marek Aleksander, Czarnecki Ryszard, Dillen, Kozlík, Mote, Rivera, Rutowicz, Vanhecke

PSE: Gurmai, Wiersma

Corrections to vote

| Against: | Jan Andersson |
| --- | --- |

Against:

Jan Andersson

21.   Report: Grossetête A6-0247/2005

For: 214

ALDE: Geremek, Staniszewska, Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Borghezio, Chruszcz, Giertych, Grabowski, Karatzaferis, Krupa, Pęk, Piotrowski, Rogalski, Salvini, Sinnott, Speroni, Tomczak, Zapałowski, Železný

NI: Allister, Bobošíková, Czarnecki Marek Aleksander, Czarnecki Ryszard, Martin Hans-Peter, Masiel, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Brok, Busuttil, Buzek, Casa, Chmielewski, Gál, Glattfelder, Gyürk, Handzlik, Jałowiecki, Járóka, Kaczmarek, Klich, Kudrycka, Kušķis, Kuźmiuk, Lewandowski, Olajos, Olbrycht, Őry, Pack, Pálfi, Peterle, Piskorski, Pleštinská, Podkański, Saryusz-Wolski, Schmitt Pál, Schöpflin, Seeberg, Siekierski, Surján, Szájer, Wojciechowski, Zaleski, Zwiefka

PSE: Andersson, Arif, Attard-Montalto, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Capoulas Santos, Casaca, Castex, Corbett, Corbey, Cottigny, De Keyser, Désir, De Vits, Douay, El Khadraoui, Estrela, Fazakas, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, Geringer de Oedenberg, Gierek, Golik, Grabowska, Grech, Hamon, Harangozó, Hazan, Hegyi, Howitt, Kósáné Kovács, Kuc, Laignel, Le Foll, Lienemann, McAvan, Martin David, Mastenbroek, Morgan, Muscat, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Siwiec, Stihler, Tabajdi, Trautmann, Van Lancker, Vaugrenard, Vergnaud, Wynn

UEN: Bielan, Camre, Fotyga, Janowski, Krasts, Kristovskis, Libicki, Roszkowski, Szymański, Vaidere, Zīle

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 444

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Chiesa, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Lynne, Maaten, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Starkevičiūtė, Sterckx, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis, Watson

IND/DEM: Batten, Bloom, Booth, Clark, Farage, Goudin, Knapman, Lundgren, Nattrass, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Oomen-Ruijten, Ouzký, Panayotopoulos-Cassiotou, Papastamkos, Pieper, Pīks, Pinheiro, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Arnaoutakis, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, Berger, Berlinguer, Bösch, Busquin, Calabuig Rull, Carnero González, Cashman, Christensen, Correia, D'Alema, De Rossa, Díez González, Dobolyi, Dührkop Dührkop, Ettl, Evans Robert, Falbr, Fava, Fernandes, García Pérez, Gebhardt, Glante, Goebbels, Gomes, Gröner, Gruber, Gurmai, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Lambrinidis, Lavarra, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, Madeira, Maňka, Mann Erika, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Crowley, Didžiokas, Foglietta, La Russa, Musumeci, Ó Neachtain, Pirilli, Ryan, Tatarella

Abstention: 13

IND/DEM: Coûteaux, Louis

NI: Baco, Claeys, Dillen, Kozlík, Mote, Mussolini, Rivera, Romagnoli, Vanhecke

PSE: Moscovici, Wiersma

Corrections to vote

| For: | Pervenche Berès, Gary Titley |
| --- | --- |
| Against: | Jan Andersson |

For:

Pervenche Berès, Gary Titley

Against:

Jan Andersson

22.   Report: Grossetête A6-0247/2005

For: 166

ALDE: Chiesa, Geremek, Maaten, Staniszewska, Szent-Iványi

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Grabowski, Krupa, Pęk, Piotrowski, Sinnott, Tomczak, Zapałowski

NI: Allister, Czarnecki Marek Aleksander, Czarnecki Ryszard, Martin Hans-Peter, Masiel, Mussolini, Romagnoli, Rutowicz

PPE-DE: Barsi-Pataky, Bauer, Becsey, Brok, Busuttil, Buzek, Casa, Cederschiöld, Chmielewski, Gál, Glattfelder, Gyürk, Handzlik, Jałowiecki, Járóka, Kaczmarek, Klich, Kudrycka, Kušķis, Kuźmiuk, Lewandowski, Olajos, Olbrycht, Őry, Pálfi, Piskorski, Pleštinská, Podkański, Saryusz-Wolski, Schmitt Pál, Schöpflin, Siekierski, Surján, Wojciechowski, Zaleski, Zwiefka

PSE: Andersson, Attard-Montalto, van den Berg, Berman, Bozkurt, van den Burg, Capoulas Santos, Casaca, Corbey, Estrela, Fazakas, Geringer de Oedenberg, Gierek, Golik, Grabowska, Grech, Harangozó, Kósáné Kovács, Kuc, Mastenbroek, Muscat, Siwiec, Tabajdi

UEN: Bielan, Camre, Fotyga, Janowski, Krasts, Kristovskis, Libicki, Roszkowski, Szymański, Zīle

Verts/ALE: Aubert, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Voggenhuber, Ždanoka

Against: 481

ALDE: Alvaro, Andrejevs, Andria, Attwooll, Beaupuy, Birutis, Bourlanges, Bowles, Budreikaitė, Busk, Carlshamre, Cavada, Chatzimarkakis, Cocilovo, Cornillet, Costa, Davies, Degutis, Deprez, De Sarnez, Di Pietro, Drčar Murko, Duff, Duquesne, Ek, Fourtou, Gentvilas, Gibault, Griesbeck, Guardans Cambó, Hall, Harkin, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lax, Lehideux, Malmström, Manders, Matsakis, Morillon, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Pistelli, Prodi, Resetarits, Ries, Samuelsen, Savi, Sbarbati, Schuth, Starkevičiūtė, Sterckx, Takkula, Toia, Väyrynen, Van Hecke, Virrankoski, Wallis

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Knapman, Lundgren, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, De Michelis, Gollnisch, Helmer, Lang, Le Pen Marine, Martinez, Mölzer, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Dombrovskis, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Liese, Lombardo, Lulling, Maat, McGuinness, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Oomen-Ruijten, Ouzký, Pack, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Arif, Arnaoutakis, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berès, Berger, Berlinguer, Bösch, Bono, Bourzai, Bullmann, Busquin, Calabuig Rull, Carlotti, Carnero González, Cashman, Castex, Christensen, Corbett, Correia, Cottigny, D'Alema, De Keyser, De Rossa, Désir, De Vits, Díez González, Dobolyi, Douay, Dührkop Dührkop, El Khadraoui, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ferreira Anne, Ferreira Elisa, Ford, Fruteau, García Pérez, Gebhardt, Glante, Goebbels, Gomes, Gröner, Gruber, Guy-Quint, Hänsch, Hamon, Hasse Ferreira, Haug, Hazan, Hedh, Hedkvist Petersen, Hegyi, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Laignel, Lambrinidis, Lavarra, Le Foll, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Lienemann, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Patrie, Peillon, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Poignant, Prets, Rapkay, Rasmussen, Reynaud, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Roure, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Thomsen, Titley, Trautmann, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vaugrenard, Vergnaud, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Crowley, Didžiokas, La Russa, Musumeci, Ó Neachtain, Pirilli, Ryan, Tatarella, Vaidere

Abstention: 22

ALDE: Hennis-Plasschaert, Watson

IND/DEM: Coûteaux, Goudin, Karatzaferis, Louis, Rogalski, Železný

NI: Baco, Bobošíková, Claeys, Dillen, Kozlík, Mote, Rivera, Vanhecke

PPE-DE: McMillan-Scott

PSE: Gurmai, Matsouka, Moscovici, Wiersma

UEN: Foglietta

Corrections to vote

| Against: | Jan Andersson |
| --- | --- |

Against:

Jan Andersson

23.   Report: Grossetête A6-0247/2005

For: 229

ALDE: Andrejevs, Attwooll, Bowles, Budreikaitė, Busk, Carlshamre, Chatzimarkakis, Chiesa, Costa, Davies, Degutis, Di Pietro, Drčar Murko, Duff, Ek, Gentvilas, Geremek, Guardans Cambó, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Kacin, Karim, Lax, Lynne, Maaten, Malmström, Manders, Matsakis, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Resetarits, Samuelsen, Savi, Staniszewska, Starkevičiūtė, Szent-Iványi, Väyrynen, Van Hecke, Wallis, Watson

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Toussas, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Grabowski, Karatzaferis, Krupa, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Zapałowski

NI: Allister, Claeys, Czarnecki Marek Aleksander, Czarnecki Ryszard, Dillen, Gollnisch, Martin Hans-Peter, Masiel, Rutowicz, Vanhecke

PPE-DE: Barsi-Pataky, Bauer, Becsey, Busuttil, Buzek, Casa, Chmielewski, Dombrovskis, Gál, Glattfelder, Gyürk, Handzlik, Jałowiecki, Járóka, Kaczmarek, Klich, Kudrycka, Kuźmiuk, Lewandowski, Olajos, Olbrycht, Őry, Pálfi, Piskorski, Pleštinská, Podkański, Saryusz-Wolski, Schmitt Pál, Schöpflin, Siekierski, Surján, Szájer, Wojciechowski, Zaleski, Zwiefka

PSE: Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Carlotti, Casaca, Castex, Corbey, Cottigny, Désir, Douay, Estrela, Fazakas, Ferreira Anne, Ferreira Elisa, Fruteau, Golik, Grabowska, Grech, Hamon, Harangozó, Hazan, Hegyi, Kósáné Kovács, Kuc, Laignel, Le Foll, Lienemann, Mastenbroek, Muscat, Patrie, Peillon, Poignant, Reynaud, Roure, Savary, Siwiec, Tabajdi, Trautmann, Vaugrenard, Vergnaud

UEN: Bielan, Camre, Janowski, Libicki, Roszkowski, Szymański

Verts/ALE: Aubert, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Voggenhuber, Ždanoka

Against: 419

ALDE: Andria, Beaupuy, Birutis, Bourlanges, Cavada, Cocilovo, Cornillet, Deprez, De Sarnez, Duquesne, Fourtou, Gibault, Griesbeck, Klinz, Krahmer, Laperrouze, Lehideux, Morillon, Pistelli, Prodi, Ries, Sbarbati, Sterckx, Takkula, Virrankoski

IND/DEM: Batten, Bloom, Booth, Borghezio, Clark, Farage, Knapman, Lundgren, Nattrass, Salvini, Speroni, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, De Michelis, Helmer, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Mussolini, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Beazley, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Bushill-Matthews, Cabrnoch, Callanan, Carollo, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fernández Martín, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Hannan, Harbour, Hatzidakis, Heaton-Harris, Hennicot-Schoepges, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kušķis, Lamassoure, Landsbergis, Langen, Langendries, Lauk, Lechner, Lehne, Liese, Lombardo, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Oomen-Ruijten, Ouzký, Pack, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Saïfi, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schnellhardt, Schröder, Schwab, Seeber, Seeberg, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Sumberg, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Varela Suanzes-Carpegna, Vatanen, Ventre, Vernola, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Andersson, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Bösch, Bullmann, Busquin, Calabuig Rull, Capoulas Santos, Carnero González, Cashman, Christensen, Corbett, Correia, D'Alema, De Keyser, De Rossa, De Vits, Díez González, Dobolyi, Dührkop Dührkop, El Khadraoui, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ford, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Gomes, Gröner, Gruber, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jöns, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Lambrinidis, Lavarra, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Paleckis, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Crowley, Didžiokas, Foglietta, Kristovskis, La Russa, Musumeci, Ó Neachtain, Pirilli, Ryan, Tatarella, Vaidere, Zīle

Abstention: 15

ALDE: Alvaro, Schuth

IND/DEM: Goudin, Louis, Železný

NI: Baco, Bobošíková, Kozlík, Mote, Rivera, Romagnoli

PSE: Gurmai, Moscovici, Wiersma

UEN: Fotyga

Corrections to vote

| For: | Claude Turmes |
| --- | --- |
| Against: | Bruno Gollnisch, Jorgo Chatzimarkakis |

For:

Claude Turmes

Against:

Bruno Gollnisch, Jorgo Chatzimarkakis

24.   Report: Grossetête A6-0247/2005

For: 198

ALDE: Andrejevs, Attwooll, Birutis, Budreikaitė, Busk, Carlshamre, Chiesa, Costa, Davies, Degutis, Di Pietro, Drčar Murko, Duff, Gentvilas, Geremek, Hall, Harkin, Hennis-Plasschaert, in 't Veld, Jäätteenmäki, Jensen, Juknevičienė, Lax, Maaten, Malmström, Manders, Matsakis, Mulder, Newton Dunn, Nicholson of Winterbourne, Onyszkiewicz, Ortuondo Larrea, Oviir, Resetarits, Samuelsen, Savi, Staniszewska, Starkevičiūtė, Szent-Iványi, Väyrynen, Van Hecke, Virrankoski, Wallis

GUE/NGL: Adamou, Agnoletto, Bertinotti, Brie, Catania, de Brún, Figueiredo, Flasarová, Guerreiro, Guidoni, Henin, Kaufmann, Kohlíček, Krarup, Liotard, Markov, Maštálka, Meijer, Meyer Pleite, Morgantini, Musacchio, Papadimoulis, Pflüger, Portas, Remek, Rizzo, Seppänen, Sjöstedt, Strož, Svensson, Triantaphyllides, Uca, Wurtz, Zimmer

IND/DEM: Belder, Blokland, Bonde, Chruszcz, Giertych, Grabowski, Krupa, Pęk, Piotrowski, Rogalski, Sinnott, Tomczak, Zapałowski

NI: Bobošíková, Claeys, Dillen, Masiel, Mussolini, Romagnoli

PPE-DE: Buzek, Chmielewski, Dombrovskis, Handzlik, Jałowiecki, Kaczmarek, Klich, Kudrycka, Kuźmiuk, Lewandowski, Olbrycht, Piskorski, Pleštinská, Podkański, Saryusz-Wolski, Siekierski, Surján, Varela Suanzes-Carpegna, Zaleski, Zwiefka

PSE: Arif, Berès, van den Berg, Berman, Bono, Bourzai, Bozkurt, van den Burg, Carlotti, Casaca, Castex, Corbey, Désir, Douay, Estrela, Fazakas, Ferreira Anne, Fruteau, Golik, Grabowska, Harangozó, Hazan, Hegyi, Kósáné Kovács, Kuc, Laignel, Lavarra, Le Foll, Lienemann, Mastenbroek, Patrie, Peillon, Poignant, Reynaud, Roure, Siwiec, Tabajdi, Trautmann, Vaugrenard, Vergnaud

UEN: Camre

Verts/ALE: Aubert, Auken, Beer, Bennahmias, Breyer, Buitenweg, Cohn-Bendit, Cramer, Evans Jillian, Flautre, Frassoni, Graefe zu Baringdorf, de Groen-Kouwenhoven, Hammerstein Mintz, Harms, Hassi, Horáček, Hudghton, Isler Béguin, Joan i Marí, Jonckheer, Kallenbach, Kusstatscher, Lagendijk, Lambert, Lichtenberger, Lipietz, Lucas, Özdemir, Onesta, Romeva i Rueda, Rühle, Schlyter, Schmidt, Schroedter, Smith, Staes, Trüpel, Turmes, Voggenhuber, Ždanoka

Against: 441

ALDE: Andria, Beaupuy, Bourlanges, Cavada, Chatzimarkakis, Cornillet, Deprez, De Sarnez, Duquesne, Fourtou, Gibault, Griesbeck, Guardans Cambó, Kacin, Karim, Klinz, Krahmer, Laperrouze, Lehideux, Lynne, Morillon, Pistelli, Prodi, Ries, Sbarbati, Schuth, Sterckx, Takkula

IND/DEM: Batten, Booth, Borghezio, Clark, Farage, Goudin, Knapman, Lundgren, Nattrass, Speroni, Titford, Whittaker, Wise, Wohlin

NI: Battilocchio, Belohorská, Czarnecki Marek Aleksander, Czarnecki Ryszard, De Michelis, Gollnisch, Helmer, Lang, Le Pen Jean-Marie, Le Pen Marine, Martinez, Mölzer, Rutowicz, Schenardi

PPE-DE: Albertini, Andrikienė, Antoniozzi, Ashworth, Atkins, Audy, Ayuso González, Bachelot-Narquin, Barsi-Pataky, Bauer, Beazley, Becsey, Belet, Berend, Böge, Bonsignore, Bowis, Bradbourn, Braghetto, Brejc, Brepoels, Březina, Brok, Brunetta, Busuttil, Cabrnoch, Callanan, Carollo, Casa, Caspary, Castiglione, del Castillo Vera, Cederschiöld, Cesa, Chichester, Coelho, Coveney, Demetriou, Descamps, Deß, Deva, De Veyrac, Díaz de Mera García Consuegra, Dimitrakopoulos, Dionisi, Doorn, Dover, Doyle, Duchoň, Duka-Zólyomi, Ebner, Ehler, Elles, Esteves, Eurlings, Evans Jonathan, Fajmon, Fatuzzo, Ferber, Fjellner, Florenz, Fontaine, Fraga Estévez, Freitas, Friedrich, Gahler, Gál, Gaľa, Galeote Quecedo, García-Margallo y Marfil, Gargani, Garriga Polledo, Gaubert, Gauzès, Gawronski, Gklavakis, Glattfelder, Goepel, Gomolka, Graça Moura, Gräßle, de Grandes Pascual, Grosch, Grossetête, Guellec, Gyürk, Hannan, Harbour, Hatzidakis, Heaton-Harris, Herranz García, Herrero-Tejedor, Hieronymi, Higgins, Hökmark, Hoppenstedt, Hudacký, Hybášková, Ibrisagic, Itälä, Iturgaiz Angulo, Járóka, Jarzembowski, Jeggle, Jordan Cizelj, Kamall, Karas, Kasoulides, Kelam, Kirkhope, Klamt, Klaß, Koch, Konrad, Korhola, Kratsa-Tsagaropoulou, Kušķis, Lamassoure, Langen, Langendries, Lauk, Lehne, Liese, Lulling, Maat, McGuinness, McMillan-Scott, Mann Thomas, Mantovani, Marques, Martens, Mathieu, Mato Adrover, Matsis, Mauro, Mavrommatis, Mayer, Mayor Oreja, Méndez de Vigo, Mikolášik, Millán Mon, Mitchell, Montoro Romero, Musotto, Nassauer, Nicholson, Niebler, van Nistelrooij, Novak, Olajos, Oomen-Ruijten, Őry, Ouzký, Pack, Pálfi, Panayotopoulos-Cassiotou, Papastamkos, Peterle, Pieper, Pīks, Pinheiro, Podestà, Poettering, Pomés Ruiz, Posselt, Purvis, Queiró, Rack, Radwan, Reul, Ribeiro e Castro, Roithová, Rudi Ubeda, Rübig, Salafranca Sánchez-Neyra, Samaras, Sartori, Schierhuber, Schmitt Pál, Schnellhardt, Schöpflin, Schröder, Schwab, Seeber, Seeberg, Silva Peneda, Škottová, Sommer, Spautz, Stenzel, Stevenson, Strejček, Stubb, Sturdy, Sudre, Szájer, Tajani, Tannock, Thyssen, Toubon, Trakatellis, Ulmer, Vakalis, Van Orden, Vatanen, Ventre, Vidal-Quadras Roca, Vlasák, Vlasto, Weber Manfred, Weisgerber, Wieland, Wijkman, von Wogau, Wortmann-Kool, Wuermeling, Záborská, Zahradil, Zappalà, Zatloukal, Zieleniec, Zimmerling, Zvěřina

PSE: Andersson, Arnaoutakis, Attard-Montalto, Ayala Sender, Badía i Cutchet, Barón Crespo, Batzeli, Beglitis, Beňová, Berger, Berlinguer, Bösch, Busquin, Calabuig Rull, Capoulas Santos, Carnero González, Cashman, Christensen, Corbett, Correia, Cottigny, D'Alema, De Keyser, De Rossa, De Vits, Díez González, Dobolyi, Dührkop Dührkop, El Khadraoui, Ettl, Evans Robert, Falbr, Fava, Fernandes, Ferreira Elisa, Ford, García Pérez, Gebhardt, Geringer de Oedenberg, Gierek, Glante, Goebbels, Gomes, Grech, Gröner, Gruber, Gurmai, Hänsch, Hasse Ferreira, Haug, Hedh, Hedkvist Petersen, Herczog, Honeyball, Howitt, Hughes, Hutchinson, Ilves, Jørgensen, Kindermann, Kinnock, Koterec, Krehl, Kreissl-Dörfler, Kristensen, Kuhne, Lambrinidis, Lehtinen, Leichtfried, Leinen, Lévai, Liberadzki, Locatelli, McAvan, Madeira, Maňka, Mann Erika, Martin David, Martínez Martínez, Masip Hidalgo, Matsouka, Medina Ortega, Menéndez del Valle, Miguélez Ramos, Mikko, Moraes, Moreno Sánchez, Morgan, Muscat, Myller, Napoletano, Navarro, Obiols i Germà, Öger, Paasilinna, Pahor, Piecyk, Pinior, Pittella, Pleguezuelos Aguilar, Prets, Rapkay, Rasmussen, Riera Madurell, Roth-Behrendt, Rothe, Rouček, Sacconi, Sakalas, Salinas García, Sánchez Presedo, Savary, Scheele, Schulz, Segelström, Sifunakis, Skinner, Sornosa Martínez, Sousa Pinto, Stihler, Stockmann, Swoboda, Szejna, Tarabella, Tarand, Thomsen, Titley, Tzampazi, Valenciano Martínez-Orozco, Van Lancker, Vincenzi, Walter, Weber Henri, Weiler, Westlund, Whitehead, Wynn, Xenogiannakopoulou, Yañez-Barnuevo García, Zani, Zingaretti

UEN: Angelilli, Aylward, Berlato, Bielan, Crowley, Didžiokas, Foglietta, Fotyga, Janowski, Kristovskis, La Russa, Libicki, Musumeci, Ó Neachtain, Pirilli, Roszkowski, Ryan, Szymański, Tatarella, Vaidere, Zīle

Abstention: 17

ALDE: Alvaro, Ek

GUE/NGL: Toussas

IND/DEM: Coûteaux, Karatzaferis, Železný

NI: Allister, Baco, Kozlík, Martin Hans-Peter, Mote, Rivera, Vanhecke

PPE-DE: Landsbergis

PSE: Guy-Quint, Moscovici, Wiersma

---

TEXTS ADOPTED

P6_TA(2005)0323

Mobilisation of the flexibility instrument (Tsunami)

European Parliament resolution on the proposal for a decision of the European Parliament and of the Council on the mobilisation of the flexibility instrument in favour of the rehabilitation and reconstruction assistance to Tsunami affected countries according to point 24 of the Interinstitutional Agreement of 6 May 1999 (SEC(2005)0548 — C6-0127/2005 — 2005/2083(ACI))

The European Parliament,

| — | having regard to the Commission proposal (SEC(2005)0548 — C6-0127/2005), |
| --- | --- |

—

having regard to the Commission proposal (SEC(2005)0548 — C6-0127/2005),

| — | having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1),

| — | having regard to the outcome of the trialogue of 11 July 2005, |
| --- | --- |

—

having regard to the outcome of the trialogue of 11 July 2005,

| — | having regard to the report of the Committee on Budgets (A6-0254/2005), |
| --- | --- |

—

having regard to the report of the Committee on Budgets (A6-0254/2005),

| A. | whereas the possibility of an EU contribution to the reconstruction of the Tsunami-affected countries was absolutely unforeseeable when the financial perspectives were adopted on 6 May 1999, |
| --- | --- |

A.

whereas the possibility of an EU contribution to the reconstruction of the Tsunami-affected countries was absolutely unforeseeable when the financial perspectives were adopted on 6 May 1999,

| B. | whereas the pledge of EUR 350 million made by the Commission on behalf of the European Union at the Jakarta Tsunami Aid Conference of 6 January 2005 to set up the Community's contribution to the Tsunami-affected countries' rehabilitation and reconstruction was preceded by prior consultation of the budgetary authority, |
| --- | --- |

B.

whereas the pledge of EUR 350 million made by the Commission on behalf of the European Union at the Jakarta Tsunami Aid Conference of 6 January 2005 to set up the Community's contribution to the Tsunami-affected countries' rehabilitation and reconstruction was preceded by prior consultation of the budgetary authority,

| C. | whereas the Parliament entered an amount of EUR 123 million as emergency aid in the 2005 budget for the Tsunami-affected countries without reducing the funding for existing policies, |
| --- | --- |

C.

whereas the Parliament entered an amount of EUR 123 million as emergency aid in the 2005 budget for the Tsunami-affected countries without reducing the funding for existing policies,

| D. | recalling that, according to point 24 of the Interinstitutional Agreement of 6 May 1999, the portion of the annual amount which is not used may be carried over up to the year n+2 and that, if the instrument is mobilised, any carryovers will be drawn on in order of age; taking the view, therefore, that the mobilised amount of EUR 15 million is coming from the amount carried over from the year 2004; noting also that, after this mobilisation, the amount remaining available for 2005 under the flexibility instrument will be EUR 293 million, |
| --- | --- |

D.

recalling that, according to point 24 of the Interinstitutional Agreement of 6 May 1999, the portion of the annual amount which is not used may be carried over up to the year n+2 and that, if the instrument is mobilised, any carryovers will be drawn on in order of age; taking the view, therefore, that the mobilised amount of EUR 15 million is coming from the amount carried over from the year 2004; noting also that, after this mobilisation, the amount remaining available for 2005 under the flexibility instrument will be EUR 293 million,

| E. | recalling that, on 7 January 2005, the Council committed to ensuring that any resources released in this context are additional to commitments already made, |
| --- | --- |

E.

recalling that, on 7 January 2005, the Council committed to ensuring that any resources released in this context are additional to commitments already made,

| 1. | Stresses that the mobilisation of the flexibility instrument provided for in point 24 of the Interinstitutional Agreement of 6 May 1999 was decided in December 2004 for 2005, as the necessary funding to face international crises since 2000 could not be provided within the initial ceilings of heading 4 of the financial perspective; |
| --- | --- |

1.

Stresses that the mobilisation of the flexibility instrument provided for in point 24 of the Interinstitutional Agreement of 6 May 1999 was decided in December 2004 for 2005, as the necessary funding to face international crises since 2000 could not be provided within the initial ceilings of heading 4 of the financial perspective;

| 2. | Is willing to provide the European Union with the means appropriate to assuming its new responsibilities in the world, without affecting its traditional priorities; |
| --- | --- |

2.

Is willing to provide the European Union with the means appropriate to assuming its new responsibilities in the world, without affecting its traditional priorities;

| 3. | Approves, therefore, the decision, annexed to this resolution, to further mobilise the flexibility instrument provided for in point 24 of the Interinstitutional Agreement; |
| --- | --- |

3.

Approves, therefore, the decision, annexed to this resolution, to further mobilise the flexibility instrument provided for in point 24 of the Interinstitutional Agreement;

| 4. | Nevertheless criticises the Council's unwillingness to mobilise the flexibility instrument in the amount of EUR 98 million, as proposed by the Commission, which delayed adoption of the decision to mobilise the flexibility instrument; |
| --- | --- |

4.

Nevertheless criticises the Council's unwillingness to mobilise the flexibility instrument in the amount of EUR 98 million, as proposed by the Commission, which delayed adoption of the decision to mobilise the flexibility instrument;

| 5. | Instructs its President to forward this resolution, including the Annex, to the Council and to the Commission for information. |
| --- | --- |

5.

Instructs its President to forward this resolution, including the Annex, to the Council and to the Commission for information.

---

(1)  OJ C 172 of 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

ANNEX

DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 7 September 2005

on the mobilisation of the flexibility instrument in favour of the rehabilitation and reconstruction assistance to Tsunami affected countries according to point 24 of the Interinstitutional Agreement of 6 May 1999

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1), and in particular point 24 thereof,

Having regard to the proposal from the Commission,

Whereas:

The Budget Authority has agreed to support the rehabilitation and reconstruction needs in the earthquake/Tsunami affected countries (mainly Indonesia, Sri Lanka and the Maldives,) for a total amount of EUR 350 million, of which EUR 170 million in 2005, part of the required response will be delivered by redefining indicative and not yet committed programmes for the region in agreement with the governments concerned (EUR 60 million), by recourse to the Rapid Reaction Mechanism (EUR 12 million) and by the mobilisation of the emergency reserve (EUR 70 million). Since the ceiling for Heading 4: ‘External actions’ is already exceeded by EUR 100 million in 2005, and all possibilities for re-allocating appropriations under this heading have been examined, EUR 15 million will be financed by an additional deployment of the flexibility instrument.

HAVE DECIDED AS FOLLOWS:

Article 1

For the amending budget No 4/2005 to the general budget of the European Union for the financial year 2005, the flexibility instrument shall be used to provide the sum of EUR 15 000 000 in commitment appropriations.

This amount shall be used for the financing of the aid for rehabilitation and reconstruction of the earthquake/Tsunami affected countries in Asia, covered by Heading 4 ‘External actions’ of the financial perspective, under the article 19 10 04 ‘Rehabilitation and reconstruction operations in developing countries in Asia’ of the 2005 budget.

Article 2

This Decision shall be published in the Official Journal of the European Union.

Done at Strasbourg, 7 September 2005

For the European Parliament

The President

For the Council

The President

---

(1)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

1

P6_TA(2005)0324

Mobilisation of the European Union Solidarity Fund

European Parliament resolution on the proposal for a decision of the European Parliament and of the Council on the mobilisation of the European Union Solidarity Fund according to point 3 of the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (COM(2005)0247 — C6-0183/2005 — 2005/2127(ACI))

The European Parliament,

| — | having regard to the Commission proposal (COM(2005)0247 — C6-0183/2005), |
| --- | --- |

—

having regard to the Commission proposal (COM(2005)0247 — C6-0183/2005),

| — | having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1),

| — | having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (2), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (2),

| — | having regard to Council Regulation (EC) No 2012/2002 of 11 November 2002 establishing the European Union Solidarity Fund (3), |
| --- | --- |

—

having regard to Council Regulation (EC) No 2012/2002 of 11 November 2002 establishing the European Union Solidarity Fund (3),

| — | having regard to its position of 10 October 2002 on the proposal for a Council regulation establishing the European Union Solidarity Fund (4), |
| --- | --- |

—

having regard to its position of 10 October 2002 on the proposal for a Council regulation establishing the European Union Solidarity Fund (4),

| — | having regard to the results of the Trialogue of 22 June 2005, |
| --- | --- |

—

having regard to the results of the Trialogue of 22 June 2005,

| — | having regard to the report of the Committee on Budgets (A6-0229/2005), |
| --- | --- |

—

having regard to the report of the Committee on Budgets (A6-0229/2005),

| A. | whereas the European Union has set up the appropriate institutional and budgetary instruments to provide financial assistance in relation to damage resulting from major natural disasters, |
| --- | --- |

A.

whereas the European Union has set up the appropriate institutional and budgetary instruments to provide financial assistance in relation to damage resulting from major natural disasters,

| B. | whereas Slovakia has requested assistance in relation to the damage resulting from the storm of 19 and 20 November 2004, |
| --- | --- |

B.

whereas Slovakia has requested assistance in relation to the damage resulting from the storm of 19 and 20 November 2004,

| 1. | Calls on the Commission to present a concise quantitative assessment of the initial instances of Fund intervention, and particularly the implementation criteria according to Article 2(2) of Regulation (EC) No 2012/2002, so that the European Parliament can evaluate the Fund's operation; |
| --- | --- |

1.

Calls on the Commission to present a concise quantitative assessment of the initial instances of Fund intervention, and particularly the implementation criteria according to Article 2(2) of Regulation (EC) No 2012/2002, so that the European Parliament can evaluate the Fund's operation;

| 2. | Approves the decision annexed to this resolution on the mobilisation of the EU Solidarity Fund; |
| --- | --- |

2.

Approves the decision annexed to this resolution on the mobilisation of the EU Solidarity Fund;

| 3. | Instructs its President to forward this resolution, including the Annex, to the Council and to the Commission for information. |
| --- | --- |

3.

Instructs its President to forward this resolution, including the Annex, to the Council and to the Commission for information.

---

(1)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

(2)  OJ C 283, 20.11.2002, p. 1.

(3)  OJ L 311, 14.11.2002, p. 3.

(4)  OJ C 279 E, 20.11.2003, p. 118.

ANNEX

DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 7 September 2005

on the mobilisation of the European Union Solidarity Fund according to point 3 of the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (1), and in particular point 3 thereof,

Having regard to Council Regulation (EC) No 2012/2002 of 11 November 2002 establishing the European Union Solidarity Fund (2),

Having regard to the proposal from the Commission,

Whereas:

| (1) | The European Union has created a Solidarity Fund (the ‘Fund’) to show solidarity with the population of regions struck by disasters. |
| --- | --- |

(1)

The European Union has created a Solidarity Fund (the ‘Fund’) to show solidarity with the population of regions struck by disasters.

| (2) | Slovakia submitted an application to mobilise the Fund on 24 January 2005, following a disaster caused by a storm. |
| --- | --- |

(2)

Slovakia submitted an application to mobilise the Fund on 24 January 2005, following a disaster caused by a storm.

| (3) | The Interinstitutional Agreement of 7 November 2002 allows mobilisation of the Fund within an annual ceiling of EUR 1 billion. |
| --- | --- |

(3)

The Interinstitutional Agreement of 7 November 2002 allows mobilisation of the Fund within an annual ceiling of EUR 1 billion.

| (4) | The storm disaster in Slovakia in November 2004 fulfils the criteria for mobilising the European Union Solidarity Fund, |
| --- | --- |

(4)

The storm disaster in Slovakia in November 2004 fulfils the criteria for mobilising the European Union Solidarity Fund,

HAVE ADOPTED THIS DECISION:

Article 1

The European Union Solidarity Fund shall be mobilised to provide the sum of EUR 5 667 578 in commitment appropriations from the general budget of the European Union for the financial year 2005.

Article 2

This Decision shall be published in the Official Journal of the European Union.

Done at Strasbourg, 7 September 2005

For the European Parliament

The President

For the Council

The President

---

(1)  OJ C 283, 20.11.2002, p. 1.

1

(2)  OJ L 311, 14.11.2002, p. 3.

2

P6_TA(2005)0325

Revision of the financial perspective 2000-2006

European Parliament resolution on the proposal for a decision of the European Parliament and the Council on the revision of the financial perspective 2000-2006 (COM(2004)0666 — C6-0219/2004 — 2004/2222(ACI))

The European Parliament,

| — | having regard to the Commission proposal to the European Parliament and the Council (COM(2004) 0666 — C6-0219/2004), |
| --- | --- |

—

having regard to the Commission proposal to the European Parliament and the Council (COM(2004) 0666 — C6-0219/2004),

| — | having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1),

| — | having regard to the outcome of the conciliation meeting of 15 July 2005 with the Council, |
| --- | --- |

—

having regard to the outcome of the conciliation meeting of 15 July 2005 with the Council,

| — | having regard to the report of the Committee on Budgets (A6-0252/2005), |
| --- | --- |

—

having regard to the report of the Committee on Budgets (A6-0252/2005),

| A. | whereas Council Regulation (EC) No 1782/2003 of 29 September 2003 establishing common rules for direct support schemes under the common agricultural policy and establishing certain support schemes for farmers and amending Regulations (EEC) No 2019/93, (EC) No 1452/2001, (EC) No 1453/2001, (EC) No 1454/2001, (EC) 1868/94, (EC) No 1251/1999, (EC) No 1254/1999, (EC) No 1673/2000, (EEC) No 2358/71 and (EC) No 2529/2001 (2) provides for a reduction in direct payments (‘modulation’) to finance rural development policy, |
| --- | --- |

A.

whereas Council Regulation (EC) No 1782/2003 of 29 September 2003 establishing common rules for direct support schemes under the common agricultural policy and establishing certain support schemes for farmers and amending Regulations (EEC) No 2019/93, (EC) No 1452/2001, (EC) No 1453/2001, (EC) No 1454/2001, (EC) 1868/94, (EC) No 1251/1999, (EC) No 1254/1999, (EC) No 1673/2000, (EEC) No 2358/71 and (EC) No 2529/2001 (2) provides for a reduction in direct payments (‘modulation’) to finance rural development policy,

| B. | whereas as a result, part of the commitment appropriations currently foreseen for direct payments under subheading 1a ‘Common Agricultural Policy’ of the financial perspective will be transferred to subheading 1b ‘Rural development’, |
| --- | --- |

B.

whereas as a result, part of the commitment appropriations currently foreseen for direct payments under subheading 1a ‘Common Agricultural Policy’ of the financial perspective will be transferred to subheading 1b ‘Rural development’,

| C. | whereas this transfer will have no effect on the overall ceiling of heading 1 ‘Agriculture’ since modulation simply implies a zero-sum shift between its two subheadings, |
| --- | --- |

C.

whereas this transfer will have no effect on the overall ceiling of heading 1 ‘Agriculture’ since modulation simply implies a zero-sum shift between its two subheadings,

| D. | whereas the Commission proposal had to be modified to reflect the outcome of the conciliation meetings of 25 November 2004 and 15 July 2005, |
| --- | --- |

D.

whereas the Commission proposal had to be modified to reflect the outcome of the conciliation meetings of 25 November 2004 and 15 July 2005,

| 1. | Stresses its willingness to allow the transfer of funds from subheading 1a to subheading 1b, in line with the adopted reform of the Common Agricultural Policy, through a formal revision of the subceilings according to the procedures set out in the Interinstitutional Agreement of 6 May 1999; |
| --- | --- |

1.

Stresses its willingness to allow the transfer of funds from subheading 1a to subheading 1b, in line with the adopted reform of the Common Agricultural Policy, through a formal revision of the subceilings according to the procedures set out in the Interinstitutional Agreement of 6 May 1999;

| 2. | Approves the decision annexed to this resolution, including the tables of the financial perspective as revised; |
| --- | --- |

2.

Approves the decision annexed to this resolution, including the tables of the financial perspective as revised;

| 3. | Instructs its President to sign the act with the President of the Council; |
| --- | --- |

3.

Instructs its President to sign the act with the President of the Council;

| 4. | Instructs its President to forward this resolution, including the Annex, to the Council and to the Commission for information. |
| --- | --- |

4.

Instructs its President to forward this resolution, including the Annex, to the Council and to the Commission for information.

---

(1)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

(2)  OJ L 270, 21.10.2003, p. 1.

ANNEX I

DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 7 September 2005

on the revision of the financial perspective 2000-2006

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community,

Having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (1), and in particular to points 19, 20 and 21 thereof,

Having regard to Decision 2003/430/EC of the European Parliament and of the Council of 19 May 2003 on the revision of the financial perspective (2),

Having regard to the proposals from the Commission,

Acting in accordance with the procedure laid down in the fifth subparagraph of Article 272(9) of the Treaty (3),

Whereas:

The reform of the common agricultural policy adopted by the Council in September 2003 (4) provides for a reduction in direct payments (‘modulation’) to finance rural development policy to achieve a better balance between policy tools designed to promote sustainable agriculture and those designed to promote rural development and to finance additional rural development measures. The financial perspective set out in Annex I to the Interinstitutional Agreement on budgetary discipline and improvement of the budgetary procedure as revised by Decision 2003/430/EC of the European Parliament and of the Council, hereinafter referred to as the ‘financial perspective’, should therefore be modified to take into account the effect of ‘modulation’ for the year 2006. As a consequence, commitment appropriations from subheading 1a ‘Common Agricultural Policy’ can be used to finance additional measures under subheading 1b ‘Rural development’, with no change in the ceiling of heading 1 ‘Agriculture’.

HAVE DECIDED AS FOLLOWS:

Article 1

The financial perspective is revised as follows:

The annual ceilings for appropriations for commitments in heading 1 of Table 1a, Table 1b, Table 2a and Table 2b shall be amended as follows:

| (a) | the figure for the subheading 1a ‘Common Agricultural Policy’ shall be reduced in 2006 by the amount corresponding to the modulation;






  Reduced amounts in Common Agricultural Policy | 2006 |
| --- | --- | --- |
| EUR million at 1999 prices | - 570 |
| EUR million at 2006 prices | - 655 |

(a)

the figure for the subheading 1a ‘Common Agricultural Policy’ shall be reduced in 2006 by the amount corresponding to the modulation;

Reduced amounts in Common Agricultural Policy

2006

EUR million at 1999 prices

- 570

EUR million at 2006 prices

- 655

| (b) | the figure for the subheading 1b ‘Rural Development’ shall be increased in 2006 by the amount corresponding to the modulation;






  Increased amounts in Rural Development | 2006 |
| --- | --- | --- |
| EUR million at 1999 prices | + 570 |
| EUR million at 2006 prices | + 655 |

(b)

the figure for the subheading 1b ‘Rural Development’ shall be increased in 2006 by the amount corresponding to the modulation;

Increased amounts in Rural Development

2006

EUR million at 1999 prices

- 570

EUR million at 2006 prices

- 655

Article 2

1.   The financial perspective for the European Union, in 1999 prices, is set out in Tables 1a and 1b in the Annex.

2.   The corresponding financial perspective resulting from the technical adjustment for 2005, in line with movements in Gross National Income (GNI) and prices, is set out in Tables 2a and 2b in the Annex.

Article 3

This decision shall be published in the Official Journal of the European Union.

Done at Strasbourg, 7 September 2005

For the European Parliament

The President

For the Council

The President

---

(1)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

1

(2)  OJ L 147, 14.6.2003, p. 31.

2

(3)  Decision of the European Parliament of 7 September 2005 and Decision of the Council of 18 July 2005.

3

(4)  Regulation (EC) No 1782/2003 (OJ L 270, 21.10.2003, p. 1).

4

ANNEX II

TABLE 1a: REVISED FINANCIAL PERSPECTIVE (EU-25) AT 1999 PRICES

| (EUR million) |
| --- |
| COMMITMENT APPROPRIATIONS | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
| 1. AGRICULTURE | 40 920 | 42 800 | 43 900 | 43 770 | 44 657 | 45 677 | 45 807 |
| 1a Common Agricultural Policy | 36 620 | 38 480 | 39 570 | 39 430 | 38 737 | 39 602 | 39 042 |
| 1b Rural development | 4 300 | 4 320 | 4 330 | 4 340 | 5 920 | 6 075 | 6 765 |
| 2. STRUCTURAL ACTIONS | 32 045 | 31 455 | 30 865 | 30 285 | 35 665 | 36 502 | 37 940 |
| Structural funds | 29 430 | 28 840 | 28 250 | 27 670 | 30 533 | 31 835 | 32 608 |
| Cohesion fund | 2 615 | 2 615 | 2 615 | 2 615 | 5 132 | 4 667 | 5 332 |
| 3. INTERNAL POLICIES | 5 930 | 6 040 | 6 150 | 6 260 | 7 877 | 8 098 | 8 212 |
| 4. EXTERNAL ACTIONS | 4 550 | 4 560 | 4 570 | 4 580 | 4 590 | 4 600 | 4 610 |
| 5. ADMINISTRATION
   (1) | 4 560 | 4 600 | 4 700 | 4 800 | 5 403 | 5 558 | 5 712 |
| 6. RESERVES | 900 | 900 | 650 | 400 | 400 | 400 | 400 |
| Monetary reserve | 500 | 500 | 250 | | | | |
| Emergency aid reserve | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
| Guarantee reserve | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
| 7. PRE-ACCESSION STRATEGY | 3 120 | 3 120 | 3 120 | 3 120 | 3 120 | 3 120 | 3 120 |
| Agriculture | 520 | 520 | 520 | 520 | | | |
| Pre-accession structural instrument | 1 040 | 1 040 | 1 040 | 1 040 | | | |
| PHARE (applicant countries) | 1 560 | 1 560 | 1 560 | 1 560 | | | |
| 8. COMPENSATION | | | | | 1 273 | 1 173 | 940 |
| TOTAL APPROPRIATIONS FOR COMMITMENTS | 92 025 | 93 475 | 93 955 | 93 215 | 102 985 | 105 128 | 106 741 |
| TOTAL APPROPRIATIONS FOR PAYMENTS | 89 600 | 91 110 | 94 220 | 94 880 | 100 800 | 101 600 | 103 840 |
| Ceiling, appropriations for payments as% of GNI (ESA 95) | 1,07% | 1,07% | 1,10% | 1,11% | 1,10% | 1,07% | 1,07% |
| Margin for unforeseen expenditure | 0,17% | 0,17% | 0,14% | 0,13% | 0,14% | 0,17% | 0,17% |
| Own resources ceiling | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% |

(EUR million)

COMMITMENT APPROPRIATIONS

2000

2001

2002

2003

2004

2005

2006

1. AGRICULTURE

40 920

42 800

43 900

43 770

44 657

45 677

45 807

1a Common Agricultural Policy

36 620

38 480

39 570

39 430

38 737

39 602

39 042

1b Rural development

4 300

4 320

4 330

4 340

5 920

6 075

6 765

2. STRUCTURAL ACTIONS

32 045

31 455

30 865

30 285

35 665

36 502

37 940

Structural funds

29 430

28 840

28 250

27 670

30 533

31 835

32 608

Cohesion fund

2 615

2 615

2 615

2 615

5 132

4 667

5 332

3. INTERNAL POLICIES

5 930

6 040

6 150

6 260

7 877

8 098

8 212

4. EXTERNAL ACTIONS

4 550

4 560

4 570

4 580

4 590

4 600

4 610

5. ADMINISTRATION
   (1)

4 560

4 600

4 700

4 800

5 403

5 558

5 712

6. RESERVES

900

900

650

400

400

400

400

Monetary reserve

500

500

250

Emergency aid reserve

200

200

200

200

200

200

200

Guarantee reserve

200

200

200

200

200

200

200

7. PRE-ACCESSION STRATEGY

3 120

3 120

3 120

3 120

3 120

3 120

3 120

Agriculture

520

520

520

520

Pre-accession structural instrument

1 040

1 040

1 040

1 040

PHARE (applicant countries)

1 560

1 560

1 560

1 560

8. COMPENSATION

1 273

1 173

940

TOTAL APPROPRIATIONS FOR COMMITMENTS

92 025

93 475

93 955

93 215

102 985

105 128

106 741

TOTAL APPROPRIATIONS FOR PAYMENTS

89 600

91 110

94 220

94 880

100 800

101 600

103 840

Ceiling, appropriations for payments as% of GNI (ESA 95)

1,07%

1,07%

1,10%

1,11%

1,10%

1,07%

1,07%

Margin for unforeseen expenditure

0,17%

0,17%

0,14%

0,13%

0,14%

0,17%

0,17%

Own resources ceiling

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

TABLE 1b: REVISED FINANCIAL PERSPECTIVE (EU-25) AT 1999 PRICES

(including budgetary implications of a political settlement in Cyprus)

| (EUR million) |
| --- |
| COMMITMENT APPROPRIATIONS | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
| 1. AGRICULTURE | 40 920 | 42 800 | 43 900 | 43 770 | 44 650 | 45 675 | 45 805 |
| 1a Common Agricultural Policy | 36 620 | 38 480 | 39 570 | 39 430 | 38 740 | 39 611 | 39 052 |
| 1b Rural development | 4 300 | 4 320 | 4 330 | 4 340 | 5 910 | 6 064 | 6 753 |
| 2. STRUCTURAL ACTIONS | 32 045 | 31 455 | 30 865 | 30 285 | 35 718 | 36 579 | 38 052 |
| Structural funds | 29 430 | 28 840 | 28 250 | 27 670 | 30 571 | 31 899 | 32 703 |
| Cohesion fund | 2 615 | 2 615 | 2 615 | 2 615 | 5 147 | 4 680 | 5 349 |
| 3. INTERNAL POLICIES | 5 930 | 6 040 | 6 150 | 6 260 | 7 891 | 8 112 | 8 226 |
| 4. EXTERNAL ACTIONS | 4 550 | 4 560 | 4 570 | 4 580 | 4 590 | 4 600 | 4 610 |
| 5. ADMINISTRATION
   (2) | 4 560 | 4 600 | 4 700 | 4 800 | 5 403 | 5 558 | 5 712 |
| 6. RESERVES | 900 | 900 | 650 | 400 | 400 | 400 | 400 |
| Monetary reserve | 500 | 500 | 250 | | | | |
| Emergency aid reserve | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
| Guarantee reserve | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
| 7. PRE-ACCESSION STRATEGY | 3 120 | 3 120 | 3 120 | 3 120 | 3 120 | 3 120 | 3 120 |
| Agriculture | 520 | 520 | 520 | 520 | | | |
| Pre-accession structural instrument | 1 040 | 1 040 | 1 040 | 1 040 | | | |
| PHARE (applicant countries) | 1 560 | 1 560 | 1 560 | 1 560 | | | |
| 8. COMPENSATION | | | | | 1 273 | 1 173 | 940 |
| TOTAL APPROPRIATIONS FOR COMMITMENTS | 92 025 | 93 475 | 93 955 | 93 215 | 103 045 | 105 218 | 106 865 |
| TOTAL APPROPRIATIONS FOR PAYMENTS | 89 600 | 91 110 | 94 220 | 94 880 | 100 800 | 101 600 | 103 840 |
| Ceiling, appropriations for payments as% of GNI (ESA 95) | 1,07% | 1,07% | 1,10% | 1,11% | 1,10% | 1,07% | 1,07% |
| Margin for unforeseen expenditure | 0,17% | 0,17% | 0,14% | 0,13% | 0,14% | 0,17% | 0,17% |
| Own resources ceiling | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% |

(EUR million)

COMMITMENT APPROPRIATIONS

2000

2001

2002

2003

2004

2005

2006

1. AGRICULTURE

40 920

42 800

43 900

43 770

44 650

45 675

45 805

1a Common Agricultural Policy

36 620

38 480

39 570

39 430

38 740

39 611

39 052

1b Rural development

4 300

4 320

4 330

4 340

5 910

6 064

6 753

2. STRUCTURAL ACTIONS

32 045

31 455

30 865

30 285

35 718

36 579

38 052

Structural funds

29 430

28 840

28 250

27 670

30 571

31 899

32 703

Cohesion fund

2 615

2 615

2 615

2 615

5 147

4 680

5 349

3. INTERNAL POLICIES

5 930

6 040

6 150

6 260

7 891

8 112

8 226

4. EXTERNAL ACTIONS

4 550

4 560

4 570

4 580

4 590

4 600

4 610

5. ADMINISTRATION
   (2)

4 560

4 600

4 700

4 800

5 403

5 558

5 712

6. RESERVES

900

900

650

400

400

400

400

Monetary reserve

500

500

250

Emergency aid reserve

200

200

200

200

200

200

200

Guarantee reserve

200

200

200

200

200

200

200

7. PRE-ACCESSION STRATEGY

3 120

3 120

3 120

3 120

3 120

3 120

3 120

Agriculture

520

520

520

520

Pre-accession structural instrument

1 040

1 040

1 040

1 040

PHARE (applicant countries)

1 560

1 560

1 560

1 560

8. COMPENSATION

1 273

1 173

940

TOTAL APPROPRIATIONS FOR COMMITMENTS

92 025

93 475

93 955

93 215

103 045

105 218

106 865

TOTAL APPROPRIATIONS FOR PAYMENTS

89 600

91 110

94 220

94 880

100 800

101 600

103 840

Ceiling, appropriations for payments as% of GNI (ESA 95)

1,07%

1,07%

1,10%

1,11%

1,10%

1,07%

1,07%

Margin for unforeseen expenditure

0,17%

0,17%

0,14%

0,13%

0,14%

0,17%

0,17%

Own resources ceiling

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

TABLE 2a: REVISED FINANCIAL PERSPECTIVE (EU-25) AT CURRENT PRICES

| (EUR million) |
| --- |
| COMMITMENT APPROPRIATIONS | Current prices |
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
| 1. AGRICULTURE | 41 738 | 44 530 | 46 587 | 47 378 | 49 305 | 51 439 | 52 618 |
| 1a Common Agricultural Policy | 37 352 | 40 035 | 41 992 | 42 680 | 42 769 | 44 598 | 44 847 |
| 1b Rural development | 4 386 | 4 495 | 4 595 | 4 698 | 6 536 | 6 841 | 7 771 |
| 2. STRUCTURAL ACTIONS | 32 678 | 32 720 | 33 638 | 33 968 | 41 035 | 42 441 | 44 617 |
| Structural funds | 30 019 | 30 005 | 30 849 | 31 129 | 35 353 | 37 247 | 38 523 |
| Cohesion fund | 2 659 | 2 715 | 2 789 | 2 839 | 5 682 | 5 194 | 6 094 |
| 3. INTERNAL POLICIES | 6 031 | 6 272 | 6 558 | 6 796 | 8 722 | 9 012 | 9 385 |
| 4. EXTERNAL ACTIONS | 4 627 | 4 735 | 4 873 | 4 972 | 5 082 | 5 119 | 5 269 |
| 5. ADMINISTRATION
   (3) | 4 638 | 4 776 | 5 012 | 5 211 | 5 983 | 6 185 | 6 528 |
| 6. RESERVES | 906 | 916 | 676 | 434 | 442 | 446 | 458 |
| Monetary reserve | 500 | 500 | 250 | | | | |
| Emergency aid reserve | 203 | 208 | 213 | 217 | 221 | 223 | 229 |
| Guarantee reserve | 203 | 208 | 213 | 217 | 221 | 223 | 229 |
| 7. PRE-ACCESSION STRATEGY | 3 174 | 3 240 | 3 328 | 3 386 | 3 455 | 3 472 | 3 566 |
| Agriculture | 529 | 540 | 555 | 564 | | | |
| Pre-accession structural instrument | 1 058 | 1 080 | 1 109 | 1 129 | | | |
| PHARE (applicant countries) | 1 587 | 1 620 | 1 664 | 1 693 | | | |
| 8. COMPENSATION | | | | | 1 410 | 1 305 | 1 074 |
| TOTAL APPROPRIATIONS FOR COMMITMENTS | 93 792 | 97 189 | 100 672 | 102 145 | 115 434 | 119 419 | 123 515 |
| TOTAL APPROPRIATIONS FOR PAYMENTS | 91 322 | 94 730 | 100 078 | 102 767 | 111 380 | 114 060 | 119 112 |
| Ceiling, appropriations for payments as% of GNI (ESA 95) | 1,07% | 1,08% | 1,11% | 1,09% | 1,09% | 1,08% | 1,08% |
| Margin for unforeseen expenditure | 0,17% | 0,16% | 0,13% | 0,15% | 0,15% | 0,16% | 0,16% |
| Own resources ceiling | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% |

(EUR million)

COMMITMENT APPROPRIATIONS

Current prices

2000

2001

2002

2003

2004

2005

2006

1. AGRICULTURE

41 738

44 530

46 587

47 378

49 305

51 439

52 618

1a Common Agricultural Policy

37 352

40 035

41 992

42 680

42 769

44 598

44 847

1b Rural development

4 386

4 495

4 595

4 698

6 536

6 841

7 771

2. STRUCTURAL ACTIONS

32 678

32 720

33 638

33 968

41 035

42 441

44 617

Structural funds

30 019

30 005

30 849

31 129

35 353

37 247

38 523

Cohesion fund

2 659

2 715

2 789

2 839

5 682

5 194

6 094

3. INTERNAL POLICIES

6 031

6 272

6 558

6 796

8 722

9 012

9 385

4. EXTERNAL ACTIONS

4 627

4 735

4 873

4 972

5 082

5 119

5 269

5. ADMINISTRATION
   (3)

4 638

4 776

5 012

5 211

5 983

6 185

6 528

6. RESERVES

906

916

676

434

442

446

458

Monetary reserve

500

500

250

Emergency aid reserve

203

208

213

217

221

223

229

Guarantee reserve

203

208

213

217

221

223

229

7. PRE-ACCESSION STRATEGY

3 174

3 240

3 328

3 386

3 455

3 472

3 566

Agriculture

529

540

555

564

Pre-accession structural instrument

1 058

1 080

1 109

1 129

PHARE (applicant countries)

1 587

1 620

1 664

1 693

8. COMPENSATION

1 410

1 305

1 074

TOTAL APPROPRIATIONS FOR COMMITMENTS

93 792

97 189

100 672

102 145

115 434

119 419

123 515

TOTAL APPROPRIATIONS FOR PAYMENTS

91 322

94 730

100 078

102 767

111 380

114 060

119 112

Ceiling, appropriations for payments as% of GNI (ESA 95)

1,07%

1,08%

1,11%

1,09%

1,09%

1,08%

1,08%

Margin for unforeseen expenditure

0,17%

0,16%

0,13%

0,15%

0,15%

0,16%

0,16%

Own resources ceiling

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

TABLE 2b: REVISED FINANCIAL PERSPECTIVE (EU-25) AT CURRENT PRICES

(including budgetary implications of a political settlement in Cyprus).

| (EUR million) |
| --- |
| COMMITMENT APPROPRIATIONS | Current prices |
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
| 1. AGRICULTURE | 41 738 | 44 530 | 46 587 | 47 378 | 49 297 | 51 437 | 52 615 |
| 1a Common Agricultural Policy | 37 352 | 40 035 | 41 992 | 42 680 | 42 772 | 44 608 | 44 858 |
| 1b Rural development | 4 386 | 4 495 | 4 595 | 4 698 | 6 525 | 6 829 | 7 757 |
| 2. STRUCTURAL ACTIONS | 32 678 | 32 720 | 33 638 | 33 968 | 41 094 | 42 528 | 44 746 |
| Structural funds | 30 019 | 30 005 | 30 849 | 31 129 | 35 395 | 37 319 | 38 632 |
| Cohesion fund | 2 659 | 2 715 | 2 789 | 2 839 | 5 699 | 5 209 | 6 114 |
| 3. INTERNAL POLICIES | 6 031 | 6 272 | 6 558 | 6 796 | 8 737 | 9 027 | 9 401 |
| 4. EXTERNAL ACTIONS | 4 627 | 4 735 | 4 873 | 4 972 | 5 082 | 5 119 | 5 269 |
| 5. ADMINISTRATION
   (4) | 4 638 | 4 776 | 5 012 | 5 211 | 5 983 | 6 185 | 6 528 |
| 6. RESERVES | 906 | 916 | 676 | 434 | 442 | 446 | 458 |
| Monetary reserve | 500 | 500 | 250 | 0 | 0 | 0 | 0 |
| Emergency aid reserve | 203 | 208 | 213 | 217 | 221 | 223 | 229 |
| Guarantee reserve | 203 | 208 | 213 | 217 | 221 | 223 | 229 |
| 7. PRE-ACCESSION STRATEGY | 3 174 | 3 240 | 3 328 | 3 386 | 3 455 | 3 472 | 3 566 |
| Agriculture | 529 | 540 | 555 | 564 | | | |
| Pre-accession structural instrument | 1 058 | 1 080 | 1 109 | 1 129 | | | |
| PHARE (applicant countries) | 1 587 | 1 620 | 1 664 | 1 693 | | | |
| 8. COMPENSATION | | | | | 1 410 | 1 305 | 1 074 |
| TOTAL APPROPRIATIONS FOR COMMITMENTS | 93 792 | 97 189 | 100 672 | 102 145 | 115 500 | 119 519 | 123 657 |
| TOTAL APPROPRIATIONS FOR PAYMENTS | 91 322 | 94 730 | 100 078 | 102 767 | 111 380 | 114 060 | 119 112 |
| Ceiling, appropriations for payments as% of GNI (ESA 95) | 1,07% | 1,08% | 1,11% | 1,09% | 1,09% | 1,08% | 1,08% |
| Margin for unforeseen expenditure | 0,17% | 0,16% | 0,13% | 0,15% | 0,15% | 0,16% | 0,16% |
| Own resources ceiling | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% | 1,24% |

(EUR million)

COMMITMENT APPROPRIATIONS

Current prices

2000

2001

2002

2003

2004

2005

2006

1. AGRICULTURE

41 738

44 530

46 587

47 378

49 297

51 437

52 615

1a Common Agricultural Policy

37 352

40 035

41 992

42 680

42 772

44 608

44 858

1b Rural development

4 386

4 495

4 595

4 698

6 525

6 829

7 757

2. STRUCTURAL ACTIONS

32 678

32 720

33 638

33 968

41 094

42 528

44 746

Structural funds

30 019

30 005

30 849

31 129

35 395

37 319

38 632

Cohesion fund

2 659

2 715

2 789

2 839

5 699

5 209

6 114

3. INTERNAL POLICIES

6 031

6 272

6 558

6 796

8 737

9 027

9 401

4. EXTERNAL ACTIONS

4 627

4 735

4 873

4 972

5 082

5 119

5 269

5. ADMINISTRATION
   (4)

4 638

4 776

5 012

5 211

5 983

6 185

6 528

6. RESERVES

906

916

676

434

442

446

458

Monetary reserve

500

500

250

0

0

0

0

Emergency aid reserve

203

208

213

217

221

223

229

Guarantee reserve

203

208

213

217

221

223

229

7. PRE-ACCESSION STRATEGY

3 174

3 240

3 328

3 386

3 455

3 472

3 566

Agriculture

529

540

555

564

Pre-accession structural instrument

1 058

1 080

1 109

1 129

PHARE (applicant countries)

1 587

1 620

1 664

1 693

8. COMPENSATION

1 410

1 305

1 074

TOTAL APPROPRIATIONS FOR COMMITMENTS

93 792

97 189

100 672

102 145

115 500

119 519

123 657

TOTAL APPROPRIATIONS FOR PAYMENTS

91 322

94 730

100 078

102 767

111 380

114 060

119 112

Ceiling, appropriations for payments as% of GNI (ESA 95)

1,07%

1,08%

1,11%

1,09%

1,09%

1,08%

1,08%

Margin for unforeseen expenditure

0,17%

0,16%

0,13%

0,15%

0,15%

0,16%

0,16%

Own resources ceiling

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

1,24%

---

(1)  The expenditure on pensions included under the ceiling for this heading is calculated net of staff contributions to the pension scheme, up to a maximum of EUR 1 100 million at 1999 prices for the period 2000-2006.

(2)  The expenditure on pensions included under the ceiling for this heading is calculated net of staff contributions to the pension scheme, up to a maximum of EUR 1 100 million at 1999 prices for the period 2000-2006.

(3)  The expenditure on pensions included under the ceiling for this heading is calculated net of staff contributions to the pension scheme, up to a maximum of EUR 1 100 million at 1999 prices for the period 2000-2006.

(4)  The expenditure on pensions included under the ceiling for this heading is calculated net of staff contributions to the pension scheme, up to a maximum of EUR 1 100 million at 1999 prices for the period 2000-2006.

P6_TA(2005)0326

Draft amending budget No 4/2005

European Parliament resolution on Draft amending budget No 4/2005 of the European Union for the financial year 2005 — Section III — Commission (11220/2005 — C6-0239/2005 — 2005/2079 (BUD))

The European Parliament,

| — | having regard to the Treaty establishing the European Community, and in particular Article 272(4), penultimate subparagraph, thereof, |
| --- | --- |

—

having regard to the Treaty establishing the European Community, and in particular Article 272(4), penultimate subparagraph, thereof,

| — | having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 177 thereof, |
| --- | --- |

—

having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 177 thereof,

| — | having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (1), and in particular Articles 37 and 38 thereof, |
| --- | --- |

—

having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (1), and in particular Articles 37 and 38 thereof,

| — | having regard to the general budget of the European Union for the financial year 2005, as finally adopted on 16 December 2004 (2), |
| --- | --- |

—

having regard to the general budget of the European Union for the financial year 2005, as finally adopted on 16 December 2004 (2),

| — | having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (3), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (3),

| — | having regard to the decision of the European Parliament and of the Council of 7 September 2005 on the mobilisation of the flexibility instrument in favour of the rehabilitation and reconstruction assistance to Tsunami affected countries according to point 24 of the Interinstitutional Agreement of 6 May 1999, |
| --- | --- |

—

having regard to the decision of the European Parliament and of the Council of 7 September 2005 on the mobilisation of the flexibility instrument in favour of the rehabilitation and reconstruction assistance to Tsunami affected countries according to point 24 of the Interinstitutional Agreement of 6 May 1999,

| — | having regard to Preliminary draft amending budget No 3/2005 for the financial year 2005, which the Commission presented on 27 April 2005 (SEC(2005)0548), |
| --- | --- |

—

having regard to Preliminary draft amending budget No 3/2005 for the financial year 2005, which the Commission presented on 27 April 2005 (SEC(2005)0548),

| — | having regard to Draft amending budget No 4/2005, which the Council established on 15 July 2005 (11220/2005 — C6-0239/2005), |
| --- | --- |

—

having regard to Draft amending budget No 4/2005, which the Council established on 15 July 2005 (11220/2005 — C6-0239/2005),

| — | having regard to Rule 69 of and Annex IV to its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 69 of and Annex IV to its Rules of Procedure,

| — | having regard to the report of the Committee on Budgets (A6-0255/2005), |
| --- | --- |

—

having regard to the report of the Committee on Budgets (A6-0255/2005),

| A. | whereas the European Union should fulfil its pledge of EUR 350 million for rehabilitation and reconstruction measures following the tsunami disaster, out of which EUR 170 million should be budgeted in 2005, |
| --- | --- |

A.

whereas the European Union should fulfil its pledge of EUR 350 million for rehabilitation and reconstruction measures following the tsunami disaster, out of which EUR 170 million should be budgeted in 2005,

| B. | whereas on 7 January 2005, the Council committed to ensuring that any resources released in this context are additional to commitments already made, |
| --- | --- |

B.

whereas on 7 January 2005, the Council committed to ensuring that any resources released in this context are additional to commitments already made,

| C. | whereas the Parliament, in addition to the abovementioned pledge, already entered EUR 123 million as emergency aid into the 2005 budget for the countries affected by the tsunami without reducing the existing policies, |
| --- | --- |

C.

whereas the Parliament, in addition to the abovementioned pledge, already entered EUR 123 million as emergency aid into the 2005 budget for the countries affected by the tsunami without reducing the existing policies,

| D. | whereas a supplementary contribution of EUR 70 million will be provided by the mobilisation of the emergency reserve and the corresponding proposal for a transfer, |
| --- | --- |

D.

whereas a supplementary contribution of EUR 70 million will be provided by the mobilisation of the emergency reserve and the corresponding proposal for a transfer,

| E. | whereas the purpose of the Draft amending budget No 4/2005 is to enter into the budget the EUR 15 million mobilised through the decision of the European Parliament and the Council on the mobilisation of the flexibility instrument, |
| --- | --- |

E.

whereas the purpose of the Draft amending budget No 4/2005 is to enter into the budget the EUR 15 million mobilised through the decision of the European Parliament and the Council on the mobilisation of the flexibility instrument,

| F. | whereas, in addition, supplementary resources to an amount of EUR 60 million will be made available through a limited redeployment which shall not prejudice the existing Asia programmes, |
| --- | --- |

F.

whereas, in addition, supplementary resources to an amount of EUR 60 million will be made available through a limited redeployment which shall not prejudice the existing Asia programmes,

| G. | whereas an amount of EUR 12 million will be financed through the rapid reaction mechanism, |
| --- | --- |

G.

whereas an amount of EUR 12 million will be financed through the rapid reaction mechanism,

| H. | whereas Draft amending budget No 4/2005 also covers a modification of the remarks against budget line 19 10 04 by adding a reference to Council Regulation (EEC) No 443/92 of 25 February 1992 on financial and technical assistance to, and economic cooperation with, the developing countries in Asia and Latin America (4) (the ALA regulation) to allow the implementation of the proposed amount through Trust Funds and budget support, |
| --- | --- |

H.

whereas Draft amending budget No 4/2005 also covers a modification of the remarks against budget line 19 10 04 by adding a reference to Council Regulation (EEC) No 443/92 of 25 February 1992 on financial and technical assistance to, and economic cooperation with, the developing countries in Asia and Latin America (4) (the ALA regulation) to allow the implementation of the proposed amount through Trust Funds and budget support,

| I. | whereas Draft amending budget No 4/2005 covers as well a modification of budget line 05 08 03, to make possible the disbursement of a subsidy to the OECD for the analysis and collection of data of several third countries and New Member States, |
| --- | --- |

I.

whereas Draft amending budget No 4/2005 covers as well a modification of budget line 05 08 03, to make possible the disbursement of a subsidy to the OECD for the analysis and collection of data of several third countries and New Member States,

| 1. | Reaffirms its commitment urgently to respond to rehabilitation and reconstruction needs following the devastating tsunami of 26 December 2004; |
| --- | --- |

1.

Reaffirms its commitment urgently to respond to rehabilitation and reconstruction needs following the devastating tsunami of 26 December 2004;

| 2. | Is willing to provide the European Union with the appropriate means to face new challenges while safeguarding ongoing development programmes and without jeopardising its traditional priorities; |
| --- | --- |

2.

Is willing to provide the European Union with the appropriate means to face new challenges while safeguarding ongoing development programmes and without jeopardising its traditional priorities;

| 3. | Stresses that an initial mobilisation of the flexibility instrument in accordance with point 24 of the Interinstitutional Agreement of 6 May 1999 was decided on in December 2004 for the year 2005 for the financing of reconstruction and rehabilitation of Iraq (5), as the needs of facing international crises since 2000 could not be financed within the initial ceilings of heading 4 of the Financial Perspective; |
| --- | --- |

3.

Stresses that an initial mobilisation of the flexibility instrument in accordance with point 24 of the Interinstitutional Agreement of 6 May 1999 was decided on in December 2004 for the year 2005 for the financing of reconstruction and rehabilitation of Iraq (5), as the needs of facing international crises since 2000 could not be financed within the initial ceilings of heading 4 of the Financial Perspective;

| 4. | Agrees on a further mobilisation of the flexibility instrument for the year 2005 for an amount of EUR 15 million for the financing of the reconstruction and rehabilitation measures in the countries affected by the tsunami; |
| --- | --- |

4.

Agrees on a further mobilisation of the flexibility instrument for the year 2005 for an amount of EUR 15 million for the financing of the reconstruction and rehabilitation measures in the countries affected by the tsunami;

| 5. | Nevertheless criticises the Council's unwillingness to mobilise the flexibility instrument in the amount of EUR 98 million, as proposed by the Commission, which delayed adoption of the amending budget; |
| --- | --- |

5.

Nevertheless criticises the Council's unwillingness to mobilise the flexibility instrument in the amount of EUR 98 million, as proposed by the Commission, which delayed adoption of the amending budget;

| 6. | Recalls that according to point 24 of the Interinstitutional Agreement the portion of the annual amount which is not used may be carried over up to the year n+2 and that if the instrument is mobilised, any carryovers will be drawn on in order of age; takes the view, therefore, that the mobilised amount of EUR 15 million comes from the amount carried over from the year 2004; notes also that after this mobilisation the amount remaining available for 2005 under the flexibility instrument will be EUR 293 million; |
| --- | --- |

6.

Recalls that according to point 24 of the Interinstitutional Agreement the portion of the annual amount which is not used may be carried over up to the year n+2 and that if the instrument is mobilised, any carryovers will be drawn on in order of age; takes the view, therefore, that the mobilised amount of EUR 15 million comes from the amount carried over from the year 2004; notes also that after this mobilisation the amount remaining available for 2005 under the flexibility instrument will be EUR 293 million;

| 7. | Recalls that the re-deployments agreed for 2005 must be re-programmed by means of an equivalent additional amount (that is, EUR 60 million) in the 2007 budget, so as to respect the commitment that resources released are additional to commitments already made; |
| --- | --- |

7.

Recalls that the re-deployments agreed for 2005 must be re-programmed by means of an equivalent additional amount (that is, EUR 60 million) in the 2007 budget, so as to respect the commitment that resources released are additional to commitments already made;

| 8. | Approves Draft amending budget No 4/2005 unamended; |
| --- | --- |

8.

Approves Draft amending budget No 4/2005 unamended;

| 9. | Instructs its President to forward this resolution to the Council and Commission. |
| --- | --- |

9.

Instructs its President to forward this resolution to the Council and Commission.

---

(1)  OJ L 248, 16.9.2002, p. 1.

(2)  OJ L 60, 8.3.2005, p. 1.

(3)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

(4)  OJ L 52, 27.2.1992, p. 1.

(5)  OJ L 54, 23.2.2004, p. 1.

P6_TA(2005)0327

Draft amending budget No 3/2005

European Parliament resolution on Draft amending budget No 3/2005 of the European Union for the financial year 2005 — Section III — Commission (9760/2005 — C6-0214/2005 — 2005/2102 (BUD))

The European Parliament,

| — | having regard to the Treaty establishing the European Community, and in particular Article 272(4), penultimate subparagraph, thereof, |
| --- | --- |

—

having regard to the Treaty establishing the European Community, and in particular Article 272(4), penultimate subparagraph, thereof,

| — | having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 177 thereof, |
| --- | --- |

—

having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 177 thereof,

| — | having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (1), and in particular Articles 37 and 38 thereof, |
| --- | --- |

—

having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (1), and in particular Articles 37 and 38 thereof,

| — | having regard to the general budget of the European Union for the financial year 2005, as finally adopted on 16 December 2004 (2), |
| --- | --- |

—

having regard to the general budget of the European Union for the financial year 2005, as finally adopted on 16 December 2004 (2),

| — | having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (3), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (3),

| — | having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (4), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (4),

| — | having regard to Preliminary draft amending budget No 4/2005 of the European Union for the financial year 2005, which the Commission presented on 13 May 2005 (SEC(2005)0650), |
| --- | --- |

—

having regard to Preliminary draft amending budget No 4/2005 of the European Union for the financial year 2005, which the Commission presented on 13 May 2005 (SEC(2005)0650),

| — | having regard to Draft amending budget No 3/2005, which the Council established on 24 June 2005 (9760/2005 — C6-0214/2005), |
| --- | --- |

—

having regard to Draft amending budget No 3/2005, which the Council established on 24 June 2005 (9760/2005 — C6-0214/2005),

| — | having regard to Rule 69 of and Annex IV to its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 69 of and Annex IV to its Rules of Procedure,

| — | having regard to the report of the Committee on Budgets (A6-0248/2005), |
| --- | --- |

—

having regard to the report of the Committee on Budgets (A6-0248/2005),

| A. | whereas the aim of Draft amending budget No 3/2005 is to enter in the 2005 budget the surplus of the 2004 financial year, amounting to EUR 2,7 billion, |
| --- | --- |

A.

whereas the aim of Draft amending budget No 3/2005 is to enter in the 2005 budget the surplus of the 2004 financial year, amounting to EUR 2,7 billion,

| B. | whereas this surplus consists of various elements, the most important being the over- registration in revenue of EUR 1 596 million, |
| --- | --- |

B.

whereas this surplus consists of various elements, the most important being the over- registration in revenue of EUR 1 596 million,

| C. | whereas the highest difference between result and initial budget in 2004 occurred in Agriculture with the balance of expenditure amounting to EUR 330,8 million, although this represents an improvement compared with last year of around EUR 107 million, accounting for 27,8 % of the amount underspent, |
| --- | --- |

C.

whereas the highest difference between result and initial budget in 2004 occurred in Agriculture with the balance of expenditure amounting to EUR 330,8 million, although this represents an improvement compared with last year of around EUR 107 million, accounting for 27,8 % of the amount underspent,

| D. | whereas there have been considerable improvements in the uptake of funds in the fields of structural funds, internal policies and external actions, |
| --- | --- |

D.

whereas there have been considerable improvements in the uptake of funds in the fields of structural funds, internal policies and external actions,

| 1. | Welcomes the positive development compared to last year, when the real surplus of the 2003 budget due to underspending amounted to nearly EUR 10 500 million taking into account the reduction of EUR 5 000 million resulting from Amending budget No 6/2003 following a large overestimation of payments in the Structural Funds; |
| --- | --- |

1.

Welcomes the positive development compared to last year, when the real surplus of the 2003 budget due to underspending amounted to nearly EUR 10 500 million taking into account the reduction of EUR 5 000 million resulting from Amending budget No 6/2003 following a large overestimation of payments in the Structural Funds;

| 2. | Expresses, nevertheless, its dissatisfaction with the additional surplus of EUR 2,7 billion for the 2004 budget; considers that the challenges that the European Union is facing today cannot justify such an underspending, in particular in Headings 3 and 4 of the financial perspective as well as pre-accession aid; therefore expects a better level of implementation to be obtained in 2005 in order to reduce significantly the level of EU surplus; |
| --- | --- |

2.

Expresses, nevertheless, its dissatisfaction with the additional surplus of EUR 2,7 billion for the 2004 budget; considers that the challenges that the European Union is facing today cannot justify such an underspending, in particular in Headings 3 and 4 of the financial perspective as well as pre-accession aid; therefore expects a better level of implementation to be obtained in 2005 in order to reduce significantly the level of EU surplus;

| 3. | Has decided to accept Draft amending budget No 3/2005 unamended; |
| --- | --- |

3.

Has decided to accept Draft amending budget No 3/2005 unamended;

| 4. | Instructs its President to forward this resolution to the Council and Commission. |
| --- | --- |

4.

Instructs its President to forward this resolution to the Council and Commission.

---

(1)  OJ L 248, 16.9.2002, p. 1.

(2)  OJ L 60, 8.3.2005, p. 1.

(3)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC of the European Parliament and of the Council (OJ L 147, 14.6.2003, p. 25).

(4)  OJ C 283, 20.11.2002, p. 1.

P6_TA(2005)0328

Draft amending budget No 5/2005

European Parliament resolution on Draft amending budget No 5/2005 of the European Union for the financial year 2005 — Section III — Commission (11221/2005 — C6-0240/2005 — 2005/2126 (BUD))

The European Parliament,

| — | having regard to the Treaty establishing the European Community, and in particular Article 272(4), penultimate subparagraph, thereof, |
| --- | --- |

—

having regard to the Treaty establishing the European Community, and in particular Article 272(4), penultimate subparagraph, thereof,

| — | having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 177 thereof, |
| --- | --- |

—

having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 177 thereof,

| — | having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (1), and in particular Articles 37 and 38 thereof, |
| --- | --- |

—

having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities (1), and in particular Articles 37 and 38 thereof,

| — | having regard to the general budget of the European Union for the financial year 2005, as finally adopted on 16 December 2004 (2), |
| --- | --- |

—

having regard to the general budget of the European Union for the financial year 2005, as finally adopted on 16 December 2004 (2),

| — | having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (3), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 6 May 1999 between the European Parliament, the Council and the Commission on budgetary discipline and improvement of the budgetary procedure (3),

| — | having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (4), |
| --- | --- |

—

having regard to the Interinstitutional Agreement of 7 November 2002 between the European Parliament, the Council and the Commission on the financing of the European Union Solidarity Fund supplementing the Interinstitutional Agreement of 6 May 1999 on budgetary discipline and improvement of the budgetary procedure (4),

| — | having regard to Preliminary draft amending budget No 5/2005 of the European Union for the financial year 2005, which the Commission presented on 6 June 2005 (SEC(2005)0758), |
| --- | --- |

—

having regard to Preliminary draft amending budget No 5/2005 of the European Union for the financial year 2005, which the Commission presented on 6 June 2005 (SEC(2005)0758),

| — | having regard to Draft amending budget No 5/2005, which the Council established on 15 July 2005 (11221/2005 — C6-0240/2005), |
| --- | --- |

—

having regard to Draft amending budget No 5/2005, which the Council established on 15 July 2005 (11221/2005 — C6-0240/2005),

| — | having regard to Rule 69 of and Annex IV to its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 69 of and Annex IV to its Rules of Procedure,

| — | having regard to the report of the Committee on Budgets (A6-0253/2005), |
| --- | --- |

—

having regard to the report of the Committee on Budgets (A6-0253/2005),

| A. | whereas the European Union should give a response of solidarity to assist in the work following the damage resulting from the storm in Slovakia, |
| --- | --- |

A.

whereas the European Union should give a response of solidarity to assist in the work following the damage resulting from the storm in Slovakia,

| B. | whereas the purpose of Draft amending budget No 5/2005 is to enter these budgetary resources formally in the 2005 budget, |
| --- | --- |

B.

whereas the purpose of Draft amending budget No 5/2005 is to enter these budgetary resources formally in the 2005 budget,

| C. | whereas Draft amending budget No 5/2005 relates also to the revenue side of the budget and comprises a number of elements affecting the level of contributions from Member States to the Community's own resources, |
| --- | --- |

C.

whereas Draft amending budget No 5/2005 relates also to the revenue side of the budget and comprises a number of elements affecting the level of contributions from Member States to the Community's own resources,

| D. | whereas these elements relate to the repayment of the surplus from the Guarantee Fund for External Measures from 2004 as well as to the annual revision of the forecasts for customs duties, VAT bases, GNI bases and a technical re-calculation of the contributions necessary to finance the UK rebate, |
| --- | --- |

D.

whereas these elements relate to the repayment of the surplus from the Guarantee Fund for External Measures from 2004 as well as to the annual revision of the forecasts for customs duties, VAT bases, GNI bases and a technical re-calculation of the contributions necessary to finance the UK rebate,

| E. | whereas on 14 July 2004 the Commission adopted its report on the operation of the own resources system and the related legislative proposals, which are under examination in the European Parliament, |
| --- | --- |

E.

whereas on 14 July 2004 the Commission adopted its report on the operation of the own resources system and the related legislative proposals, which are under examination in the European Parliament,

| 1. | Approves the Council's Draft amending budget No 5/2005 unamended; |
| --- | --- |

1.

Approves the Council's Draft amending budget No 5/2005 unamended;

| 2. | Instructs its President to forward this resolution to the Council and the Commission. |
| --- | --- |

2.

Instructs its President to forward this resolution to the Council and the Commission.

---

(1)  OJ L 248, 16.9.2002, p. 1.

(2)  OJ L 60, 8.3.2005, p. 1.

(3)  OJ C 172, 18.6.1999, p. 1. Agreement amended by Decision 2003/429/EC (OJ L 147, 14.6.2003, p. 25).

(4)  OJ C 283, 20.11.2002, p. 1.

P6_TA(2005)0329

Health and safety at work: Exposure to optical radiation ***II

European Parliament legislative resolution on the Council common position for adopting a directive of the European Parliament and of the Council on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (optical radiation) (19th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (5571/6/2005 — C6-0129/2005 — 1992/0449B(COD))

(Codecision procedure: second reading)

The European Parliament,

| — | having regard to the Council common position (5571/6/2005 — C6-0129/2005), |
| --- | --- |

—

having regard to the Council common position (5571/6/2005 — C6-0129/2005),

| — | having regard to its position at first reading (1) on the Commission proposal to Parliament and the Council (COM(1992)0560) (2), and on the amended proposal (COM(1994)0284) (3), |
| --- | --- |

—

having regard to its position at first reading (1) on the Commission proposal to Parliament and the Council (COM(1992)0560) (2), and on the amended proposal (COM(1994)0284) (3),

| — | having regard to Article 251(2) of the EC Treaty, |
| --- | --- |

—

having regard to Article 251(2) of the EC Treaty,

| — | having regard to Rule 62 of its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 62 of its Rules of Procedure,

| — | having regard to the recommendation for second reading of the Committee on Employment and Social Affairs (A6-0249/2005), |
| --- | --- |

—

having regard to the recommendation for second reading of the Committee on Employment and Social Affairs (A6-0249/2005),

| 1. | Approves the common position as amended; |
| --- | --- |

1.

Approves the common position as amended;

| 2. | Instructs its President to forward its position to the Council and Commission. |
| --- | --- |

2.

Instructs its President to forward its position to the Council and Commission.

---

(1)  OJ C 128, 9.5.1994, p. 128.

(2)  OJ C 77, 18.3.1993, p. 12.

(3)  OJ C 230, 19.8.1994, p. 3.

P6_TC2-COD(1992)0449B

Position of the European Parliament adopted at second reading on 7 September 2005 with a view to the adoption of Directive 2005/.../EC of the European Parliament and of the Council on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (optical radiation) (19th individual Directive within the meaning of Article 16 (1) of Directive 89/391/EEC)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 137(2) thereof,

Having regard to the proposal from the Commission (1), presented after consultation with the Advisory Committee on Safety and Health at Work,

Having regard to the Opinion of the European Economic and Social Committee (2),

After consulting the Committee of the Regions,

Acting in accordance with the procedure laid down in Article 251 of the Treaty (3),

Whereas:

| (1) | Under the Treaty the Council may, by means of directives, adopt minimum requirements for encouraging improvements, especially in the working environment, to guarantee a better level of protection of the health and safety of workers. Such directives are to avoid imposing administrative, financial and legal constraints in a way which would hold back the creation and development of small and mediumsized undertakings. |
| --- | --- |

(1)

Under the Treaty the Council may, by means of directives, adopt minimum requirements for encouraging improvements, especially in the working environment, to guarantee a better level of protection of the health and safety of workers. Such directives are to avoid imposing administrative, financial and legal constraints in a way which would hold back the creation and development of small and mediumsized undertakings.

| (2) | The communication from the Commission concerning its action programme relating to the implementation of the Community Charter of the Fundamental Social Rights of Workers provides for the introduction of minimum health and safety requirements regarding the exposure of workers to the risks caused by physical agents. In September 1990 the European Parliament adopted a Resolution concerning this action programme (4), inviting the Commission in particular to draw up a specific directive on the risks caused by noise, vibration and any other physical agents at the workplace. |
| --- | --- |

(2)

The communication from the Commission concerning its action programme relating to the implementation of the Community Charter of the Fundamental Social Rights of Workers provides for the introduction of minimum health and safety requirements regarding the exposure of workers to the risks caused by physical agents. In September 1990 the European Parliament adopted a Resolution concerning this action programme (4), inviting the Commission in particular to draw up a specific directive on the risks caused by noise, vibration and any other physical agents at the workplace.

| (3) | As a first step, the European Parliament and the Council adopted Directive 2002/44/EC of 25 June 2002 on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (vibration) (16th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (5). Next, on 6 February 2003, the European Parliament and the Council adopted Directive 2003/10/EC on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (noise) (17th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (6). Thereafter, on 29 April 2004, the European Parliament and the Council adopted Directive 2004/40/EC on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (electromagnetic fields) (18th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (7). |
| --- | --- |

(3)

As a first step, the European Parliament and the Council adopted Directive 2002/44/EC of 25 June 2002 on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (vibration) (16th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (5). Next, on 6 February 2003, the European Parliament and the Council adopted Directive 2003/10/EC on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (noise) (17th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (6). Thereafter, on 29 April 2004, the European Parliament and the Council adopted Directive 2004/40/EC on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (electromagnetic fields) (18th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (7).

| (4) | It is now considered necessary to introduce measures protecting workers from the risks associated with optical radiation, owing to its effects on the health and safety of workers, in particular damage to the eyes and to the skin. These measures are intended not only to ensure the health and safety of each worker on an individual basis, but also to create a minimum basis of protection for all Community workers, in order to avoid possible distortions of competition. |
| --- | --- |

(4)

It is now considered necessary to introduce measures protecting workers from the risks associated with optical radiation, owing to its effects on the health and safety of workers, in particular damage to the eyes and to the skin. These measures are intended not only to ensure the health and safety of each worker on an individual basis, but also to create a minimum basis of protection for all Community workers, in order to avoid possible distortions of competition.

| (5) | The aims of this Directive include the prevention and early diagnosis of any adverse health effects, as well as the prevention of any long-term health risks and any risk of chronic diseases, resulting from exposure to optical radiation. |
| --- | --- |

(5)

The aims of this Directive include the prevention and early diagnosis of any adverse health effects, as well as the prevention of any long-term health risks and any risk of chronic diseases, resulting from exposure to optical radiation.

| (6) | This Directive lays down minimum requirements, thus giving Member States the option of maintaining or adopting more stringent provisions for the protection of workers, in particular the fixing of lower exposure limit values. The implementation of this Directive
  must
  not serve to justify any deterioration in the situation which already prevails in each Member State. |
| --- | --- |

(6)

This Directive lays down minimum requirements, thus giving Member States the option of maintaining or adopting more stringent provisions for the protection of workers, in particular the fixing of lower exposure limit values. The implementation of this Directive
  must
  not serve to justify any deterioration in the situation which already prevails in each Member State.

| (7) | A system of protection against the hazards of optical radiation should limit itself to a definition, free of excessive detail, of the objectives to be attained, the principles to be observed and the basic values to be applied, in order to enable Member States to apply the minimum requirements in an equivalent manner. |
| --- | --- |

(7)

A system of protection against the hazards of optical radiation should limit itself to a definition, free of excessive detail, of the objectives to be attained, the principles to be observed and the basic values to be applied, in order to enable Member States to apply the minimum requirements in an equivalent manner.

| (8) | The level of exposure to optical radiation can be more effectively reduced by incorporating preventive measures into the design of workstations and by selecting work equipment, procedures and methods so as to give priority to reducing the risks at source. Provisions relating to work equipment and methods thus contribute to the protection of the workers involved. In accordance with the general principles of prevention as laid down in Article 6(2) of Council Directive 89/391/EEC of 12 June 1989 on the introduction of measures to encourage improvements in the safety and health of workers at work (8), collective protection measures have priority over individual protection measures. |
| --- | --- |

(8)

The level of exposure to optical radiation can be more effectively reduced by incorporating preventive measures into the design of workstations and by selecting work equipment, procedures and methods so as to give priority to reducing the risks at source. Provisions relating to work equipment and methods thus contribute to the protection of the workers involved. In accordance with the general principles of prevention as laid down in Article 6(2) of Council Directive 89/391/EEC of 12 June 1989 on the introduction of measures to encourage improvements in the safety and health of workers at work (8), collective protection measures have priority over individual protection measures.

| (9) | Employers should make adjustments in the light of technical progress and scientific knowledge regarding risks related to exposure to optical radiation, with a view to improving the safety and health protection of workers. |
| --- | --- |

(9)

Employers should make adjustments in the light of technical progress and scientific knowledge regarding risks related to exposure to optical radiation, with a view to improving the safety and health protection of workers.

| (10) | Since this Directive is an individual directive within the meaning of Article 16(1) of Directive 89/391/EEC, that Directive applies to the exposure of workers to optical radiation, without prejudice to more stringent and/or specific provisions contained in this Directive. |
| --- | --- |

(10)

Since this Directive is an individual directive within the meaning of Article 16(1) of Directive 89/391/EEC, that Directive applies to the exposure of workers to optical radiation, without prejudice to more stringent and/or specific provisions contained in this Directive.

| (11) | This Directive constitutes a practical step towards creating the social dimension of the internal market. |
| --- | --- |

(11)

This Directive constitutes a practical step towards creating the social dimension of the internal market.

| (12) | A complementary approach that both promotes the principle of better regulation and ensures a high level of protection can be achieved where the products made by the manufacturers of optical radiation sources and associated equipment comply with harmonised standards devised to protect the health and safety of users from the hazards inherent in such products; accordingly, it is not necessary for employers to repeat the measurements or calculations already undertaken by the manufacturer to determine compliance with the essential safety requirements of such equipment as specified in the applicable Community Directives
  , provided that the equipment has been properly and regularly maintained
  . |
| --- | --- |

(12)

A complementary approach that both promotes the principle of better regulation and ensures a high level of protection can be achieved where the products made by the manufacturers of optical radiation sources and associated equipment comply with harmonised standards devised to protect the health and safety of users from the hazards inherent in such products; accordingly, it is not necessary for employers to repeat the measurements or calculations already undertaken by the manufacturer to determine compliance with the essential safety requirements of such equipment as specified in the applicable Community Directives
  , provided that the equipment has been properly and regularly maintained
  .

| (13) | The measures necessary for the implementation of this Directive should be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (9). |
| --- | --- |

(13)

The measures necessary for the implementation of this Directive should be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (9).

| (14) | Adherence to the exposure limit values should provide a high level of protection as regards the health effects that may result from exposure to optical radiation. However, since the application of exposure limit values and engineering controls are not deemed appropriate in the case of exposure to natural sources of optical radiation, preventive measures, including information and training for workers, are critical to the assessment of risk and the reduction of solar exposure risks. |
| --- | --- |

(14)

Adherence to the exposure limit values should provide a high level of protection as regards the health effects that may result from exposure to optical radiation. However, since the application of exposure limit values and engineering controls are not deemed appropriate in the case of exposure to natural sources of optical radiation, preventive measures, including information and training for workers, are critical to the assessment of risk and the reduction of solar exposure risks.

| (15) | The Commission should draw up a practical guide to help employers, in particular managers of small and medium-sized enterprises (SMEs), better to understand the technical provisions of this Directive. The Commission should strive to complete this guide as quickly as possible so as to facilitate adoption by the Member States of the measures necessary to implement this Directive. |
| --- | --- |

(15)

The Commission should draw up a practical guide to help employers, in particular managers of small and medium-sized enterprises (SMEs), better to understand the technical provisions of this Directive. The Commission should strive to complete this guide as quickly as possible so as to facilitate adoption by the Member States of the measures necessary to implement this Directive.

| (16) | In accordance with paragraph 34 of the Interinstitutional Agreement on better law-making (10), Member States are encouraged to draw up, for themselves and in the interests of the Community, their own tables which will, as far as possible, illustrate the correlation between this Directive and the transposition measures, and to make them public, |
| --- | --- |

(16)

In accordance with paragraph 34 of the Interinstitutional Agreement on better law-making (10), Member States are encouraged to draw up, for themselves and in the interests of the Community, their own tables which will, as far as possible, illustrate the correlation between this Directive and the transposition measures, and to make them public,

HAVE ADOPTED THIS DIRECTIVE:

SECTION I

GENERAL PROVISIONS

Article 1

Aim and scope

1.   This Directive, which is the 19th individual Directive within the meaning of Article 16(l) of Directive 89/391/EEC, lays down minimum requirements for the protection of workers from risks to their health and safety arising or likely to arise from exposure to optical radiation during their work.

2.   This Directive concerns the risk to the health and safety of workers from exposure of the eyes and skin to optical radiation.

3.   Directive 89/391/EEC shall apply fully to the whole area referred to in paragraph 1, without prejudice to more stringent and/or more specific provisions contained in this Directive.

Article 2

Definitions

For the purposes of this Directive, the following definitions shall apply:

| (a) | optical radiation: any electromagnetic radiation in the wavelength range between 100 nm and 1 mm. The spectrum of optical radiation is divided into ultraviolet radiation, visible radiation and infrared radiation:






  (i) | ultraviolet radiation: optical radiation of wavelength range between 100 nm and 400 nm. The ultraviolet region is divided into UVA (315-400 nm), UVB (280-315 nm) and UVC (100-280 nm); |
| --- | --- | --- |

(a)

optical radiation: any electromagnetic radiation in the wavelength range between 100 nm and 1 mm. The spectrum of optical radiation is divided into ultraviolet radiation, visible radiation and infrared radiation:

(i)

ultraviolet radiation: optical radiation of wavelength range between 100 nm and 400 nm. The ultraviolet region is divided into UVA (315-400 nm), UVB (280-315 nm) and UVC (100-280 nm);

| (ii) | visible radiation: optical radiation of wavelength range between 380 nm and 780 nm; |
| --- | --- |

(ii)

visible radiation: optical radiation of wavelength range between 380 nm and 780 nm;

| (iii) | infrared radiation: optical radiation of wavelength range between 780 nm and 1 mm. The infrared region is divided into IRA (780-1400 nm), IRB (1 400-3 000 nm) and IRC (3 000 nm-1 mm); |
| --- | --- |

(iii)

infrared radiation: optical radiation of wavelength range between 780 nm and 1 mm. The infrared region is divided into IRA (780-1400 nm), IRB (1 400-3 000 nm) and IRC (3 000 nm-1 mm);

| (b) | laser (light amplification by stimulated emission of radiation): any device which can be made to produce or amplify electromagnetic radiation in the optical radiation wavelength range primarily by the process of controlled stimulated emission; |
| --- | --- |

(b)

laser (light amplification by stimulated emission of radiation): any device which can be made to produce or amplify electromagnetic radiation in the optical radiation wavelength range primarily by the process of controlled stimulated emission;

| (c) | laser radiation: optical radiation from a laser; |
| --- | --- |

(c)

laser radiation: optical radiation from a laser;

| (d) | non-coherent radiation: any optical radiation other than laser radiation; |
| --- | --- |

(d)

non-coherent radiation: any optical radiation other than laser radiation;

| (e) | exposure limit values: limits on exposure to optical radiation which are based directly on established health effects and biological considerations. Compliance with these limits will ensure that workers exposed to artificial sources of optical radiation are protected against all known adverse health effects; |
| --- | --- |

(e)

exposure limit values: limits on exposure to optical radiation which are based directly on established health effects and biological considerations. Compliance with these limits will ensure that workers exposed to artificial sources of optical radiation are protected against all known adverse health effects;

| (f) | irradiance (E) or power density: the radiant power incident per unit area upon a surface expressed in watts per square metre (W m-2); |
| --- | --- |

(f)

irradiance (E) or power density: the radiant power incident per unit area upon a surface expressed in watts per square metre (W m-2);

| (g) | radiant exposure (H): the time integral of the irradiance, expressed in joules per square metre (J m-2); |
| --- | --- |

(g)

radiant exposure (H): the time integral of the irradiance, expressed in joules per square metre (J m-2);

| (h) | radiance (L): the radiant flux or power output per unit solid angle per unit area, expressed in watts per square metre per steradian (W m-2 sr-1); |
| --- | --- |

(h)

radiance (L): the radiant flux or power output per unit solid angle per unit area, expressed in watts per square metre per steradian (W m-2 sr-1);

| (i) | level: the combination of irradiance, radiant exposure and radiance to which a worker is exposed. |
| --- | --- |

(i)

level: the combination of irradiance, radiant exposure and radiance to which a worker is exposed.

Article 3

Exposure limit values

1.   The exposure limit values for non-coherent radiation, other than that emitted by natural sources of optical radiation, are as set out in Annex I.

2.   The exposure limit values for laser radiation are as set out in Annex II.

SECTION II

OBLIGATIONS OF EMPLOYERS

Article 4

Determination of exposure and assessment of risks

1.   In carrying out the obligations laid down in Articles 6(3) and 9(1) of Directive 89/391/EEC, the employer, in the case of workers exposed to artificial sources of optical radiation, shall assess and, if necessary, measure and/or calculate the levels of optical radiation to which workers are likely to be exposed so that the measures needed to prevent exposure from exceeding the applicable limits can be identified and put into effect. The methodology applied in assessment, measurement and/or calculations shall follow the standards of the International Electrotechnical Commission (IEC) in respect of laser radiation and the recommendations of the International Commission on Illumination (CIE) and the European Committee for Standardisation (CEN) in respect of non-coherent radiation. In exposure situations which are not covered by these standards and recommendations, and until appropriate EU standards or recommendations become available, assessment, measurement and/or calculations shall be carried out using available national or international sciencebased guidelines. In both types of exposure situation, the assessment may take account of data provided by the manufacturers of the equipment when it is covered by relevant Community Directives.

2.   
  In the
  case of workers exposed to natural sources of optical radiation,
  the definition of any obligations imposed on the employer to assess risks
  to health and safety
  shall come within the regulatory competence of the Member States
  .

3.   The assessment, measurement and/or calculations referred to in
  paragraph 1 shall
  be planned and carried out by competent services or persons at suitable intervals, taking particular account of the provisions of Articles 7 and 11 of Directive 89/391/EEC concerning the necessary competent services or persons and the consultation and participation of workers. The data obtained from the assessment, including those obtained from the measurement and/or calculations of the level of exposure referred to in paragraph 1 shall be preserved in a suitable form so as to permit their consultation at a later stage.

4.   Pursuant to Article 6(3) of Directive 89/391/EEC, the employer shall give particular attention, when carrying out the risk assessment, to the following:

| (a) | the level, wavelength range and duration of exposure to artificial sources of optical
  radiation
  ; |
| --- | --- |

(a)

the level, wavelength range and duration of exposure to artificial sources of optical
  radiation
  ;

| (b) | the
  exposure limit values referred to in Article 3 of this Directive; |
| --- | --- |

(b)

the
  exposure limit values referred to in Article 3 of this Directive;

| (c) | any effects concerning the health and safety of workers belonging to particularly sensitive risk groups; |
| --- | --- |

(c)

any effects concerning the health and safety of workers belonging to particularly sensitive risk groups;

| (d) | any possible effects on workers' health and safety resulting from workplace interactions between optical radiation and photosensitising chemical substances; |
| --- | --- |

(d)

any possible effects on workers' health and safety resulting from workplace interactions between optical radiation and photosensitising chemical substances;

| (e) | any indirect effects such as temporary blinding, explosion or fire; |
| --- | --- |

(e)

any indirect effects such as temporary blinding, explosion or fire;

| (f) | the existence of replacement equipment designed to reduce the levels of exposure to
  artificial
  optical radiation; |
| --- | --- |

(f)

the existence of replacement equipment designed to reduce the levels of exposure to
  artificial
  optical radiation;

| (g) | appropriate information obtained from health surveillance, including published information, as far as possible; |
| --- | --- |

(g)

appropriate information obtained from health surveillance, including published information, as far as possible;

| (h) | multiple sources of exposure to
  artificial
  optical radiation; |
| --- | --- |

(h)

multiple sources of exposure to
  artificial
  optical radiation;

| (i) | a classification applied to a laser as defined in accordance with the relevant IEC standard and, in relation to any artificial source likely to cause damage similar to that of a laser of class 3B or 4, any similar classification; |
| --- | --- |

(i)

a classification applied to a laser as defined in accordance with the relevant IEC standard and, in relation to any artificial source likely to cause damage similar to that of a laser of class 3B or 4, any similar classification;

| (j) | information provided by the manufacturers of optical radiation sources and associated work equipment in accordance with the relevant Community Directives. |
| --- | --- |

(j)

information provided by the manufacturers of optical radiation sources and associated work equipment in accordance with the relevant Community Directives.

5.   The employer shall be in possession of an assessment of the risk in accordance with Article 9(1)(a) of Directive 89/391/EEC and shall identify which measures must be taken in accordance with Articles 5 and 6 of this Directive. The risk assessment shall be recorded on a suitable medium, according to national law and practice; it may include a justification by the employer that the nature and extent of the risks related to optical radiation make a further, detailed risk assessment unnecessary. The risk assessment shall be updated on a regular basis, particularly if there have been significant changes which could render it out of date, or if the results of health surveillance show it to be necessary.

Article 5

Provisions aimed at eliminating or reducing risks

1.   Taking account of technical progress and of the availability of measures to control the risk at source, the risks arising from exposure to
  artificial
  optical radiation shall be eliminated or reduced to a minimum.

The reduction of risks arising from exposure to
  artificial
  optical radiation shall be based on the general principles of prevention set out in Directive 89/391/EEC.

2.   Where the risk assessment carried out in accordance with Article 4(1) for workers exposed to artificial sources of optical radiation indicates
  any possibility
  that the exposure limit values may be exceeded, the employer shall devise and implement an action plan comprising technical and/or organisational measures
  designed to prevent the exposure exceeding the limit values,
  taking into account in particular:

| (a) | other working methods that reduce the risk from optical radiation; |
| --- | --- |

(a)

other working methods that reduce the risk from optical radiation;

| (b) | the choice of equipment emitting less optical radiation, taking account of the work to be done; |
| --- | --- |

(b)

the choice of equipment emitting less optical radiation, taking account of the work to be done;

| (c) | technical measures to reduce the emission of optical radiation including, where necessary, the use of interlocks, shielding or similar health protection mechanisms; |
| --- | --- |

(c)

technical measures to reduce the emission of optical radiation including, where necessary, the use of interlocks, shielding or similar health protection mechanisms;

| (d) | appropriate maintenance programmes for work equipment, workplaces and workstation systems; |
| --- | --- |

(d)

appropriate maintenance programmes for work equipment, workplaces and workstation systems;

| (e) | the design and layout of workplaces and workstations; |
| --- | --- |

(e)

the design and layout of workplaces and workstations;

| (f) | limitation of the duration and level of the exposure; |
| --- | --- |

(f)

limitation of the duration and level of the exposure;

| (g) | the availability of appropriate personal protective equipment; |
| --- | --- |

(g)

the availability of appropriate personal protective equipment;

| (h) | the instructions of the manufacturer of the equipment where it is covered by relevant Community
  Directives
  . |
| --- | --- |

(h)

the instructions of the manufacturer of the equipment where it is covered by relevant Community
  Directives
  .

3.   
  On
  the basis of the risk assessment carried out in accordance with Article 4, workplaces where workers could be exposed to levels of optical radiation from artificial sources exceeding the exposure limit values shall be indicated by appropriate signs in accordance with Council Directive 92/58/EEC of 24 June 1992 on the minimum requirements for the provision of safety and/or health signs at work (9th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) (11). The areas in question shall be identified, and access to them limited where this is technically possible and where there is a risk that the exposure limit values could be exceeded.

4.   Workers shall not be exposed above the exposure limit values. However, if, despite the measures taken by the employer to comply with this Directive in respect of artificial sources of optical radiation, the exposure limit values are exceeded, the employer shall take immediate action to reduce exposure below the exposure limit values. The employer shall identify the reasons why the exposure limit values have been exceeded and shall adapt the protection and prevention measures accordingly in order to prevent them being exceeded again.

5.   Pursuant to Article 15 of Directive 89/391/EEC, the employer shall adapt the measures referred to in this Article to the requirements of workers belonging to particularly sensitive risk groups.

Article 6

Worker information and training

Without prejudice to Articles 10 and 12 of Directive 89/391/EEC, the employer shall ensure that workers who are exposed to risks from
  artificial
  optical radiation at work and/or their representatives receive any necessary information and training relating to the outcome of the risk assessment provided for in Article 4 of this Directive, concerning in particular:

| (a) | measures taken to implement this Directive; |
| --- | --- |

(a)

measures taken to implement this Directive;

| (b) | the exposure limit values and the associated potential risks; |
| --- | --- |

(b)

the exposure limit values and the associated potential risks;

| (c) | the results of the assessment, measurement and/or calculations of the levels of exposure to
  artificial
  optical radiation carried out in accordance with Article 4 of this Directive together with an explanation of their significance and potential risks; |
| --- | --- |

(c)

the results of the assessment, measurement and/or calculations of the levels of exposure to
  artificial
  optical radiation carried out in accordance with Article 4 of this Directive together with an explanation of their significance and potential risks;

| (d) | how to detect adverse health effects of exposure and how to report them; |
| --- | --- |

(d)

how to detect adverse health effects of exposure and how to report them;

| (e) | the circumstances in which workers are entitled to health surveillance; |
| --- | --- |

(e)

the circumstances in which workers are entitled to health surveillance;

| (f) | safe working practices to minimise risks from exposure; |
| --- | --- |

(f)

safe working practices to minimise risks from exposure;

| (g) | proper use of appropriate personal protective equipment. |
| --- | --- |

(g)

proper use of appropriate personal protective equipment.

Article 7

Consultation and participation of workers

Consultation and participation of workers and/or of their representatives shall take place in accordance with Article 11 of Directive 89/391/EEC on the matters covered by this Directive.

SECTION III

MISCELLANEOUS PROVISIONS

Article 8

Health surveillance

1.   
  With the objectives of prevention and early diagnosis of any adverse health effects, as well as the prevention of any long-term health risks and any risk of chronic diseases, resulting from exposure to optical radiation,
  Member States shall adopt provisions to ensure appropriate health surveillance of workers
  pursuant to Article 14 of Directive 89/391/EEC.

2.
     
  Member States shall ensure that health surveillance is carried out by a doctor, an occupational health professional or a medical authority responsible for health surveillance in accordance with national law and practice.

3.   Member States shall establish arrangements to ensure that, for each worker who undergoes health surveillance in accordance with paragraph 1, individual health records are made and kept up to date. Health records shall contain a summary of the results of the health surveillance carried out. They shall be kept in a suitable form so as to permit consultation at a later date, taking into account any confidentiality. Copies of the appropriate records shall be supplied to the competent authority on request, taking into account any confidentiality.
  The employer shall take appropriate measures to ensure that the doctor, the occupational health professional or the medical authority responsible for the health surveillance, as determined by Member States as appropriate, has access to the results of the risk assessment referred to in Article 4 where such results may be relevant to the health surveillance.
  Individual workers shall, at their request, have access to their own personal health records.

4.   
  In any event, where exposure above the limit values is detected, a medical examination shall be made available to the worker(s) concerned in accordance with national law and practice. This medical examination shall also be carried out where
  , as a result of health surveillance, a worker is found to have an identifiable disease or adverse health effect which is considered by a doctor or occupational health professional to be the result of exposure to
  artificial
  optical radiation at work
  . In both cases
  :

| (a) | the worker shall be informed by the doctor or other suitably qualified person of the result which relates to him personally. He shall, in particular, receive information and advice regarding any health surveillance which he should undergo following the end of exposure; |
| --- | --- |

(a)

the worker shall be informed by the doctor or other suitably qualified person of the result which relates to him personally. He shall, in particular, receive information and advice regarding any health surveillance which he should undergo following the end of exposure;

| (b) | the employer shall be informed of any significant findings of the health surveillance, taking into account any medical confidentiality; |
| --- | --- |

(b)

the employer shall be informed of any significant findings of the health surveillance, taking into account any medical confidentiality;

| (c) | the employer shall:






  — | review the risk assessment carried out pursuant to Article 4, |
| --- | --- | --- |

(c)

the employer shall:

—

review the risk assessment carried out pursuant to Article 4,

| — | review the measures provided for to eliminate or reduce risks pursuant to Article 5, |
| --- | --- |

—

review the measures provided for to eliminate or reduce risks pursuant to Article 5,

| — | take into account the advice of the occupational health professional or other suitably qualified person or the competent authority in implementing any measure required to eliminate or reduce risk in accordance with
  Article 5, and |
| --- | --- |

—

take into account the advice of the occupational health professional or other suitably qualified person or the competent authority in implementing any measure required to eliminate or reduce risk in accordance with
  Article 5, and

| — | arrange continued health surveillance and provide for a review of the health status of any other worker who has been similarly exposed. In such cases, the competent doctor or occupational health professional or the competent authority may propose that the exposed persons undergo a medical examination. |
| --- | --- |

—

arrange continued health surveillance and provide for a review of the health status of any other worker who has been similarly exposed. In such cases, the competent doctor or occupational health professional or the competent authority may propose that the exposed persons undergo a medical examination.

Article 9

Penalties

Member States shall provide for adequate penalties to be applicable in the event of infringement of the national legislation adopted pursuant to this Directive. These penalties must be effective, proportionate and dissuasive.

Article 10

Technical amendments

1.   Any modification of the exposure limit values set out in the Annexes shall be adopted by the European Parliament and the Council in accordance with the procedure laid down in Article 137(2) of the Treaty.

2.   Amendments to the Annexes of a strictly technical nature in line with:

| (a) | the adoption of Directives in the field of technical harmonisation and standardisation with regard to the design, building, manufacture or construction of work equipment and/or workplaces; |
| --- | --- |

(a)

the adoption of Directives in the field of technical harmonisation and standardisation with regard to the design, building, manufacture or construction of work equipment and/or workplaces;

| (b) | technical progress, changes in the most relevant harmonised European standards or international specifications, and new scientific findings concerning occupational exposure to optical radiation, |
| --- | --- |

(b)

technical progress, changes in the most relevant harmonised European standards or international specifications, and new scientific findings concerning occupational exposure to optical radiation,

shall be adopted in accordance with the procedure laid down in Article 11(2).

Article 11

Committee

1.   The Commission shall be assisted by the Committee referred to in Article 17 of Directive 89/391/EEC.

2.   Where reference is made to this paragraph, Articles 5 and 7 of Decision 1999/468/EC shall apply, having regard to the provisions of Article 8 thereof.

The period laid down in Article 5(6) of Decision 1999/468/EC shall be set at three months.

3.   The Committee shall adopt its rules of procedure.

SECTION IV

FINAL PROVISIONS

Article 12

Reports

Every five years Member States shall provide the Commission with a report on the practical implementation of this Directive, indicating the points of view of the social partners.

Every five years the Commission shall inform the European Parliament, the Council, the European Economic and Social Committee and the Advisory Committee on Safety and Health at Work of the content of these reports, of its assessment
  of these reports,
  of developments in the field in question and of any action that may be warranted in the light of new scientific knowledge.

Article 13

Practical guide

In order to facilitate application of this Directive the Commission shall draw up a practical guide to the provisions of Articles 4 and 5 and Annexes I and II.

Article 14

Transposition

1.   Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by ... (12). They shall forthwith inform the Commission thereof.

When Member States adopt these measures, they shall contain a reference to this Directive or shall be accompanied by such reference on the occasion of their official publication. The methods of making such reference shall be laid down by Member States.

2.   Member States shall communicate to the Commission the text of the provisions of national law which they adopt or have already adopted in the field covered by this Directive.

Article 15

Entry into force

This Directive shall enter into force on the day of its publication in the Official Journal of the European Union.

Article 16

Addressees

This Directive is addressed to the Member States.

Done at ..., on ...

For the European Parliament

The President

For the Council

The President

---

(1)  OJ C 77, 18.3.1993, p. 12 and OJ C 230, 19.8.1994, p. 3.

1

(2)  OJ C 249, 13.9.1993, p. 28.

2

(3)  Position of the European Parliament of 20 April 1994 (OJ C 128, 9.5.1994, p. 146) confirmed on 16 September 1999 (OJ C 54, 25.2.2000, p. 75), Council Common Position of 18 April 2005 (OJ C 172 E, 12.7.2005, p. 26) and Position of the European Parliament of 7 September 2005.

3

Position

of 18 April 2005

7 September 2005

(4)  OJ C 260, 15.10.1990, p. 167.

4

(5)  OJ L 177, 6.7.2002, p. 13.

5

(6)  OJ L 42, 15.2.2003, p. 38.

6

(7)  OJ L 184, 24.5.2004, p. 1.

7

(8)  OJ L 183, 29.6.1989, p. 1. Directive as amended by Regulation (EC) No 1882/2003 of the European Parliament and the Council (OJ L 284, 31.10.2003, p. 1).

8

(9)  OJ L 184, 17.7.1999, p. 23.

9

(10)  OJ C 321, 31.12.2003, p. 1.

10

(11)  OJ L 245, 26.8.1992, p. 23.

11

(12)  Four years after the date of entry into force of this Directive.

12

date of

ANNEX I

NON-COHERENT OPTICAL RADIATION

The biophysically relevant exposure values to optical radiation can be determined with the formulae below. The formulae to be used depend on the range of radiation emitted by the source and the results should be compared with the corresponding exposure limit values indicated in Table 1.1. More than one exposure value and corresponding exposure limit can be relevant for a given source of optical radiation.

Numbering (a) to (o) refers to corresponding rows of Table 1.1.

| (a) | | (Heff is only relevant in the range 180 to 400 nm) |
| --- | --- | --- |
| (b) | | (HUVA is only relevant in the range 315 to 400 nm) |
| (c), (d) | | (LB is only relevant in the range 300 to 700 nm) |
| (e), (f) | | (EB is only relevant in the range 300 to 700 nm) |
| (g) to (l) | | (See Table 1.1 for appropriate values of λ1 and λ2) |
| (m), (n) | | (EIR is only relevant in the range 780 to 3 000 nm) |
| (o) | | (Hskin is only relevant in the range 380 to 3 000 nm) |

(a)

Formula

(Heff is only relevant in the range 180 to 400 nm)

(b)

Formula

(HUVA is only relevant in the range 315 to 400 nm)

(c), (d)

Formula

(LB is only relevant in the range 300 to 700 nm)

(e), (f)

Formula

(EB is only relevant in the range 300 to 700 nm)

(g) to (l)

Formula

(See Table 1.1 for appropriate values of λ1 and λ2)

(m), (n)

Formula

(EIR is only relevant in the range 780 to 3 000 nm)

(o)

Formula

(Hskin is only relevant in the range 380 to 3 000 nm)

For the purposes of this Directive, the formulae above can be replaced by the following expressions and the use of discrete values as set out in the following tables:

| (a) | | and Heff = Eeff · Δt |
| --- | --- | --- |
| (b) | | and HUVA = EUVA · Δt |
| (c), (d) | | |
| (e), (f) | | |
| (g) to (l) | | (See Table 1.1 for appropriate values of λ1 and λ2) |
| (m), (n) | | |
| (o) | | and Hskin = Eskin · Δt |

(a)

Formula

and Heff = Eeff · Δt

(b)

Formula

and HUVA = EUVA · Δt

(c), (d)

Formula

(e), (f)

Formula

(g) to (l)

Formula

(See Table 1.1 for appropriate values of λ1 and λ2)

(m), (n)

Formula

(o)

Formula

and Hskin = Eskin · Δt

Notes:

| Eλ (λ,t), Eλ | spectral irradiance or spectral power density: the radiant power incident per unit area upon a surface, expressed in watts per square metre per nanometre [W m-2 nm-1]; values of Eλ (λ,t) and Eλ come from measurements or may be provided by the manufacturer of the equipment; |
| --- | --- |
| Eeff | effective irradiance (UV range): calculated irradiance within the UV wavelength range 180 to 400 nm spectrally weighted by S(λ), expressed in watts per square metre [W m-2]; |
| H | radiant exposure: the time integral of the irradiance, expressed in joules per square metre [J m-2]; |
| Heff | effective radiant exposure: radiant exposure spectrally weighted by S (λ), expressed in joules per square metre [J m-2]; |
| EUVA | total irradiance (UVA): calculated irradiance within the UVA wavelength range 315 to 400 nm, expressed in watts per square metre [W m-2]; |
| HUVA | radiant exposure, the time and wavelength integral or sum of the irradiance within the UVA wavelength range 315 to 400 nm, expressed in joules per square metre [J m-2]; |
| S(λ) | spectral weighting taking into account the wavelength dependence of the health effects of UV radiation on eye and skin (Table 1.2) [dimensionless]; |
| t,Δt | time, duration of the exposure, expressed in seconds [s]; |
| λ | wavelength, expressed in nanometres [nm]; |
| Δλ | bandwidth, expressed in nanometres [nm], of the calculation or measurement intervals; |
| Lλ(λ),Lλ | spectral radiance of the source expressed in watts per square metre per steradian per nanometre [W m-2 sr-1 nm -1]; |
| R(λ) | spectral weighting taking into account the wavelength dependence of the thermal injury caused to the eye by visible and IRA radiation (Table 1.3) [dimensionless]; |
| LR | effective radiance (thermal injury): calculated radiance spectrally weighted by R (λ) expressed in watts per square metre per steradian [W m-2 sr-1]; |
| B(λ) | spectral weighting taking into account the wavelength dependence of the photochemical injury caused to the eye by blue light radiation (Table 1.3) [dimensionless]; |
| LB | effective radiance (blue light): calculated radiance spectrally weighted by B (λ), expressed in watts per square metre per steradian [W m-2 sr-1]; |
| EB | effective irradiance (blue light): calculated irradiance spectrally weighted by B (λ) expressed in watts per square metre [W m-2]; |
| EIR | total irradiance (thermal injury): calculated irradiance within the infrared wavelength range 780 nm to 3 000 nm expressed in watts per square metre [W m-2]; |
| Eskin | total irradiance (visible, IRA and IRB): calculated irradiance within the visible and infrared wavelength range 380 nm to 3 000 nm, expressed in watts per square metre [W m-2]; |
| Hskin | radiant exposure, the time and wavelength integral or sum of the irradiance within the visible and infrared wavelength range 380 to 3 000 nm, expressed in joules per square metre (J m-2); |
| α | angular subtense: the angle subtended by an apparent source, as viewed at a point in space, expressed in milliradians (mrad). Apparent source is the real or virtual object that forms the smallest possible retinal image. |

Eλ (λ,t), Eλ

spectral irradiance or spectral power density: the radiant power incident per unit area upon a surface, expressed in watts per square metre per nanometre [W m-2 nm-1]; values of Eλ (λ,t) and Eλ come from measurements or may be provided by the manufacturer of the equipment;

Eeff

effective irradiance (UV range): calculated irradiance within the UV wavelength range 180 to 400 nm spectrally weighted by S(λ), expressed in watts per square metre [W m-2];

H

radiant exposure: the time integral of the irradiance, expressed in joules per square metre [J m-2];

Heff

effective radiant exposure: radiant exposure spectrally weighted by S (λ), expressed in joules per square metre [J m-2];

EUVA

total irradiance (UVA): calculated irradiance within the UVA wavelength range 315 to 400 nm, expressed in watts per square metre [W m-2];

HUVA

radiant exposure, the time and wavelength integral or sum of the irradiance within the UVA wavelength range 315 to 400 nm, expressed in joules per square metre [J m-2];

S(λ)

spectral weighting taking into account the wavelength dependence of the health effects of UV radiation on eye and skin (Table 1.2) [dimensionless];

t,Δt

time, duration of the exposure, expressed in seconds [s];

λ

wavelength, expressed in nanometres [nm];

Δλ

bandwidth, expressed in nanometres [nm], of the calculation or measurement intervals;

Lλ(λ),Lλ

spectral radiance of the source expressed in watts per square metre per steradian per nanometre [W m-2 sr-1 nm -1];

R(λ)

spectral weighting taking into account the wavelength dependence of the thermal injury caused to the eye by visible and IRA radiation (Table 1.3) [dimensionless];

LR

effective radiance (thermal injury): calculated radiance spectrally weighted by R (λ) expressed in watts per square metre per steradian [W m-2 sr-1];

B(λ)

spectral weighting taking into account the wavelength dependence of the photochemical injury caused to the eye by blue light radiation (Table 1.3) [dimensionless];

LB

effective radiance (blue light): calculated radiance spectrally weighted by B (λ), expressed in watts per square metre per steradian [W m-2 sr-1];

EB

effective irradiance (blue light): calculated irradiance spectrally weighted by B (λ) expressed in watts per square metre [W m-2];

EIR

total irradiance (thermal injury): calculated irradiance within the infrared wavelength range 780 nm to 3 000 nm expressed in watts per square metre [W m-2];

Eskin

total irradiance (visible, IRA and IRB): calculated irradiance within the visible and infrared wavelength range 380 nm to 3 000 nm, expressed in watts per square metre [W m-2];

Hskin

radiant exposure, the time and wavelength integral or sum of the irradiance within the visible and infrared wavelength range 380 to 3 000 nm, expressed in joules per square metre (J m-2);

α

angular subtense: the angle subtended by an apparent source, as viewed at a point in space, expressed in milliradians (mrad). Apparent source is the real or virtual object that forms the smallest possible retinal image.

Table 1.1: Exposure limit values for non-coherent optical radiation

| Index | Wavelength nm | Exposure limit value | Units | Comment | Part of the body | Hazard |
| --- | --- | --- | --- | --- | --- | --- |
| a. | 180-400
  (UVA, UVB and UVC) | Heff = 30
  Daily value
  8 hours | [J m-2] | | eye (cornea, conjunctiva, lens) skin | photokeratitis, conjunctivitis, cataractogenesis, erythema, elastosis, skin cancer |
| b. | 315-400
  (UVA) | HUVA = 104

  Daily value 8 hours | [J m-2] | | eye lens | cataractogenesis |
| c. | 300-700
  (Blue light) (1) | for t ≤ 10 000 s | LB: [W m-2 sr-1]
  t: [seconds] | for α ≥ 11 mrad | eye retina | photoretinitis |
| d. | 300-700
  (Blue light) (1) | LB = 100
  for t > 10 000 s | [W m-2 sr-1] |
| e. | 300-700
  (Blue light) (1) | for t ≤ 10 000 s | EB: [W m-2]
  t: [seconds] | for α < 11 mrad (2) |
| f. | 300-700
  (Blue light) (1) | EB = 0,01
  t >10 000 s | [W m-2] |
| g. | 380-1 400
  (Visible and IRA) | for t >10 s | [W m-2 sr-1] | Cα = 1,7 for α ≤ 1,7 mrad
  Cα = α for 1,7 ≤ α ≤ 100 mrad
  Cα = 100 for α > 100 mrad
  λ1 = 380; λ2 = 1 400 | eye retina | retinal burn |
| h. | 380-1 400
  (Visible and IRA) | for 10 μs ≤ t ≤ 10 s | LR: [W m-2 sr-1]
  t: [seconds] |
| i. | 380-1 400
  (Visible and IRA) | for t <10 μs | [W m-2 sr-1] |
| j. | 780-1 400
  (IRA) | for t > 10 s | [W m-2 sr-1] | Cα = 11 for α ≤ 11 mrad
  Cα = α for 11≤ α ≤ 100 mrad
  Cα = 100 for α > 100 mrad
  (measurement field-of-view: 11 mrad)
  λ1 = 780; λ2 = 1 400 | eye retina | retinal burn |
| k. | 780-1 400
  (IRA) | for 10 μs ≤ t ≤ 10 s | LR: [W m-2 sr-1]
  t: [seconds] |
| l. | 780-1 400
  (IRA) | for t < 10 μs | [W m-2 sr-1] |
| m. | 780-3 000
  (IRA and IRB) | EIR = 18 000 t-0,75

  for t ≤ 1000 s | E: [W m-2]
  t: [seconds] | | eye (cornea, lens) | corneal burn, cataractogenesis |
| n. | 780-3 000
  (IRA and IRB) | EIR = 100
  for t > 1 000 s | [W m-2] |
| o. | 380-3 000
  (Visible, IRA and IRB) | Hskin = 20 000 t0,25

  for t < 10 s | H: [J m-2]
  t: [seconds] | | skin | burn |

Index

Wavelength nm

Exposure limit value

Units

Comment

Part of the body

Hazard

a.

180-400

(UVA, UVB and UVC)

Heff = 30

Daily value

8 hours

[J m-2]

eye (cornea, conjunctiva, lens) skin

photokeratitis, conjunctivitis, cataractogenesis, erythema, elastosis, skin cancer

b.

315-400

(UVA)

HUVA = 104

Daily value 8 hours

[J m-2]

eye lens

cataractogenesis

c.

300-700

(Blue light) (1)

Formula

for t ≤ 10 000 s

LB: [W m-2 sr-1]

t: [seconds]

for α ≥ 11 mrad

eye retina

photoretinitis

d.

300-700

(Blue light) (1)

LB = 100

for t > 10 000 s

[W m-2 sr-1]

e.

300-700

(Blue light) (1)

Formula

for t ≤ 10 000 s

EB: [W m-2]

t: [seconds]

for α < 11 mrad (2)

f.

300-700

(Blue light) (1)

EB = 0,01

t >10 000 s

[W m-2]

g.

380-1 400

(Visible and IRA)

Formula

for t >10 s

[W m-2 sr-1]

Cα = 1,7 for α ≤ 1,7 mrad

Cα = α for 1,7 ≤ α ≤ 100 mrad

Cα = 100 for α > 100 mrad

λ1 = 380; λ2 = 1 400

eye retina

retinal burn

h.

380-1 400

(Visible and IRA)

Formula

for 10 μs ≤ t ≤ 10 s

LR: [W m-2 sr-1]

t: [seconds]

i.

380-1 400

(Visible and IRA)

Formula

for t <10 μs

[W m-2 sr-1]

j.

780-1 400

(IRA)

Formula

for t > 10 s

[W m-2 sr-1]

Cα = 11 for α ≤ 11 mrad

Cα = α for 11≤ α ≤ 100 mrad

Cα = 100 for α > 100 mrad

(measurement field-of-view: 11 mrad)

λ1 = 780; λ2 = 1 400

eye retina

retinal burn

k.

780-1 400

(IRA)

Formula

for 10 μs ≤ t ≤ 10 s

LR: [W m-2 sr-1]

t: [seconds]

l.

780-1 400

(IRA)

Formula

for t < 10 μs

[W m-2 sr-1]

m.

780-3 000

(IRA and IRB)

EIR = 18 000 t-0,75

for t ≤ 1000 s

E: [W m-2]

t: [seconds]

eye (cornea, lens)

corneal burn, cataractogenesis

n.

780-3 000

(IRA and IRB)

EIR = 100

for t > 1 000 s

[W m-2]

o.

380-3 000

(Visible, IRA and IRB)

Hskin = 20 000 t0,25

for t < 10 s

H: [J m-2]

t: [seconds]

skin

burn

Table 1.2: S(λ) [dimensionless], 180 nm to 400 nm

| λ in nm | S(λ) | λ in nm | S(λ) | λ in nm | S(λ) | λ in nm | S(λ) | λ in nm | S(λ) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 180 | 0,0120 | 228 | 0,1737 | 276 | 0,9434 | 324 | 0,000520 | 372 | 0,000086 |
| 181 | 0,0126 | 229 | 0,1819 | 277 | 0,9272 | 325 | 0,000500 | 373 | 0,000083 |
| 182 | 0,0132 | 230 | 0,1900 | 278 | 0,9112 | 326 | 0,000479 | 374 | 0,000080 |
| 183 | 0,0138 | 231 | 0,1995 | 279 | 0,8954 | 327 | 0,000459 | 375 | 0,000077 |
| 184 | 0,0144 | 232 | 0,2089 | 280 | 0,8800 | 328 | 0,000440 | 376 | 0,000074 |
| 185 | 0,0151 | 233 | 0,2188 | 281 | 0,8568 | 329 | 0,000425 | 377 | 0,000072 |
| 186 | 0,0158 | 234 | 0,2292 | 282 | 0,8342 | 330 | 0,000410 | 378 | 0,000069 |
| 187 | 0,0166 | 235 | 0,2400 | 283 | 0,8122 | 331 | 0,000396 | 379 | 0,000066 |
| 188 | 0,0173 | 236 | 0,2510 | 284 | 0,7908 | 332 | 0,000383 | 380 | 0,000064 |
| 189 | 0,0181 | 237 | 0,2624 | 285 | 0,7700 | 333 | 0,000370 | 381 | 0,000062 |
| 190 | 0,0190 | 238 | 0,2744 | 286 | 0,7420 | 334 | 0,000355 | 382 | 0,000059 |
| 191 | 0,0199 | 239 | 0,2869 | 287 | 0,7151 | 335 | 0,000340 | 383 | 0,000057 |
| 192 | 0,0208 | 240 | 0,3000 | 288 | 0,6891 | 336 | 0,000327 | 384 | 0,000055 |
| 193 | 0,0218 | 241 | 0,3111 | 289 | 0,6641 | 337 | 0,000315 | 385 | 0,000053 |
| 194 | 0,0228 | 242 | 0,3227 | 290 | 0,6400 | 338 | 0,000303 | 386 | 0,000051 |
| 195 | 0,0239 | 243 | 0,3347 | 291 | 0,6186 | 339 | 0,000291 | 387 | 0,000049 |
| 196 | 0,0250 | 244 | 0,3471 | 292 | 0,5980 | 340 | 0,000280 | 388 | 0,000047 |
| 197 | 0,0262 | 245 | 0,3600 | 293 | 0,5780 | 341 | 0,000271 | 389 | 0,000046 |
| 198 | 0,0274 | 246 | 0,3730 | 294 | 0,5587 | 342 | 0,000263 | 390 | 0,000044 |
| 199 | 0,0287 | 247 | 0,3865 | 295 | 0,5400 | 343 | 0,000255 | 391 | 0,000042 |
| 200 | 0,0300 | 248 | 0,4005 | 296 | 0,4984 | 344 | 0,000248 | 392 | 0,000041 |
| 201 | 0,0334 | 249 | 0,4150 | 297 | 0,4600 | 345 | 0,000240 | 393 | 0,000039 |
| 202 | 0,0371 | 250 | 0,4300 | 298 | 0,3989 | 346 | 0,000231 | 394 | 0,000037 |
| 203 | 0,0412 | 251 | 0,4465 | 299 | 0,3459 | 347 | 0,000223 | 395 | 0,000036 |
| 204 | 0,0459 | 252 | 0,4637 | 300 | 0,3000 | 348 | 0,000215 | 396 | 0,000035 |
| 205 | 0,0510 | 253 | 0,4815 | 301 | 0,2210 | 349 | 0,000207 | 397 | 0,000033 |
| 206 | 0,0551 | 254 | 0,5000 | 302 | 0,1629 | 350 | 0,000200 | 398 | 0,000032 |
| 207 | 0,0595 | 255 | 0,5200 | 303 | 0,1200 | 351 | 0,000191 | 399 | 0,000031 |
| 208 | 0,0643 | 256 | 0,5437 | 304 | 0,0849 | 352 | 0,000183 | 400 | 0,000030 |
| 209 | 0,0694 | 257 | 0,5685 | 305 | 0,0600 | 353 | 0,000175 | | |
| 210 | 0,0750 | 258 | 0,5945 | 306 | 0,0454 | 354 | 0,000167 | | |
| 211 | 0,0786 | 259 | 0,6216 | 307 | 0,0344 | 355 | 0,000160 | | |
| 212 | 0,0824 | 260 | 0,6500 | 308 | 0,0260 | 356 | 0,000153 | | |
| 213 | 0,0864 | 261 | 0,6792 | 309 | 0,0197 | 357 | 0,000147 | | |
| 214 | 0,0906 | 262 | 0,7098 | 310 | 0,0150 | 358 | 0,000141 | | |
| 215 | 0,0950 | 263 | 0,7417 | 311 | 0,0111 | 359 | 0,000136 | | |
| 216 | 0,0995 | 264 | 0,7751 | 312 | 0,0081 | 360 | 0,000130 | | |
| 217 | 0,1043 | 265 | 0,8100 | 313 | 0,0060 | 361 | 0,000126 | | |
| 218 | 0,1093 | 266 | 0,8449 | 314 | 0,0042 | 362 | 0,000122 | | |
| 219 | 0,1145 | 267 | 0,8812 | 315 | 0,0030 | 363 | 0,000118 | | |
| 220 | 0,1200 | 268 | 0,9192 | 316 | 0,0024 | 364 | 0,000114 | | |
| 221 | 0,1257 | 269 | 0,9587 | 317 | 0,0020 | 365 | 0,000110 | | |
| 222 | 0,1316 | 270 | 1,0000 | 318 | 0,0016 | 366 | 0,000106 | | |
| 223 | 0,1378 | 271 | 0,9919 | 319 | 0,0012 | 367 | 0,000103 | | |
| 224 | 0,1444 | 272 | 0,9838 | 320 | 0,0010 | 368 | 0,000099 | | |
| 225 | 0,1500 | 273 | 0,9758 | 321 | 0,000819 | 369 | 0,000096 | | |
| 226 | 0,1583 | 274 | 0,9679 | 322 | 0,000670 | 370 | 0,000093 | | |
| 227 | 0,1658 | 275 | 0,9600 | 323 | 0,000540 | 371 | 0,000090 | | |

λ in nm

S(λ)

λ in nm

S(λ)

λ in nm

S(λ)

λ in nm

S(λ)

λ in nm

S(λ)

180

0,0120

228

0,1737

276

0,9434

324

0,000520

372

0,000086

181

0,0126

229

0,1819

277

0,9272

325

0,000500

373

0,000083

182

0,0132

230

0,1900

278

0,9112

326

0,000479

374

0,000080

183

0,0138

231

0,1995

279

0,8954

327

0,000459

375

0,000077

184

0,0144

232

0,2089

280

0,8800

328

0,000440

376

0,000074

185

0,0151

233

0,2188

281

0,8568

329

0,000425

377

0,000072

186

0,0158

234

0,2292

282

0,8342

330

0,000410

378

0,000069

187

0,0166

235

0,2400

283

0,8122

331

0,000396

379

0,000066

188

0,0173

236

0,2510

284

0,7908

332

0,000383

380

0,000064

189

0,0181

237

0,2624

285

0,7700

333

0,000370

381

0,000062

190

0,0190

238

0,2744

286

0,7420

334

0,000355

382

0,000059

191

0,0199

239

0,2869

287

0,7151

335

0,000340

383

0,000057

192

0,0208

240

0,3000

288

0,6891

336

0,000327

384

0,000055

193

0,0218

241

0,3111

289

0,6641

337

0,000315

385

0,000053

194

0,0228

242

0,3227

290

0,6400

338

0,000303

386

0,000051

195

0,0239

243

0,3347

291

0,6186

339

0,000291

387

0,000049

196

0,0250

244

0,3471

292

0,5980

340

0,000280

388

0,000047

197

0,0262

245

0,3600

293

0,5780

341

0,000271

389

0,000046

198

0,0274

246

0,3730

294

0,5587

342

0,000263

390

0,000044

199

0,0287

247

0,3865

295

0,5400

343

0,000255

391

0,000042

200

0,0300

248

0,4005

296

0,4984

344

0,000248

392

0,000041

201

0,0334

249

0,4150

297

0,4600

345

0,000240

393

0,000039

202

0,0371

250

0,4300

298

0,3989

346

0,000231

394

0,000037

203

0,0412

251

0,4465

299

0,3459

347

0,000223

395

0,000036

204

0,0459

252

0,4637

300

0,3000

348

0,000215

396

0,000035

205

0,0510

253

0,4815

301

0,2210

349

0,000207

397

0,000033

206

0,0551

254

0,5000

302

0,1629

350

0,000200

398

0,000032

207

0,0595

255

0,5200

303

0,1200

351

0,000191

399

0,000031

208

0,0643

256

0,5437

304

0,0849

352

0,000183

400

0,000030

209

0,0694

257

0,5685

305

0,0600

353

0,000175

210

0,0750

258

0,5945

306

0,0454

354

0,000167

211

0,0786

259

0,6216

307

0,0344

355

0,000160

212

0,0824

260

0,6500

308

0,0260

356

0,000153

213

0,0864

261

0,6792

309

0,0197

357

0,000147

214

0,0906

262

0,7098

310

0,0150

358

0,000141

215

0,0950

263

0,7417

311

0,0111

359

0,000136

216

0,0995

264

0,7751

312

0,0081

360

0,000130

217

0,1043

265

0,8100

313

0,0060

361

0,000126

218

0,1093

266

0,8449

314

0,0042

362

0,000122

219

0,1145

267

0,8812

315

0,0030

363

0,000118

220

0,1200

268

0,9192

316

0,0024

364

0,000114

221

0,1257

269

0,9587

317

0,0020

365

0,000110

222

0,1316

270

1,0000

318

0,0016

366

0,000106

223

0,1378

271

0,9919

319

0,0012

367

0,000103

224

0,1444

272

0,9838

320

0,0010

368

0,000099

225

0,1500

273

0,9758

321

0,000819

369

0,000096

226

0,1583

274

0,9679

322

0,000670

370

0,000093

227

0,1658

275

0,9600

323

0,000540

371

0,000090

Table 1.3: B(λ), R(λ) [dimensionless], 380 nm to 1400 nm

| λ in nm | B(λ) | R(λ) |
| --- | --- | --- |
| 300 ≤ λ < 380 | 0,01 | - |
| 380 | 0,01 | 0,1 |
| 385 | 0,013 | 0,13 |
| 390 | 0,025 | 0,25 |
| 395 | 0,05 | 0,5 |
| 400 | 0,1 | 1 |
| 405 | 0,2 | 2 |
| 410 | 0,4 | 4 |
| 415 | 0,8 | 8 |
| 420 | 0,9 | 9 |
| 425 | 0,95 | 9,5 |
| 430 | 0,98 | 9,8 |
| 435 | 1 | 10 |
| 440 | 1 | 10 |
| 445 | 0,97 | 9,7 |
| 450 | 0,94 | 9,4 |
| 455 | 0,9 | 9 |
| 460 | 0,8 | 8 |
| 465 | 0,7 | 7 |
| 470 | 0,62 | 6,2 |
| 475 | 0,55 | 5,5 |
| 480 | 0,45 | 4,5 |
| 485 | 0,32 | 3,2 |
| 490 | 0,22 | 2,2 |
| 495 | 0,16 | 1,6 |
| 500 | 0,1 | 1 |
| 500 < λ ≤ 600 | 100,02·(450-λ) | 1 |
| 600 < λ ≤ 700 | 0,001 | 1 |
| 700 < λ ≤ 1 050 | - | 100,002·(700-λ) |
| 1 050 < λ ≤ 1 150 | - | 0,2 |
| 1 150 < λ ≤ 1 200 | - | 0,2·100,02·(1150-λ) |
| 1 200 < λ ≤ 1 400 | - | 0,02 |

λ in nm

B(λ)

R(λ)

300 ≤ λ < 380

0,01

-

380

0,01

0,1

385

0,013

0,13

390

0,025

0,25

395

0,05

0,5

400

0,1

1

405

0,2

2

410

0,4

4

415

0,8

8

420

0,9

9

425

0,95

9,5

430

0,98

9,8

435

1

10

440

1

10

445

0,97

9,7

450

0,94

9,4

455

0,9

9

460

0,8

8

465

0,7

7

470

0,62

6,2

475

0,55

5,5

480

0,45

4,5

485

0,32

3,2

490

0,22

2,2

495

0,16

1,6

500

0,1

1

500 < λ ≤ 600

100,02·(450-λ)

1

600 < λ ≤ 700

0,001

1

700 < λ ≤ 1 050

-

100,002·(700-λ)

1 050 < λ ≤ 1 150

-

0,2

1 150 < λ ≤ 1 200

-

0,2·100,02·(1150-λ)

1 200 < λ ≤ 1 400

-

0,02

---

(1)  The range of 300 to 700 nm covers parts of UVB, all UVA and most of visible radiation; however, the associated hazard is commonly referred to as ‘blue light’ hazard. Blue light strictly speaking covers only the range of approximately 400 to 490 nm.

(2)  For steady fixation of very small sources with an angular subtense < 11 mrad, LB can be converted to EB. This normally applies only for ophthalmic instruments or a stabilized eye during anaesthesia. The maximum ‘stare time’ is found by: tmax = 100 / EB with EB expressed in W m-2. Due to eye movements during normal visual tasks this does not exceed 100s.

ANNEX II

LASER OPTICAL RADIATION

The biophysically relevant exposure values to optical radiation can be determined with the formulae below. The formulae to be used depend on the wavelength and duration of radiation emitted by the source and the results should be compared with the corresponding exposure limit values indicated in the Tables 2.2-2.4. More than one exposure value and corresponding exposure limit can be relevant for a given source of laser optical radiation.

Coefficients used as calculation tools within the Tables 2.2, 2.3 and 2.4 are listed in Table 2.5 and corrections for repetitive exposure are listed in Table 2.6.

Formula

Formula

Notes:

| dP | power expressed in watt [W]; |
| --- | --- |
| dA | surface expressed in square meter [m2]; |
| E(t),E | irradiance or power density: the radiant power incident per unit area upon a surface, generally expressed in watts per square metre [W m-2]. Values of E(t), E come from measurements or may be provided by the manufacturer of the equipment; |
| H | radiant exposure, the time integral of the irradiance, expressed in joules per square metre [J m-2]; |
| t | time, duration of the exposure, expressed in seconds [s]; |
| λ | wavelength, expressed in nanometres [nm]; |
| γ | limiting cone angle of measurement field-of-view expressed in milliradians [mrad]; |
| γm | measurement field of view expressed in milliradians [mrad]; |
| α | angular subtense of a source expressed in milliradians [mrad];
  limiting aperture: the circular area over which irradiance and radiant exposure are averaged; |
| G | integrated radiance: the integral of the radiance over a given exposure time expressed as radiant energy per unit area of a radiating surface per unit solid angle of emission, in joules per square metre per steradian [J m-2 sr-1]. |

dP

power expressed in watt [W];

dA

surface expressed in square meter [m2];

E(t),E

irradiance or power density: the radiant power incident per unit area upon a surface, generally expressed in watts per square metre [W m-2]. Values of E(t), E come from measurements or may be provided by the manufacturer of the equipment;

H

radiant exposure, the time integral of the irradiance, expressed in joules per square metre [J m-2];

t

time, duration of the exposure, expressed in seconds [s];

λ

wavelength, expressed in nanometres [nm];

γ

limiting cone angle of measurement field-of-view expressed in milliradians [mrad];

γm

measurement field of view expressed in milliradians [mrad];

α

angular subtense of a source expressed in milliradians [mrad];

limiting aperture: the circular area over which irradiance and radiant exposure are averaged;

G

integrated radiance: the integral of the radiance over a given exposure time expressed as radiant energy per unit area of a radiating surface per unit solid angle of emission, in joules per square metre per steradian [J m-2 sr-1].

Table 2.1: Radiation hazards

| Wavelength [nm]
  λ | Radiation range | Affected organ | Hazard | Exposure limit value table |
| --- | --- | --- | --- | --- |
| 180 to 400 | UV | eye | photochemical damage and thermal damage | 2.2, 2.3 |
| 180 to 400 | UV | skin | erythema | 2.4 |
| 400 to 700 | visible | eye | retinal damage | 2.2 |
| 400 to 600 | visible | eye | photochemical damage | 2.3 |
| 400 to 700 | visible | skin | thermal damage | 2.4 |
| 700 to 1 400 | IRA | eye | thermal damage | 2.2, 2.3 |
| 700 to 1 400 | IRA | skin | thermal damage | 2.4 |
| 1 400 to 2 600 | IRB | eye | thermal damage | 2.2 |
| 2 600 to 106 | IRC | eye | thermal damage | 2.2 |
| 1 400 to 106 | IRB, IRC | eye | thermal damage | 2.3 |
| 1 400 to 106 | IRB, IRC | skin | thermal damage | 2.4 |

Wavelength [nm]

λ

Radiation range

Affected organ

Hazard

Exposure limit value table

180 to 400

UV

eye

photochemical damage and thermal damage

2.2, 2.3

180 to 400

UV

skin

erythema

2.4

400 to 700

visible

eye

retinal damage

2.2

400 to 600

visible

eye

photochemical damage

2.3

400 to 700

visible

skin

thermal damage

2.4

700 to 1 400

IRA

eye

thermal damage

2.2, 2.3

700 to 1 400

IRA

skin

thermal damage

2.4

1 400 to 2 600

IRB

eye

thermal damage

2.2

2 600 to 106

IRC

eye

thermal damage

2.2

1 400 to 106

IRB, IRC

eye

thermal damage

2.3

1 400 to 106

IRB, IRC

skin

thermal damage

2.4

Table 2.2: Exposure limit values for laser exposure to the eye Short exposure duration < 10 s

| Wavelength (1) [nm] | Aperture | Duration [s] |
| --- | --- | --- |
| 10-13 - 10-11 | 10-11 - 10-9 | 10-9 - 10-7 | 10-7 - 1,8 · 10-5 | 1,8 · 10-5 - 5 · 10-5 | 5 · 10-5 - 10-3 | 10-3 - 101 |
| UVC | 180-280 | 1 mm for t < 0,3 s;
  1,5 · t0,375

  for 0,3< t < 10 s | E = 3 · 1010 · [W m-2] (2) | H = 30 [J m-2] |
| UVB | 280-302 |
| 303 | H = 40 [J m-2]; if t < 2,6 · 10-9 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 304 | H = 60 [J m-2]; if t < 1,3 · 10-8 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 305 | H = 100 [J m-2]; if t < 1,0 · 10-7 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 306 | H = 160 [J m-2]; if t < 6,7 · 10-7 then H = 5,6 · 103 t 0,25[J m-2] (3) |
| 307 | H = 250 [J m-2]; if t < 4,0 · 10-6 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 308 | H = 400 [J m-2]; if t < 2,6 · 10-5 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 309 | H = 630 [J m-2]; if t < 1,6 · 10-4 then H = 5,6 · 103 t 0,25[J m-2] (3) |
| 310 | H = 103 [J m-2]; if t < 1,0 · 10-3 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 311 | H = 1,6 · 103 [J m-2]; if t < 6,7 · 10-3 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 312 | H = 2,5 · 103 [J m-2]; if t < 4,0 · 10-2 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 313 | H = 4,0 · 103 [J m-2]; if t < 2,6 · 10-1 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| 314 | H = 6,3 · 103 [J m-2]; if t < 1,6 · 100 then H = 5,6 · 103 t 0,25 [J m-2] (3) |
| UVA | 315-400 | H = 5,6 · 103 t0,25 [J m-2] |
| Visible & IRA | 400-700 | 7 mm | H = 1,5 · 10-4 CE [J m-2] | H = 2,7 · 104 t0,75 CE [J m-2] | H=5·10-3 CE [J m-2] | H= 18 · t0,75 CE [J m-2] |
| 700-1 050 | H = 1,5 · 10-4 CA CE [J m-2] | H = 2,7 · 104 t0,75 CA CE [J m-2] | H=5·10-3 CA CE [J m-2] | H= 18 · t0,75 CA CE [J m-2] |
| 1 050-1 400 | H = 1,5 · 10-3 CC CE [J m-2] | H =2,7 · 105 t0,75 CC CE [J m-2] | H= 5 · 10-2 CC CE [J m-2] | H= 90 · t0,75 CC CE [J m-2] |
| IRB & IRC | 1 400-1 500 | (4) | E = 1012 [W m-2] (2) | H= 103 [J m-2] | H=5,6 · 103 · t0,25 [J m-2] |
| 1 500-1 800 | E = 1013 [W m-2] (2) | H= 104 [J m-2] |
| 1 800-2 600 | E = 1012 [W m-2] (2) | H= 103 [J m-2] | H=5,6 ·103 · t0,25 [J m-2] |
| 2 600-106 | E = 1011 [W m-2] (2) | H=100 [J m-2] | H = 5,6 · 103 · t0,25 [J m-2] |

Wavelength (1) [nm]

Aperture

Duration [s]

10-13 - 10-11

10-11 - 10-9

10-9 - 10-7

10-7 - 1,8 · 10-5

1,8 · 10-5 - 5 · 10-5

5 · 10-5 - 10-3

10-3 - 101

UVC

180-280

1 mm for t < 0,3 s;

1,5 · t0,375

for 0,3< t < 10 s

E = 3 · 1010 · [W m-2] (2)

H = 30 [J m-2]

UVB

280-302

303

H = 40 [J m-2]; if t < 2,6 · 10-9 then H = 5,6 · 103 t 0,25 [J m-2] (3)

304

H = 60 [J m-2]; if t < 1,3 · 10-8 then H = 5,6 · 103 t 0,25 [J m-2] (3)

305

H = 100 [J m-2]; if t < 1,0 · 10-7 then H = 5,6 · 103 t 0,25 [J m-2] (3)

306

H = 160 [J m-2]; if t < 6,7 · 10-7 then H = 5,6 · 103 t 0,25[J m-2] (3)

307

H = 250 [J m-2]; if t < 4,0 · 10-6 then H = 5,6 · 103 t 0,25 [J m-2] (3)

308

H = 400 [J m-2]; if t < 2,6 · 10-5 then H = 5,6 · 103 t 0,25 [J m-2] (3)

309

H = 630 [J m-2]; if t < 1,6 · 10-4 then H = 5,6 · 103 t 0,25[J m-2] (3)

310

H = 103 [J m-2]; if t < 1,0 · 10-3 then H = 5,6 · 103 t 0,25 [J m-2] (3)

311

H = 1,6 · 103 [J m-2]; if t < 6,7 · 10-3 then H = 5,6 · 103 t 0,25 [J m-2] (3)

312

H = 2,5 · 103 [J m-2]; if t < 4,0 · 10-2 then H = 5,6 · 103 t 0,25 [J m-2] (3)

313

H = 4,0 · 103 [J m-2]; if t < 2,6 · 10-1 then H = 5,6 · 103 t 0,25 [J m-2] (3)

314

H = 6,3 · 103 [J m-2]; if t < 1,6 · 100 then H = 5,6 · 103 t 0,25 [J m-2] (3)

UVA

315-400

H = 5,6 · 103 t0,25 [J m-2]

Visible & IRA

400-700

7 mm

H = 1,5 · 10-4 CE [J m-2]

H = 2,7 · 104 t0,75 CE [J m-2]

H=5·10-3 CE [J m-2]

H= 18 · t0,75 CE [J m-2]

700-1 050

H = 1,5 · 10-4 CA CE [J m-2]

H = 2,7 · 104 t0,75 CA CE [J m-2]

H=5·10-3 CA CE [J m-2]

H= 18 · t0,75 CA CE [J m-2]

1 050-1 400

H = 1,5 · 10-3 CC CE [J m-2]

H =2,7 · 105 t0,75 CC CE [J m-2]

H= 5 · 10-2 CC CE [J m-2]

H= 90 · t0,75 CC CE [J m-2]

IRB & IRC

1 400-1 500

(4)

E = 1012 [W m-2] (2)

H= 103 [J m-2]

H=5,6 · 103 · t0,25 [J m-2]

1 500-1 800

E = 1013 [W m-2] (2)

H= 104 [J m-2]

1 800-2 600

E = 1012 [W m-2] (2)

H= 103 [J m-2]

H=5,6 ·103 · t0,25 [J m-2]

2 600-106

E = 1011 [W m-2] (2)

H=100 [J m-2]

H = 5,6 · 103 · t0,25 [J m-2]

Table 2.3: Exposure limit values for laser exposure to the eye Long exposure duration ≥ 10 s

| Wavelength (5)[nm] | Aperture | Duration [s] |
| --- | --- | --- |
| 101 - 102 | 102 - 104 | 104 -3 · 104 |
| UVC | 180-280 | 3,5 mm | H = 30 [J m-2] |
| UVB | 280-302 |
| 303 | H = 40 [J m-2] |
| 304 | H = 60 [J m-2] |
| 305 | H = 100 [J m-2] |
| 306 | H = 160 [J m-2] |
| 307 | H = 250 [J m-2] |
| 308 | H = 400 [J m-2] |
| 309 | H = 630 [J m-2] |
| 310 | H = 1,0 103 [J m-2] |
| 311 | H = 1,6 103 [J m-2] |
| 312 | H = 2,5 103 [J m-2] |
| 313 | H = 4,0 103 [J m-2] |
| 314 | H = 6,3 103 [J m-2] |
| UVA | 315-400 | H = 104 [J m-2] |
| Visible
  400-700 | 400-600
  Photochemical (6)

  Retinal damage | 7 mm | H = 100 CB [J m-2]
  (γ = 11 mrad) (7) | E = 1 CB [W m-2]; (γ = 1,1 t0,5 mrad) (7) | E = 1 CB [W m-2]
  (γ = 110 mrad) (7) |
| 400-700
  Thermal (6)

  Retinal damage | if α < 1,5 mrad then E = 10 [W m-2]
  if α > 1,5 mrad and t ≤ T2 then H = 18CE t0,75 [J m-2]
  if α > 1,5 mrad and t > T2 then E = 18CE T2
  -0,25 [W m-2] |
| IRA | 700-1 400 | 7 mm | if α < 1,5 mrad then E = 10 CA CC [W m-2]
  if α > 1,5 mrad and t ≤ T2 then H = 18 CA CC CE t0,75 [J m-2]
  if α > 1,5 mrad and t > T2 then E = 18 CA CC CE T2
  -0,25 [W m-2] (not to exceed 1 000 W m-2) |
| IRB & IRC | 1 400-106 | (8) | E = 1 000 [W m-2] |

Wavelength (5)[nm]

Aperture

Duration [s]

101 - 102

102 - 104

104 -3 · 104

UVC

180-280

3,5 mm

H = 30 [J m-2]

UVB

280-302

303

H = 40 [J m-2]

304

H = 60 [J m-2]

305

H = 100 [J m-2]

306

H = 160 [J m-2]

307

H = 250 [J m-2]

308

H = 400 [J m-2]

309

H = 630 [J m-2]

310

H = 1,0 103 [J m-2]

311

H = 1,6 103 [J m-2]

312

H = 2,5 103 [J m-2]

313

H = 4,0 103 [J m-2]

314

H = 6,3 103 [J m-2]

UVA

315-400

H = 104 [J m-2]

Visible

400-700

400-600

Photochemical (6)

Retinal damage

7 mm

H = 100 CB [J m-2]

(γ = 11 mrad) (7)

E = 1 CB [W m-2]; (γ = 1,1 t0,5 mrad) (7)

E = 1 CB [W m-2]

(γ = 110 mrad) (7)

400-700

Thermal (6)

Retinal damage

if α < 1,5 mrad then E = 10 [W m-2]

if α > 1,5 mrad and t ≤ T2 then H = 18CE t0,75 [J m-2]

if α > 1,5 mrad and t > T2 then E = 18CE T2
  -0,25 [W m-2]

IRA

700-1 400

7 mm

if α < 1,5 mrad then E = 10 CA CC [W m-2]

if α > 1,5 mrad and t ≤ T2 then H = 18 CA CC CE t0,75 [J m-2]

if α > 1,5 mrad and t > T2 then E = 18 CA CC CE T2
  -0,25 [W m-2] (not to exceed 1 000 W m-2)

IRB & IRC

1 400-106

(8)

E = 1 000 [W m-2]

Table 2.4: Exposure limit values for laser exposure of skin

| Wavelength (9)[nm] | Aperture | Duration [s] |
| --- | --- | --- |
| < 10-9 | 10-9 - 10-7 | 10-7 - 10-3 | 10-3 - 101 | 101 - 103 | 103 - 3 · 104 |
| UV (A, B, C) | 180-400 | 3,5 mm | E = 3 · 1010 [W m-2] | Same as Eye Exposure Limits |
| Visible & IRA | 400-700 | 3,5 mm | E = 2 · 1011 [W m-2] | H = 200 CA [J m-2] | H = 1,1 · 104 CA t 0,25 [J m-2] | E = 2 · 103 CA [W m-2] |
| 700 -1 400 | E = 2 · 1011 CA [W m-2] |
| IRB & IRC | 1 400-1 500 | E = 1012 [W m-2] | Same as Eye Exposure Limits |
| 1 500-1 800 | E = 1013 [W m-2] |
| 1 800-2 600 | E = 1012 [W m-2] |
| 2 600-106 | E = 1011 [W m-2] |

Wavelength (9)[nm]

Aperture

Duration [s]

< 10-9

10-9 - 10-7

10-7 - 10-3

10-3 - 101

101 - 103

103 - 3 · 104

UV (A, B, C)

180-400

3,5 mm

E = 3 · 1010 [W m-2]

Same as Eye Exposure Limits

Visible & IRA

400-700

3,5 mm

E = 2 · 1011 [W m-2]

H = 200 CA [J m-2]

H = 1,1 · 104 CA t 0,25 [J m-2]

E = 2 · 103 CA [W m-2]

700 -1 400

E = 2 · 1011 CA [W m-2]

IRB & IRC

1 400-1 500

E = 1012 [W m-2]

Same as Eye Exposure Limits

1 500-1 800

E = 1013 [W m-2]

1 800-2 600

E = 1012 [W m-2]

2 600-106

E = 1011 [W m-2]

Table 2.5: Applied correction factors and other calculation parameters

| Parameter as
  listed in ICNIRP | Valid spectral range
  (nm) | Value |
| --- | --- | --- |
| CA | λ < 700 | CA = 1,0 |
| 700-1 050 | CA = 10 0,002(λ — 700) |
| 1 050-1 400 | CA = 5,0 |
| CB | 400-450 | CB = 1,0 |
| 450-700 | CB = 10 0,02(λ — 450) |
| CC | 700-1 150 | CC = 1,0 |
| 1 150-1 200 | CC = 10 0,018(λ — 1150) |
| 1 200-1 400 | CC = 8,0 |
| T1 | λ < 450 | T1 = 10 s |
| 450-500 | T1 = 10 · [10 0,02 (λ — 450)] s |
| λ > 500 | T1 = 100 s |
| Parameter as listed in ICNIRP | Valid for biological effect | Value |
| αmin | all thermal effects | αmin = 1,5 mrad |
| Parameter as listed in ICNIRP | Valid angular range (mrad) | Value |
| CE | α < αmin | CE = 1,0 |
| αmin < α < 100 | CE = α / αmin |
| α > 100 | CE = α2 / (αmin · αmax) mrad
  with αmax = 100 mrad |
| T2 | α < 1,5 | T2 = 10 s |
| 1,5 < α < 100 | T2 = 10 · [10 (α — 1,5) / 98,5] s |
| α > 100 | T2 = 100 s |
| Parameter as listed in ICNIRP | Valid exposure time range (s) | Value |
| γ | t ≤ 100 | γ = 11 [mrad] |
| 100 < t < 104 | γ = 1,1 t 0,5 [mrad] |
| t > 104 | γ = 110 [mrad] |

Parameter as

listed in ICNIRP

Valid spectral range

(nm)

Value

CA

λ < 700

CA = 1,0

700-1 050

CA = 10 0,002(λ — 700)

1 050-1 400

CA = 5,0

CB

400-450

CB = 1,0

450-700

CB = 10 0,02(λ — 450)

CC

700-1 150

CC = 1,0

1 150-1 200

CC = 10 0,018(λ — 1150)

1 200-1 400

CC = 8,0

T1

λ < 450

T1 = 10 s

450-500

T1 = 10 · [10 0,02 (λ — 450)] s

λ > 500

T1 = 100 s

Parameter as listed in ICNIRP

Valid for biological effect

Value

αmin

all thermal effects

αmin = 1,5 mrad

Parameter as listed in ICNIRP

Valid angular range (mrad)

Value

CE

α < αmin

CE = 1,0

αmin < α < 100

CE = α / αmin

α > 100

CE = α2 / (αmin · αmax) mrad

with αmax = 100 mrad

T2

α < 1,5

T2 = 10 s

1,5 < α < 100

T2 = 10 · [10 (α — 1,5) / 98,5] s

α > 100

T2 = 100 s

Parameter as listed in ICNIRP

Valid exposure time range (s)

Value

γ

t ≤ 100

γ = 11 [mrad]

100 < t < 104

γ = 1,1 t 0,5 [mrad]

t > 104

γ = 110 [mrad]

Table 2.6: Correction for repetitive exposure

Each of the following three general rules should be applied to all repetitive exposures as occur from repetitively pulsed or scanning laser systems:

| 1. | The exposure from any single pulse in a train of pulses shall not exceed the exposure limit value for a single pulse of that pulse duration. |
| --- | --- |

1.

The exposure from any single pulse in a train of pulses shall not exceed the exposure limit value for a single pulse of that pulse duration.

| 2. | The exposure from any group of pulses (or sub-group of pulses in a train) delivered in time t shall not exceed the exposure limit value for time t. |
| --- | --- |

2.

The exposure from any group of pulses (or sub-group of pulses in a train) delivered in time t shall not exceed the exposure limit value for time t.

| 3. | The exposure from any single pulse within a group of pulses shall not exceed the single-pulse exposure limit value multiplied by a cumulative-thermal correction factor Cp = N-0,25, where N is the number of pulses. This rule applies only to exposure limits to protect against thermal injury, where all pulses delivered in less than Tmin are treated as a single pulse. |
| --- | --- |

3.

The exposure from any single pulse within a group of pulses shall not exceed the single-pulse exposure limit value multiplied by a cumulative-thermal correction factor Cp = N-0,25, where N is the number of pulses. This rule applies only to exposure limits to protect against thermal injury, where all pulses delivered in less than Tmin are treated as a single pulse.

| Parameter | Valid spectral range (nm) | Value |
| --- | --- | --- |
| Tmin | 315 < λ ≤ 400 | Tmin = 10-9 s (= 1 ns) |
| 400 < λ ≤ 1 050 | Tmin = 18 · 10-6 s (= 18 μs) |
| 1 050< λ ≤ 1 400 | Tmin = 50 · 10-6 s (= 50 μs) |
| 1 400< λ ≤ 1 500 | Tmin = 10-3 s (= 1 ms) |
| 1 500< λ ≤ 1 800 | Tmin = 10 s |
| 1 800< λ ≤ 2 600 | Tmin = 10-3 s (= 1 ms) |
| 2 600< λ ≤ 106 | Tmin = 10-7 s (= 100 ns) |

Parameter

Valid spectral range (nm)

Value

Tmin

315 < λ ≤ 400

Tmin = 10-9 s (= 1 ns)

400 < λ ≤ 1 050

Tmin = 18 · 10-6 s (= 18 μs)

1 050< λ ≤ 1 400

Tmin = 50 · 10-6 s (= 50 μs)

1 400< λ ≤ 1 500

Tmin = 10-3 s (= 1 ms)

1 500< λ ≤ 1 800

Tmin = 10 s

1 800< λ ≤ 2 600

Tmin = 10-3 s (= 1 ms)

2 600< λ ≤ 106

Tmin = 10-7 s (= 100 ns)

---

(1)  If the wavelength of the laser is covered by two limits, then the more restrictive applies.

(2)  Due to lack of data at these pulse lengths, ICNIRP recommends the use of the 1 ns irradiance limits.

(3)  The table states values for single laser pulses. In case of multiple laser pulses, then the laser pulse durations of pulses falling within an interval Tmin (listed in Table 2.6) must be added up and the resulting time value must be filled in for t in the formula: 5,6 · 103 t 0,25.

(4)  When 1 400≤λ<105 nm: aperture diameter = 1 mm for t ≤ 0,3 s and 1,5 t0,375 mm for 0,3 s < t < 10 s; when 105≤ λ <106 nm: aperture diameter = 11 mm.

(5)  If the wavelength of the laser is covered by two limits, then the more restrictive applies.

(6)  For small sources subtending an angle of 1,5 mrad or less, the visible dual limits E from 400 nm to 600 nm reduce to the thermal limits for 10s ≤ t < T1 and to photochemical limits for longer times. For T1 and T2 see Table 2.5. The photochemical retinal hazard limit may also be expressed as a time integrated radiance G = 106 CB [J m-2 sr-1] for t > 10s up to t = 10 000 s and L = 100 CB [W m-2 sr-1] for t > 10 000 s. For the measurement of G and L γm must be used as averaging field of view. The official border between visible and infrared is 780 nm as defined by the CIE. The column with wavelength band names is only meant to provide better overview for the user. (The notation G is used by CEN; the notation Lt is used by CIE; the notation LP is used by IEC and CENELEC).

(7)  For wavelength 1 400-105 nm: aperture diameter = 3,5 mm; for wavelength 105-106 nm: aperture diameter = 11 mm.

(8)  For measurement of the exposure value the consideration of γ is defined as follows: If α (angular subtense of a source) > γ (limiting cone angle, indicated in brackets in the corresponding column) then the measurement field of view γm should be the given value of γ. (If a larger measurement field of view is used, then the hazard would be overestimated).

If α < γ then the measurement field of view γm must be large enough to fully enclose the source but is otherwise not limited and may be larger than γ.

(9)  If the wavelength or another condition of the laser is covered by two limits, then the more restrictive applies.

P6_TA(2005)0330

Competitiveness of audiovisual and information services: protection of minors and human dignity ***I

European Parliament legislative resolution on the proposal for a recommendation of the European Parliament and of the Council on the protection of minors and human dignity and the right of reply in relation to the competitiveness of the European audiovisual and information services industry (COM(2004)0341 — C6-0029/2004 — 2004/0117(COD))

(Codecision procedure: first reading)

The European Parliament,

| — | having regard to the Commission proposal to the European Parliament and the Council (COM(2004) 0341) (1), |
| --- | --- |

—

having regard to the Commission proposal to the European Parliament and the Council (COM(2004) 0341) (1),

| — | having regard to Article 251(2) and Article 157 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament (C6-0029/2004), |
| --- | --- |

—

having regard to Article 251(2) and Article 157 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament (C6-0029/2004),

| — | having regard to Rule 51 of its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 51 of its Rules of Procedure,

| — | having regard to the report of the Committee on Culture and Education and the opinion of the Committee on Civil Liberties, Justice and Home Affairs (A6-0244/2005), |
| --- | --- |

—

having regard to the report of the Committee on Culture and Education and the opinion of the Committee on Civil Liberties, Justice and Home Affairs (A6-0244/2005),

| 1. | Approves the Commission proposal as amended; |
| --- | --- |

1.

Approves the Commission proposal as amended;

| 2. | Calls on the Commission to refer the matter to Parliament again if it intends to amend the proposal substantially or replace it with another text; |
| --- | --- |

2.

Calls on the Commission to refer the matter to Parliament again if it intends to amend the proposal substantially or replace it with another text;

| 3. | Instructs its President to forward its position to the Council and Commission. |
| --- | --- |

3.

Instructs its President to forward its position to the Council and Commission.

---

(1)  Not yet published in OJ.

P6_TC1-COD(2004)0117

Position of the European Parliament adopted at first reading on 7 September 2005 with a view to the adoption of European Parliament and Council Recommendation 2005/.../EC on the protection of minors and human dignity and the right of reply in relation to the competitiveness of the European audiovisual and on-line information services industry

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 157 thereof,

Having regard to the proposal from the Commission (1),

Having regard to the Opinion of the European Economic and Social Committee (1),

Having regard to the Opinion of the Committee of the Regions (1),

Acting in accordance with the procedure referred to in Article 251 of the Treaty (2),

Whereas:

| (1) | Article I-2 of the Treaty establishing a Constitution for Europe, signed on 29 October 2004, provides that one of the values on which the European Union is founded is respect for human dignity; in the Charter of Fundamental Rights of the European Union (‘the Charter’), incorporated in Part II of the Treaty establishing a Constitution for Europe, the inviolability of human dignity is recognised under Article 1 (Article II-61 of the Treaty), which provides that it must be respected and protected. |
| --- | --- |

(1)

Article I-2 of the Treaty establishing a Constitution for Europe, signed on 29 October 2004, provides that one of the values on which the European Union is founded is respect for human dignity; in the Charter of Fundamental Rights of the European Union (‘the Charter’), incorporated in Part II of the Treaty establishing a Constitution for Europe, the inviolability of human dignity is recognised under Article 1 (Article II-61 of the Treaty), which provides that it must be respected and protected.

| (2) | Human dignity is inalienable; it does not admit any exclusion or limitation and it constitutes the foundation and origin of all legal instruments drawn up at national and international level to protect human rights; The European Union should gear its political action to preventing any form of violation of the principle of respect for human dignity. |
| --- | --- |

(2)

Human dignity is inalienable; it does not admit any exclusion or limitation and it constitutes the foundation and origin of all legal instruments drawn up at national and international level to protect human rights; The European Union should gear its political action to preventing any form of violation of the principle of respect for human dignity.

| (3) | Article I-3 of the Treaty establishing a Constitution for Europe provides that one of the European Union's objectives is to protect the rights of the child; Article 24 of the Charter (Article II-84 of the Treaty) establishes that children shall have the right to such protection and care as is necessary for their well-being and that in all actions relating to children, whether taken by public authorities or private institutions, the child's best interests must be a primary consideration. |
| --- | --- |

(3)

Article I-3 of the Treaty establishing a Constitution for Europe provides that one of the European Union's objectives is to protect the rights of the child; Article 24 of the Charter (Article II-84 of the Treaty) establishes that children shall have the right to such protection and care as is necessary for their well-being and that in all actions relating to children, whether taken by public authorities or private institutions, the child's best interests must be a primary consideration.

| (4) | Legislative measures need to be enacted at European Union level for the protection of the physical, mental and moral development of minors in relation to the content of all audiovisual and information services, the adoption of measures preventing the circulation of illegal content and the protection of minors from access to adult programmes or services. |
| --- | --- |

(4)

Legislative measures need to be enacted at European Union level for the protection of the physical, mental and moral development of minors in relation to the content of all audiovisual and information services, the adoption of measures preventing the circulation of illegal content and the protection of minors from access to adult programmes or services.

| (5) | The inevitable development of new information and communication technologies makes it urgent for the European Community to ensure full and adequate protection for consumers' interests in this field, by adopting a directive which will, throughout its territory, on the one hand guarantee the free delivery and free provision of information services and on the other ensure that their content is legal, respects the principle of human dignity and does not impair the overall development of minors. |
| --- | --- |

(5)

The inevitable development of new information and communication technologies makes it urgent for the European Community to ensure full and adequate protection for consumers' interests in this field, by adopting a directive which will, throughout its territory, on the one hand guarantee the free delivery and free provision of information services and on the other ensure that their content is legal, respects the principle of human dignity and does not impair the overall development of minors.

| (6) | Council Recommendation 98/560/EC of 24 September 1998 on the development of the competitiveness of the European audiovisual and information services industry by promoting national frameworks aimed at achieving a comparable and effective level of protection of minors and human dignity (3) is the first legal instrument at Community level
  which concerns questions involving the protection of minors and human dignity in relation to
  the content of
  all
  audiovisual and information services
  available to the public regardless of the form
  of delivery, from broadcasting to the Internet.
  Article 22 of Council Directive 89/552/EEC of 3 October 1989 on the coordination of certain provisions laid down by Law, Regulation or Administrative Action in Member States concerning the pursuit of television broadcasting activities (4) has already specifically addressed the question of the protection of minors and human dignity in television broadcasting activities. |
| --- | --- |

(6)

Council Recommendation 98/560/EC of 24 September 1998 on the development of the competitiveness of the European audiovisual and information services industry by promoting national frameworks aimed at achieving a comparable and effective level of protection of minors and human dignity (3) is the first legal instrument at Community level
  which concerns questions involving the protection of minors and human dignity in relation to
  the content of
  all
  audiovisual and information services
  available to the public regardless of the form
  of delivery, from broadcasting to the Internet.
  Article 22 of Council Directive 89/552/EEC of 3 October 1989 on the coordination of certain provisions laid down by Law, Regulation or Administrative Action in Member States concerning the pursuit of television broadcasting activities (4) has already specifically addressed the question of the protection of minors and human dignity in television broadcasting activities.

| (7) | The European Community has already intervened in the field of audiovisual and information services in order to create the necessary conditions to ensure the free movement of television broadcasts and other information services, in compliance with the principles of free competition and freedom of expression and information, but it should act with greater determination in this area with the aim of setting up a legal framework and adopting measures to protect consumers from incitement to discrimination based on sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation and combating any such discrimination. |
| --- | --- |

(7)

The European Community has already intervened in the field of audiovisual and information services in order to create the necessary conditions to ensure the free movement of television broadcasts and other information services, in compliance with the principles of free competition and freedom of expression and information, but it should act with greater determination in this area with the aim of setting up a legal framework and adopting measures to protect consumers from incitement to discrimination based on sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation and combating any such discrimination.

| (8) | By Decision No 276/1999/EC (5), the European Parliament and the Council adopted a multi-annual Community Action plan on promoting safer use of the Internet by combating illegal and harmful content on global networks (the ‘Safer Internet Action Plan’). |
| --- | --- |

(8)

By Decision No 276/1999/EC (5), the European Parliament and the Council adopted a multi-annual Community Action plan on promoting safer use of the Internet by combating illegal and harmful content on global networks (the ‘Safer Internet Action Plan’).

| (9) | The Commission should pay special attention to this Recommendation when revising or concluding new partnership agreements or new cooperation programmes with third countries, bearing in mind the global character of producers, distributors or providers of audiovisual content and Internet access. |
| --- | --- |

(9)

The Commission should pay special attention to this Recommendation when revising or concluding new partnership agreements or new cooperation programmes with third countries, bearing in mind the global character of producers, distributors or providers of audiovisual content and Internet access.

| (10) | Decision No 1151/2003/EC of the European Parliament and the Council (6) extended the Safer Internet Action Plan for two years and amended its scope to include measures to encourage exchange of information and coordination with the relevant actors at national level as well as special provisions for the accession countries. |
| --- | --- |

(10)

Decision No 1151/2003/EC of the European Parliament and the Council (6) extended the Safer Internet Action Plan for two years and amended its scope to include measures to encourage exchange of information and coordination with the relevant actors at national level as well as special provisions for the accession countries.

| (11) | Directive 2000/31/EC of the European Parliament and the Council of 8 June 2000 on certain legal aspects of information society services, in particular electronic commerce, in the Internal Market (7) clarifies some legal concepts and harmonises certain aspects in order to enable information society services to fully benefit from the internal market principles. A number of the provisions of Directive 2000/31/EC are also relevant to the protection of minors and human dignity, in particular Article 16 (1)(e), according to which Member States and the Commission are to encourage the drawing up of codes of conduct regarding the protection of minors and human dignity. |
| --- | --- |

(11)

Directive 2000/31/EC of the European Parliament and the Council of 8 June 2000 on certain legal aspects of information society services, in particular electronic commerce, in the Internal Market (7) clarifies some legal concepts and harmonises certain aspects in order to enable information society services to fully benefit from the internal market principles. A number of the provisions of Directive 2000/31/EC are also relevant to the protection of minors and human dignity, in particular Article 16 (1)(e), according to which Member States and the Commission are to encourage the drawing up of codes of conduct regarding the protection of minors and human dignity.

| (12) | The changing media landscape, resulting from new technologies and media innovation, makes it necessary to teach
  children, parents
  ,
  educators and teachers
  to use the media effectively
  , since prevention and greater parental control will always be the best form of protection against the dangers of the Internet
  . |
| --- | --- |

(12)

The changing media landscape, resulting from new technologies and media innovation, makes it necessary to teach
  children, parents
  ,
  educators and teachers
  to use the media effectively
  , since prevention and greater parental control will always be the best form of protection against the dangers of the Internet
  .

| (13) | On the whole, self-regulation of the audiovisual sector is proving an effective additional measure, but it is not sufficient to protect minors from messages with harmful content. The development of a European audiovisual area based on freedom of expression and respect for citizens' rights, as laid down in the Treaty establishing a Constitution for Europe, should be based on a continuous dialogue between national and European legislators, regulatory authorities, industries, associations, consumers and civil society. |
| --- | --- |

(13)

On the whole, self-regulation of the audiovisual sector is proving an effective additional measure, but it is not sufficient to protect minors from messages with harmful content. The development of a European audiovisual area based on freedom of expression and respect for citizens' rights, as laid down in the Treaty establishing a Constitution for Europe, should be based on a continuous dialogue between national and European legislators, regulatory authorities, industries, associations, consumers and civil society.

| (14) | Since the advent of digital terrestrial television will allow for parental control, which is essential if children are to be prevented from gaining access to televised content against their parents' wishes, the European Union should guide the process of transition to digital terrestrial television with the aim of achieving the earliest possible ‘analogue switchoff’. |
| --- | --- |

(14)

Since the advent of digital terrestrial television will allow for parental control, which is essential if children are to be prevented from gaining access to televised content against their parents' wishes, the European Union should guide the process of transition to digital terrestrial television with the aim of achieving the earliest possible ‘analogue switchoff’.

| (15) | In the public consultation concerning Directive 97/36/EC of the European Parliament and of the Council of 30 June 1997 it was suggested that
  the need to adopt educational measures in relation to the media be
  included among the subjects covered by Recommendation 98/560/EC. |
| --- | --- |

(15)

In the public consultation concerning Directive 97/36/EC of the European Parliament and of the Council of 30 June 1997 it was suggested that
  the need to adopt educational measures in relation to the media be
  included among the subjects covered by Recommendation 98/560/EC.

| (16) | The Commission encourages cooperation and the sharing of experience and good practices between
  self- and co-regulatory
  bodies, which deal with the rating or classification of audiovisual content,
  regardless of the means by which it is delivered,
  with a view to enabling all
  users
  , but especially parents
  , educators and
  teachers, to
  report illegal content and
  assess
  the content of audiovisual and on-line information services, as well as any legal content which could harm the physical or mental development of minors
  . |
| --- | --- |

(16)

The Commission encourages cooperation and the sharing of experience and good practices between
  self- and co-regulatory
  bodies, which deal with the rating or classification of audiovisual content,
  regardless of the means by which it is delivered,
  with a view to enabling all
  users
  , but especially parents
  , educators and
  teachers, to
  report illegal content and
  assess
  the content of audiovisual and on-line information services, as well as any legal content which could harm the physical or mental development of minors
  .

| (17) | As suggested during the public consultation concerning Directive 97/36/EC, it is appropriate for the right of reply to apply to all
  on-line
  media
  , and to take into account the specific features of the medium and service concerned
  . |
| --- | --- |

(17)

As suggested during the public consultation concerning Directive 97/36/EC, it is appropriate for the right of reply to apply to all
  on-line
  media
  , and to take into account the specific features of the medium and service concerned
  .

| (18) | Council resolution of 5 October 1995 on the image of women and men portrayed in advertising and the media
   (8)
  invites the Member States and the Commission to take adequate measures to promote a diversified and realistic picture of the skills and potential of women and men in society. |
| --- | --- |

(18)

Council resolution of 5 October 1995 on the image of women and men portrayed in advertising and the media
   (8)
  invites the Member States and the Commission to take adequate measures to promote a diversified and realistic picture of the skills and potential of women and men in society.

| (19) | When tabling its proposal for a Council Directive implementing the principle of equal treatment between women and men in the access to and supply of goods and services (9), the Commission noted that the portrayal of the sexes in the media and in advertising raises important questions about the protection of the dignity of men and women, but concluded that
  , in the light of other fundamental rights, including the freedom and pluralism of the media, it should take stock of these questions and, if necessary, take appropriate measures
  . |
| --- | --- |

(19)

When tabling its proposal for a Council Directive implementing the principle of equal treatment between women and men in the access to and supply of goods and services (9), the Commission noted that the portrayal of the sexes in the media and in advertising raises important questions about the protection of the dignity of men and women, but concluded that
  , in the light of other fundamental rights, including the freedom and pluralism of the media, it should take stock of these questions and, if necessary, take appropriate measures
  .

| (20) | Even though regulation is not an option, the media are nevertheless able to ban discrimination under codes of practice promoting voluntary self-regulation, or to enforce such a ban independently of their codes. The audiovisual and on-line information services
  industry
  should therefore be encouraged at Member State level
  to avoid and to combat any type of discrimination based on sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation in
  such
  media
  and all advertising, including new advertising techniques, without infringing freedom of expression or of the press
  . |
| --- | --- |

(20)

Even though regulation is not an option, the media are nevertheless able to ban discrimination under codes of practice promoting voluntary self-regulation, or to enforce such a ban independently of their codes. The audiovisual and on-line information services
  industry
  should therefore be encouraged at Member State level
  to avoid and to combat any type of discrimination based on sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation in
  such
  media
  and all advertising, including new advertising techniques, without infringing freedom of expression or of the press
  .

| (21) | This Recommendation
  covers new technological developments and complements
  Recommendation 98/560/EC
  . Its scope, on account of technological advances, includes audiovisual and on-line information services, such as newspapers, magazines and, particularly, video games, made available to the public via fixed or mobile electronic networks
  . |
| --- | --- |

(21)

This Recommendation
  covers new technological developments and complements
  Recommendation 98/560/EC
  . Its scope, on account of technological advances, includes audiovisual and on-line information services, such as newspapers, magazines and, particularly, video games, made available to the public via fixed or mobile electronic networks
  .

| (22) | Nothing in this Recommendation prevents Member States from applying their constitutional provisions and other legislation and legal practices regarding free speech. |
| --- | --- |

(22)

Nothing in this Recommendation prevents Member States from applying their constitutional provisions and other legislation and legal practices regarding free speech.

I. RECOMMEND that the Member States
  , in the interests of promoting
  the development of the audiovisual and
  on-line
  information services industry
  , take the necessary measures in their domestic law or practice to ensure better protection of minors and human dignity in all audiovisual and on-line information services,
  by:

| 1) | safeguarding the exercise of a right of reply (or equivalent remedy), with due regard for their domestic and constitutional legislative provisions, and for the characteristics of each audiovisual and on-line information service, |
| --- | --- |

1)

safeguarding the exercise of a right of reply (or equivalent remedy), with due regard for their domestic and constitutional legislative provisions, and for the characteristics of each audiovisual and on-line information service,

| 2) | in close cooperation with the industry and all relevant parties, ensuring better protection of minors, by:








  — | continuing education of educators and teachers, in liaison with child protection associations, on how to use the Internet in the context of school education and on teaching methods for safe (secure) use which children must be taught, |
| --- | --- | --- |

2)

in close cooperation with the industry and all relevant parties, ensuring better protection of minors, by:

—

continuing education of educators and teachers, in liaison with child protection associations, on how to use the Internet in the context of school education and on teaching methods for safe (secure) use which children must be taught,

| — | introduction of specific Internet training aimed at children from a very early age, including sessions open to parents, so as to explain to children and parents how to use the Internet and how to avoid the pitfalls and dangers, |
| --- | --- |

—

introduction of specific Internet training aimed at children from a very early age, including sessions open to parents, so as to explain to children and parents how to use the Internet and how to avoid the pitfalls and dangers,

| — | an integrated educational approach forming a permanent part of school curricula, and media literacy programmes, so as to maintain awareness of the dangers of the Internet, with particular regard to chat rooms and forums, |
| --- | --- |

—

an integrated educational approach forming a permanent part of school curricula, and media literacy programmes, so as to maintain awareness of the dangers of the Internet, with particular regard to chat rooms and forums,

| — | organisation of national information campaigns aimed at citizens, involving all communications media, to alert public opinion to the dangers of the Internet and the risk of criminal penalties (information about the possibility of brining complaints or activating parental control). Specific campaigns could be aimed at target groups such as schools, parents' associations, users, etc., |
| --- | --- |

—

organisation of national information campaigns aimed at citizens, involving all communications media, to alert public opinion to the dangers of the Internet and the risk of criminal penalties (information about the possibility of brining complaints or activating parental control). Specific campaigns could be aimed at target groups such as schools, parents' associations, users, etc.,

| — | distribution of information packs on the dangers of the Internet (‘How to surf the Internet safely’, ‘how to filter unwanted messages’) and on the use of hotlines to which reports or complaints concerning harmful or illegal sites can be made, |
| --- | --- |

—

distribution of information packs on the dangers of the Internet (‘How to surf the Internet safely’, ‘how to filter unwanted messages’) and on the use of hotlines to which reports or complaints concerning harmful or illegal sites can be made,

| — | adequate measures to establish or improve the performance of telephone hotlines, so as to make it easier to lodge complaints about harmful sites and make it possible to report their existence, |
| --- | --- |

—

adequate measures to establish or improve the performance of telephone hotlines, so as to make it easier to lodge complaints about harmful sites and make it possible to report their existence,

| — | action to allow one of the most serious offences against children's dignity, child pornography on the Internet, to be combated effectively, |
| --- | --- |

—

action to allow one of the most serious offences against children's dignity, child pornography on the Internet, to be combated effectively,

| — | publicity campaigns designed to condemn violence against minors and to help victims by offering psychological, moral and practical support, |
| --- | --- |

—

publicity campaigns designed to condemn violence against minors and to help victims by offering psychological, moral and practical support,

| 3) | promoting a responsible attitude on the part of professionals, intermediaries and users of new communication media such as the Internet by:








  — | encouraging vigilance and the reporting of pages considered illegal, without prejudice to Directive 2000/31/EC, |
| --- | --- | --- |

3)

promoting a responsible attitude on the part of professionals, intermediaries and users of new communication media such as the Internet by:

—

encouraging vigilance and the reporting of pages considered illegal, without prejudice to Directive 2000/31/EC,

| — | drawing up a code of conduct in cooperation with professionals and regulatory authorities at national and European level, |
| --- | --- |

—

drawing up a code of conduct in cooperation with professionals and regulatory authorities at national and European level,

| — | encouraging
  the audiovisual and on-line information services
  industry,
  without infringing freedom of opinion or of the press,
  to avoid discrimination based on sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation in all
  audiovisual and on-line information services,
  and to combat such discrimination
  , |
| --- | --- |

—

encouraging
  the audiovisual and on-line information services
  industry,
  without infringing freedom of opinion or of the press,
  to avoid discrimination based on sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation in all
  audiovisual and on-line information services,
  and to combat such discrimination
  ,

| 4) | promoting measures to combat all illegal activity on the Internet and make the web a much more secure medium; consideration could be given inter alia to the following measures:








  — | adopting a quality label for service providers, so that users can easily check whether or not a given provider subscribes to a code of conduct or not, |
| --- | --- | --- |

4)

promoting measures to combat all illegal activity on the Internet and make the web a much more secure medium; consideration could be given inter alia to the following measures:

—

adopting a quality label for service providers, so that users can easily check whether or not a given provider subscribes to a code of conduct or not,

| — | considering the inclusion in their legal systems of a system of joint or cascading liability for Internet crimes, |
| --- | --- |

—

considering the inclusion in their legal systems of a system of joint or cascading liability for Internet crimes,

| — | establishing a single telephone line for the reporting of illegal and/or suspicious activities on the web, |
| --- | --- |

—

establishing a single telephone line for the reporting of illegal and/or suspicious activities on the web,

| 5) | developing, by means of cooperation at European level and in close collaboration with consumer organisations, regulations to reduce food advertising specifically aimed at children and teenagers, especially for junk food and confectionery. |
| --- | --- |

5)

developing, by means of cooperation at European level and in close collaboration with consumer organisations, regulations to reduce food advertising specifically aimed at children and teenagers, especially for junk food and confectionery.

II. RECOMMEND that the
  audiovisual services and on-line information services industry
  and
  all
  the parties concerned:

| 1) | develop positive measures for the benefit of minors, including initiatives to facilitate
  better
  access
  by minors
  to audiovisual and
  on-line
  information services,
  by improving their media literacy and providing for closer
  cooperation between self-regulatory and co-regulatory bodies in the Member
  States through
  the exchange of best practices
  by means of
  :






  — | the systematic provision of an effective and easy-to-use filtering system for users at the time of subscription to an access provider and developing effective filtering solutions, taking into account technological progress allowing Internet access via mobile telephones, |
| --- | --- | --- |

1)

develop positive measures for the benefit of minors, including initiatives to facilitate
  better
  access
  by minors
  to audiovisual and
  on-line
  information services,
  by improving their media literacy and providing for closer
  cooperation between self-regulatory and co-regulatory bodies in the Member
  States through
  the exchange of best practices
  by means of
  :

—

the systematic provision of an effective and easy-to-use filtering system for users at the time of subscription to an access provider and developing effective filtering solutions, taking into account technological progress allowing Internet access via mobile telephones,

| — | offering access services intended specifically for children and equipped with an automatic filtering system operated by access providers and by mobile telephone operators, |
| --- | --- |

—

offering access services intended specifically for children and equipped with an automatic filtering system operated by access providers and by mobile telephone operators,

| — | introducing incentives to provide a regularly updated description of the available sites, making it easier to classify sites using abbreviations common to all Member States in order to alert users to the possible harmful content of sites visited, |
| --- | --- |

—

introducing incentives to provide a regularly updated description of the available sites, making it easier to classify sites using abbreviations common to all Member States in order to alert users to the possible harmful content of sites visited,

| — | posting warning banners on all search engines drawing attention to possible dangers and to the availability of telephone hotlines, |
| --- | --- |

—

posting warning banners on all search engines drawing attention to possible dangers and to the availability of telephone hotlines,

| 2) | examine the possibility of creating filters which would prevent information concerning child pornography or offending against human dignity from passing through the Internet, |
| --- | --- |

2)

examine the possibility of creating filters which would prevent information concerning child pornography or offending against human dignity from passing through the Internet,

| 3) | develop measures to increase the use of content labelling systems for material distributed over the web, using protocols such as PICS (Platform for Internet Content Selection) and systems to filter information exchanged among users, |
| --- | --- |

3)

develop measures to increase the use of content labelling systems for material distributed over the web, using protocols such as PICS (Platform for Internet Content Selection) and systems to filter information exchanged among users,

| 4) | develop effective measures to avoid discrimination
  as defined in Article II-81 of the Treaty establishing a Constitution for Europe and to combat all such forms of discrimination created by false and stereotyped images of human beings, the commercial exploitation of the human body, and the trivialisation of violence and war
  . |
| --- | --- |

4)

develop effective measures to avoid discrimination
  as defined in Article II-81 of the Treaty establishing a Constitution for Europe and to combat all such forms of discrimination created by false and stereotyped images of human beings, the commercial exploitation of the human body, and the trivialisation of violence and war
  .

III. INVITE the Commission to:

| 1) | organise, in connection with the 2005-2008 multiannual Community programme on promoting safer use of the Internet and new online technologies, a European information campaign aimed at citizens, using all communications media, to alert public opinion to the dangers of the Internet and the risk of criminal penalties being incurred (information about the possibility of bringing complaints or activating parental control). Specific campaigns could be aimed at target groups such as schools, parents' associations and users, |
| --- | --- |

1)

organise, in connection with the 2005-2008 multiannual Community programme on promoting safer use of the Internet and new online technologies, a European information campaign aimed at citizens, using all communications media, to alert public opinion to the dangers of the Internet and the risk of criminal penalties being incurred (information about the possibility of bringing complaints or activating parental control). Specific campaigns could be aimed at target groups such as schools, parents' associations and users,

| 2) | introduce a European freephone number providing information on existing filtering methods and intended to offset the absence in some Member States of telephone hotlines for lodging complaints with the competent authorities and report harmful sites, |
| --- | --- |

2)

introduce a European freephone number providing information on existing filtering methods and intended to offset the absence in some Member States of telephone hotlines for lodging complaints with the competent authorities and report harmful sites,

| 3) | consider the introduction of a generic top level domain name reserved for continuously monitored sites committed to respecting minors and their rights, failing which they would incur criminal penalties (.KID for example), |
| --- | --- |

3)

consider the introduction of a generic top level domain name reserved for continuously monitored sites committed to respecting minors and their rights, failing which they would incur criminal penalties (.KID for example),

| 4) | maintain a constructive and ongoing dialogue with content providers' organisations, consumer organisations and all parties concerned, |
| --- | --- |

4)

maintain a constructive and ongoing dialogue with content providers' organisations, consumer organisations and all parties concerned,

| 5) | facilitate and support the formation of networks by self-regulatory bodies and the exchanging of experience among them, so as to assess the effectiveness of codes of conduct and approaches based on self-regulation in order to ensure the highest possible standards of protection for minors. |
| --- | --- |

5)

facilitate and support the formation of networks by self-regulatory bodies and the exchanging of experience among them, so as to assess the effectiveness of codes of conduct and approaches based on self-regulation in order to ensure the highest possible standards of protection for minors.

IV. RECOMMEND that the industry, all parties concerned and the national and European authorities consider more actively the technical and legal feasibility of developing a uniform content labelling system to encourage better filtering and classification at source, regardless of the communications media used (Internet, mobile telephones) in order to improve protection for minors.

V. RECOMMEND that the Member States submit a report to the Commission on measures taken in application of this Recommendation two years after its adoption.

VI. INVITE the Commission to submit to the European Parliament by 31 December 2008, on the basis of the reports submitted by the Member States, a report on the implementation and effectiveness of the measures laid down in this Recommendation, identifying any additional measures which may be necessary, including binding legislation at European level.

Done at ..., on ...

For the European Parliament

The President

For the Council

The President

---

(1)  OJ C ...

1

(2)  Position of the European Parliament of 7 September 2005.

2

Position of the European Parliament of 7 September 2005.

(3)  OJ L 270, 7.10.1998, p. 48.

3

(4)  OJ L 298, 17.10.1989, p. 23. Directive as amended by Directive 97/36/EC of the European Parliament and of the Council (OJ L 202, 30.7.1997, p. 60).

4

(5)  OJ L 33, 6.2.1999, p. 1. Decision as last amended by Decision No 787/2004/EC (OJ L 138, 30.4.2004, p. 12
  ).

5

Decision No 787/2004/EC

138, 30.4.2004,

12

(6)  OJ L 162, 1.7.2003, p. 1.

6

(7)  OJ L 178, 17.7.2000, p. 1.

7

(8)  OJ C 296, 10.11.1995, p. 15.

8

(9)  COM(2003)0657.

9

COM(2003)0657

ANNEX

MINIMUM PRINCIPLES
  FOR THE IMPLEMENTATION, AT NATIONAL LEVEL, OF MEASURES IN DOMESTIC LAW OR PRACTICE SO AS TO ENSURE THE RIGHT OF REPLY
  AS REGARDS ALL AUDIOVISUAL AND ON-LINE INFORMATION SERVICES

Objective:
  Adapting the right of reply to the current state of technological development, particularly in audiovisual and on-line information services in Europe, taking into account the relevant constitutional and other legislation and legal practice regarding free speech
  .

| — | The right of reply should protect any legal or natural person from any assertion of incorrect facts concerning that person and affecting his or her rights, and consequently the dissemination of opinions and ideas must remain outside the scope of this Recommendation; |
| --- | --- |

—

The right of reply should protect any legal or natural person from any assertion of incorrect facts concerning that person and affecting his or her rights, and consequently the dissemination of opinions and ideas must remain outside the scope of this Recommendation;

| — | The right of reply is a particularly appropriate remedy in the on-line environment because it allows for the instant correction of contested information and it is technically easy to attach the replies from the persons affected; |
| --- | --- |

—

The right of reply is a particularly appropriate remedy in the on-line environment because it allows for the instant correction of contested information and it is technically easy to attach the replies from the persons affected;

| — | It is necessary to ensure that the author of or person responsible for the dissemination of the information continues to be under the obligation to allow a right of reply, in accordance with national laws; |
| --- | --- |

—

It is necessary to ensure that the author of or person responsible for the dissemination of the information continues to be under the obligation to allow a right of reply, in accordance with national laws;

| — | The right of reply can be ensured not only through legislation, but also through co-regulatory or self-regulatory measures; |
| --- | --- |

—

The right of reply can be ensured not only through legislation, but also through co-regulatory or self-regulatory measures;

| — | The right of reply is without prejudice to other remedies available to persons whose right to dignity, honour, reputation or privacy have been breached by the media. |
| --- | --- |

—

The right of reply is without prejudice to other remedies available to persons whose right to dignity, honour, reputation or privacy have been breached by the media.

| — | Member States should examine and, if necessary, introduce in their domestic law or practice, a right of reply or other equivalent remedy, which allows a rapid correction of incorrect facts in audiovisual and on-line information services in accordance with the minimum principles set out below, without prejudice to the possibility of adapting the exercise of this right (or any other equivalent remedy) to the specific nature of each type of medium. |
| --- | --- |

—

Member States should examine and, if necessary, introduce in their domestic law or practice, a right of reply or other equivalent remedy, which allows a rapid correction of incorrect facts in audiovisual and on-line information services in accordance with the minimum principles set out below, without prejudice to the possibility of adapting the exercise of this right (or any other equivalent remedy) to the specific nature of each type of medium.

Scope of the right of reply

| — | Any natural or legal person, irrespective of nationality or residence, should be granted a right of reply or an equivalent remedy so that they may respond to any assertion of inaccurate facts about them in audiovisual and on-line information services which affects their personal rights. |
| --- | --- |

—

Any natural or legal person, irrespective of nationality or residence, should be granted a right of reply or an equivalent remedy so that they may respond to any assertion of inaccurate facts about them in audiovisual and on-line information services which affects their personal rights.

| — | The reply should be given the same prominence as was given to the contested assertion in order for it to reach the same public and with the same impact. |
| --- | --- |

—

The reply should be given the same prominence as was given to the contested assertion in order for it to reach the same public and with the same impact.

| — | Member States shall ensure that the effective exercise of the right of reply (or equivalent remedy) and the right of freedom of expression is not unjustifiably constrained. The reply must be transmitted within a reasonable time after the justification of the request and at a time and in a manner appropriate to the publication or programme to which the request refers. |
| --- | --- |

—

Member States shall ensure that the effective exercise of the right of reply (or equivalent remedy) and the right of freedom of expression is not unjustifiably constrained. The reply must be transmitted within a reasonable time after the justification of the request and at a time and in a manner appropriate to the publication or programme to which the request refers.

| — | Provision should be made for procedures whereby disputes as to the exercise of the right of reply or the equivalent remedies
  may
  be subject to judicial review. |
| --- | --- |

—

Provision should be made for procedures whereby disputes as to the exercise of the right of reply or the equivalent remedies
  may
  be subject to judicial review.

P6_TA(2005)0331

Medicinal products for paediatric use ***I

European Parliament legislative resolution on the proposal for a regulation of the European Parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (COM(2004)0599 — C6-0159/2004 — 2004/0217(COD))

(Codecision procedure: first reading)

The European Parliament,

| — | having regard to the Commission proposal to the European Parliament and the Council (COM(2004) 0599) (1), |
| --- | --- |

—

having regard to the Commission proposal to the European Parliament and the Council (COM(2004) 0599) (1),

| — | having regard to Article 251(2) and Article 95 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament (C6-0159/2004), |
| --- | --- |

—

having regard to Article 251(2) and Article 95 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament (C6-0159/2004),

| — | having regard to Rule 51 of its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 51 of its Rules of Procedure,

| — | having regard to the report of the Committee on the Environment, Public Health and Food Safety and the opinion of the Committee on Industry, Research and Energy (A6-0247/2005), |
| --- | --- |

—

having regard to the report of the Committee on the Environment, Public Health and Food Safety and the opinion of the Committee on Industry, Research and Energy (A6-0247/2005),

| 1. | Approves the Commission proposal as amended; |
| --- | --- |

1.

Approves the Commission proposal as amended;

| 2. | Calls on the Commission to refer the matter to Parliament again if it intends to amend the proposal substantially or replace it with another text; |
| --- | --- |

2.

Calls on the Commission to refer the matter to Parliament again if it intends to amend the proposal substantially or replace it with another text;

| 3. | Instructs its President to forward its position to the Council and Commission. |
| --- | --- |

3.

Instructs its President to forward its position to the Council and Commission.

---

(1)  Not yet published in OJ.

P6_TC1-COD(2004)0217

Position of the European Parliament adopted at first reading on 7 September 2005 with a view to the adoption of Regulation (EC) No .../2005 of the European Parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,

Having regard to the proposal from the Commission,

Having regard to the Opinion of the European Economic and Social Committee (1),

Having regard to the Opinion of the Committee of the Regions (1),

In accordance with the procedure referred to in Article 251 of the Treaty (2),

Whereas:

| (1) | Before a medicinal product for human use is placed on the market of one or more Member States, it generally has to have undergone extensive studies, including pre-clinical tests and clinical trials, to ensure that it is safe, of high quality and effective for use in the target population. |
| --- | --- |

(1)

Before a medicinal product for human use is placed on the market of one or more Member States, it generally has to have undergone extensive studies, including pre-clinical tests and clinical trials, to ensure that it is safe, of high quality and effective for use in the target population.

| (2) | Such studies may not have been done for use in children and many of the medicines currently used to treat children have not been studied or authorised for such use. Market forces alone have proven insufficient to stimulate adequate research, development and authorisation of medicines for children. |
| --- | --- |

(2)

Such studies may not have been done for use in children and many of the medicines currently used to treat children have not been studied or authorised for such use. Market forces alone have proven insufficient to stimulate adequate research, development and authorisation of medicines for children.

| (3) | Problems resulting from the absence of suitably adapted medicines for children include inadequate dosing information leading to increased risks of adverse reactions including death, ineffective treatment through under-dosing, non-availability to children of therapeutic advances,
  problems resulting from the pharmaceutical form and the route of administration
  as well as the use of extemporaneous formulations to treat children which may be of poor quality. |
| --- | --- |

(3)

Problems resulting from the absence of suitably adapted medicines for children include inadequate dosing information leading to increased risks of adverse reactions including death, ineffective treatment through under-dosing, non-availability to children of therapeutic advances,
  problems resulting from the pharmaceutical form and the route of administration
  as well as the use of extemporaneous formulations to treat children which may be of poor quality.

| (4) | The aim of this Regulation is to
  facilitate
  the development
  and accessibility
  of medicines for use in children, to ensure that medicines used to treat children are
  where necessary
  subject to high quality, ethical research and are appropriately authorised for use in children, and to improve the information available on the use of medicines in the various paediatric populations. These objectives should be achieved without subjecting children to unnecessary clinical trials and without delaying the authorisation of medicinal products for other
  age
  populations. |
| --- | --- |

(4)

The aim of this Regulation is to
  facilitate
  the development
  and accessibility
  of medicines for use in children, to ensure that medicines used to treat children are
  where necessary
  subject to high quality, ethical research and are appropriately authorised for use in children, and to improve the information available on the use of medicines in the various paediatric populations. These objectives should be achieved without subjecting children to unnecessary clinical trials and without delaying the authorisation of medicinal products for other
  age
  populations.

| (5) | A specific inventory of paediatric medicinal product needs should be adopted by the Paediatric Committee set up under this Regulation after consultation with the Commission, the Member States and interested parties, and regularly updated. The inventory should identify the existing medicines used by children and highlight the therapeutic needs of children and the priorities for research and development. In this way, companies should be able to identify easily opportunities for business development; the Paediatric Committee should be able to better judge the need for medicines and studies when assessing draft paediatric investigation plans, waivers and deferrals; and healthcare professionals and patients should have a reliable information source available to support their decisions as to which medicines to choose. |
| --- | --- |

(5)

A specific inventory of paediatric medicinal product needs should be adopted by the Paediatric Committee set up under this Regulation after consultation with the Commission, the Member States and interested parties, and regularly updated. The inventory should identify the existing medicines used by children and highlight the therapeutic needs of children and the priorities for research and development. In this way, companies should be able to identify easily opportunities for business development; the Paediatric Committee should be able to better judge the need for medicines and studies when assessing draft paediatric investigation plans, waivers and deferrals; and healthcare professionals and patients should have a reliable information source available to support their decisions as to which medicines to choose.

| (6) | While taking into account the fact that any regulations on medicinal products must be fundamentally aimed at safeguarding public health, this aim must be achieved by means that do not impede the free movement of
  safe
  medicinal products within the Community. The differences between the national legislative, regulatory and administrative provisions on medicinal products tend to hinder intra-Community trade and therefore directly affect the operation of the internal market. Any action to promote the development and authorisation of medicinal products for paediatric use is therefore justified with a view to preventing or eliminating these obstacles. Article 95 of the Treaty is therefore the proper legal basis. |
| --- | --- |

(6)

While taking into account the fact that any regulations on medicinal products must be fundamentally aimed at safeguarding public health, this aim must be achieved by means that do not impede the free movement of
  safe
  medicinal products within the Community. The differences between the national legislative, regulatory and administrative provisions on medicinal products tend to hinder intra-Community trade and therefore directly affect the operation of the internal market. Any action to promote the development and authorisation of medicinal products for paediatric use is therefore justified with a view to preventing or eliminating these obstacles. Article 95 of the Treaty is therefore the proper legal basis.

| (7) | The establishment of a system of both obligations and rewards and incentives has proved necessary to achieve these objectives. The precise nature of the obligations and rewards and incentives should take account of the status of the particular medicinal product concerned. This Regulation should apply to all the medicines required by children and therefore its scope should cover products in development and yet to be authorised, authorised products still covered by intellectual property rights and authorised products no longer covered by intellectual property rights. |
| --- | --- |

(7)

The establishment of a system of both obligations and rewards and incentives has proved necessary to achieve these objectives. The precise nature of the obligations and rewards and incentives should take account of the status of the particular medicinal product concerned. This Regulation should apply to all the medicines required by children and therefore its scope should cover products in development and yet to be authorised, authorised products still covered by intellectual property rights and authorised products no longer covered by intellectual property rights.

| (8) | Any concerns about conducting trials in the paediatric population should be balanced by the ethical concerns about giving medicines to a population in which they have not been
  appropriately
  tested. The public health threat from the use of untested medicines in children can be safely addressed through the study of medicines for children, which should be carefully controlled and monitored through the specific requirements for the protection of children who take part in clinical trials in the Community laid down in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (3). |
| --- | --- |

(8)

Any concerns about conducting trials in the paediatric population should be balanced by the ethical concerns about giving medicines to a population in which they have not been
  appropriately
  tested. The public health threat from the use of untested medicines in children can be safely addressed through the study of medicines for children, which should be carefully controlled and monitored through the specific requirements for the protection of children who take part in clinical trials in the Community laid down in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (3).

| (9) | It is appropriate to create a scientific committee, the Paediatric Committee, within the European Medicines Agency set up under Regulation (EC) No 726/2004 (4)
  , hereinafter ‘the Agency’, with expertise and competence in the development and assessment of all aspects of medicinal products to treat paediatric populations.
  To this end the Committee must be independent of the pharmaceutical industry and be composed of members with recognised and documented international-level experience and knowledge of that industry.
  The Paediatric Committee should be primarily responsible for the assessment and agreement of
  scientific and ethical
  paediatric investigation plans and for the system of waivers and deferrals thereof, and it should also be central to various support measures contained in this Regulation. In all its work the Paediatric Committee should
  make sure that studies in children have significant potential therapeutic benefits for paediatric patients. The potential benefits must be weighed against the short and long term risks of participating in the clinical studies in order
  to avoid unnecessary studies
  . The Paediatric Committee
  should follow existing Community requirements, including Directive 2001/20/EC, as well as International Conference on Harmonisation (ICH) guideline E11 on the development of medicines for children, and it should avoid any delay in the authorisation of medicines for other populations as a result of the requirements for studies in children. |
| --- | --- |

(9)

It is appropriate to create a scientific committee, the Paediatric Committee, within the European Medicines Agency set up under Regulation (EC) No 726/2004 (4)
  , hereinafter ‘the Agency’, with expertise and competence in the development and assessment of all aspects of medicinal products to treat paediatric populations.
  To this end the Committee must be independent of the pharmaceutical industry and be composed of members with recognised and documented international-level experience and knowledge of that industry.
  The Paediatric Committee should be primarily responsible for the assessment and agreement of
  scientific and ethical
  paediatric investigation plans and for the system of waivers and deferrals thereof, and it should also be central to various support measures contained in this Regulation. In all its work the Paediatric Committee should
  make sure that studies in children have significant potential therapeutic benefits for paediatric patients. The potential benefits must be weighed against the short and long term risks of participating in the clinical studies in order
  to avoid unnecessary studies
  . The Paediatric Committee
  should follow existing Community requirements, including Directive 2001/20/EC, as well as International Conference on Harmonisation (ICH) guideline E11 on the development of medicines for children, and it should avoid any delay in the authorisation of medicines for other populations as a result of the requirements for studies in children.

| (10) | Procedures should be established for the Agency to agree and modify a paediatric investigation plan, the document upon which the development and authorisation of medicines for children should be based. The paediatric investigation plan should include details of the timing and the measures proposed to demonstrate the quality, safety and efficacy of the medicinal product in the paediatric population. Because the paediatric population is in fact made up of a number of subpopulations, the paediatric investigation plan should specify which subpopulations need to be studied, by what means and by when. |
| --- | --- |

(10)

Procedures should be established for the Agency to agree and modify a paediatric investigation plan, the document upon which the development and authorisation of medicines for children should be based. The paediatric investigation plan should include details of the timing and the measures proposed to demonstrate the quality, safety and efficacy of the medicinal product in the paediatric population. Because the paediatric population is in fact made up of a number of subpopulations, the paediatric investigation plan should specify which subpopulations need to be studied, by what means and by when.

| (11) | The introduction of the paediatric investigation plan in the legal framework concerning medicinal products for human use aims at ensuring that development of medicines
  that are potentially to be used
  for children becomes an integral part of the development of medicinal products, integrated into the development programme for adults. Thus, paediatric investigation plans should be submitted early during product development, in time for studies to be conducted in children
  , wherever possible
  before marketing authorisation applications are submitted. |
| --- | --- |

(11)

The introduction of the paediatric investigation plan in the legal framework concerning medicinal products for human use aims at ensuring that development of medicines
  that are potentially to be used
  for children becomes an integral part of the development of medicinal products, integrated into the development programme for adults. Thus, paediatric investigation plans should be submitted early during product development, in time for studies to be conducted in children
  , wherever possible
  before marketing authorisation applications are submitted.

| (12) | It is necessary to introduce a requirement to present, in the case of new medicinal products and authorised medicinal products covered by a patent or a supplementary protection certificate, the available
  results of any studies in children carried out in accordance with an agreed paediatric investigation plan
  that are completed at the time of the filing of the
  marketing authorisation application or an application for a new indication, new pharmaceutical form or new route of administration. The paediatric investigation plan should be the basis upon which compliance with that requirement is judged. However, that requirement should not apply to generics or similar biological medicinal products and medicinal products authorised through the well-established medicinal use procedure, or to homeopathic medicinal products and traditional herbal medicinal products authorised through the simplified registration procedures of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (5). |
| --- | --- |

(12)

It is necessary to introduce a requirement to present, in the case of new medicinal products and authorised medicinal products covered by a patent or a supplementary protection certificate, the available
  results of any studies in children carried out in accordance with an agreed paediatric investigation plan
  that are completed at the time of the filing of the
  marketing authorisation application or an application for a new indication, new pharmaceutical form or new route of administration. The paediatric investigation plan should be the basis upon which compliance with that requirement is judged. However, that requirement should not apply to generics or similar biological medicinal products and medicinal products authorised through the well-established medicinal use procedure, or to homeopathic medicinal products and traditional herbal medicinal products authorised through the simplified registration procedures of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (5).

| (13) | In view of the fact that 50% of medicinal products for paediatric use have not been tested, provision should be made for funding for research on medicines for paediatric use which are not patentprotected or do not have supplementary protection certification to be financed under Community research programmes. It is necessary to establish a Community programme for research into medicinal products for children (Medicines Investigation for the Children of Europe
  —
  MICE). |
| --- | --- |

(13)

In view of the fact that 50% of medicinal products for paediatric use have not been tested, provision should be made for funding for research on medicines for paediatric use which are not patentprotected or do not have supplementary protection certification to be financed under Community research programmes. It is necessary to establish a Community programme for research into medicinal products for children (Medicines Investigation for the Children of Europe
  —
  MICE).

| (14) | In order to ensure that research in children is only conducted to meet their therapeutic needs, there is a need to establish procedures for the Agency to waive the requirement to present the results of studies in children in the case of specific products or classes or part of classes of medicinal products, to be then published by the Agency. As knowledge on science and medicine evolves over time, provision should be made for the lists of waivers to be amended. However, if a waiver is revoked, the requirement should not apply for a given period in order to allow time for at least a paediatric investigation plan to be agreed and studies in children to be initiated prior to marketing authorisation application. |
| --- | --- |

(14)

In order to ensure that research in children is only conducted to meet their therapeutic needs, there is a need to establish procedures for the Agency to waive the requirement to present the results of studies in children in the case of specific products or classes or part of classes of medicinal products, to be then published by the Agency. As knowledge on science and medicine evolves over time, provision should be made for the lists of waivers to be amended. However, if a waiver is revoked, the requirement should not apply for a given period in order to allow time for at least a paediatric investigation plan to be agreed and studies in children to be initiated prior to marketing authorisation application.

| (15) | In certain cases, the Agency should defer the initiation or completion of some or all of the measures contained in a paediatric investigation plan, with a view to ensuring that research is done only when it is safe and ethical to do so and that the requirement for study data in children does not block or delay the authorisation of medicines for other populations. |
| --- | --- |

(15)

In certain cases, the Agency should defer the initiation or completion of some or all of the measures contained in a paediatric investigation plan, with a view to ensuring that research is done only when it is safe and ethical to do so and that the requirement for study data in children does not block or delay the authorisation of medicines for other populations.

| (16) | Free scientific advice should be provided by the Agency as an incentive to sponsors developing medicines for children. To ensure scientific consistency, the Agency should manage the interface between the Paediatric Committee and the Scientific Advice Working Group of the Committee for Medicinal Products for Human Use, as well as the interaction between the Paediatric Committee and the other Community committees and working groups concerned with medicinal products. |
| --- | --- |

(16)

Free scientific advice should be provided by the Agency as an incentive to sponsors developing medicines for children. To ensure scientific consistency, the Agency should manage the interface between the Paediatric Committee and the Scientific Advice Working Group of the Committee for Medicinal Products for Human Use, as well as the interaction between the Paediatric Committee and the other Community committees and working groups concerned with medicinal products.

| (17) | The existing procedures for the marketing authorisation of medicinal products for human use should not be changed. However, it follows from the requirement for the results of studies in children to be presented in accordance with an agreed paediatric investigation plan that competent authorities should check compliance with the agreed paediatric investigation plan and any waivers and deferrals at the existing validation step for marketing authorisation applications. The assessment of safety, quality and efficacy of medicines for children and the granting of marketing authorisations should remain the remit of the competent authorities. Provision should be made
  for the
  Paediatric Committee
  to be asked
  for an opinion on compliance and for an opinion on the safety, quality and efficacy of a medicine in children. |
| --- | --- |

(17)

The existing procedures for the marketing authorisation of medicinal products for human use should not be changed. However, it follows from the requirement for the results of studies in children to be presented in accordance with an agreed paediatric investigation plan that competent authorities should check compliance with the agreed paediatric investigation plan and any waivers and deferrals at the existing validation step for marketing authorisation applications. The assessment of safety, quality and efficacy of medicines for children and the granting of marketing authorisations should remain the remit of the competent authorities. Provision should be made
  for the
  Paediatric Committee
  to be asked
  for an opinion on compliance and for an opinion on the safety, quality and efficacy of a medicine in children.

| (18) | To provide healthcare professionals and patients with information on the safe and effective use of medicines in children, and in the interests of transparency, information regarding the results of studies in children, as well as on the status of the paediatric investigation plans, waivers and deferrals, should be included in product information. When all the measures in the paediatric investigation plan have been complied with, that fact should be recorded in the marketing authorisation, and should then be the basis upon which companies can obtain the rewards for compliance. |
| --- | --- |

(18)

To provide healthcare professionals and patients with information on the safe and effective use of medicines in children, and in the interests of transparency, information regarding the results of studies in children, as well as on the status of the paediatric investigation plans, waivers and deferrals, should be included in product information. When all the measures in the paediatric investigation plan have been complied with, that fact should be recorded in the marketing authorisation, and should then be the basis upon which companies can obtain the rewards for compliance.

| (19) | To distinguish medicines authorised for use in children following completion of an agreed paediatric investigation plan and enable their prescription, provision should be made for a specially designed European logo to be displayed below the name of medicinal products granted an indication for use in children following an agreed paediatric investigation plan. |
| --- | --- |

(19)

To distinguish medicines authorised for use in children following completion of an agreed paediatric investigation plan and enable their prescription, provision should be made for a specially designed European logo to be displayed below the name of medicinal products granted an indication for use in children following an agreed paediatric investigation plan.

| (20) | In order to establish incentives for authorised products no longer covered by intellectual property rights, it is necessary to establish a new type of marketing authorisation, the Paediatric Use Marketing Authorisation. A Paediatric Use Marketing Authorisation should be granted through existing marketing authorisation procedures but should apply specifically for medicinal products developed exclusively for use in children. It should be possible for the name of the medicinal product granted a Paediatric Use Marketing Authorisation to utilise the existing brand name of the corresponding product authorised for adults, in order to capitalise on existing brand recognition while benefiting from the data exclusivity associated with a new marketing authorisation. |
| --- | --- |

(20)

In order to establish incentives for authorised products no longer covered by intellectual property rights, it is necessary to establish a new type of marketing authorisation, the Paediatric Use Marketing Authorisation. A Paediatric Use Marketing Authorisation should be granted through existing marketing authorisation procedures but should apply specifically for medicinal products developed exclusively for use in children. It should be possible for the name of the medicinal product granted a Paediatric Use Marketing Authorisation to utilise the existing brand name of the corresponding product authorised for adults, in order to capitalise on existing brand recognition while benefiting from the data exclusivity associated with a new marketing authorisation.

| (21) | An application for a Paediatric Use Marketing Authorisation should include the submission of data concerning use of the product in the paediatric population, collected in accordance with an agreed paediatric investigation plan. These data may be derived from the published literature or from new studies. An application for a Paediatric Use Marketing Authorisation should also be able to refer to data contained in the dossier of a medicinal product which is or has been authorised in the Community. That is intended to provide an additional incentive to attract small and medium-sized enterprises, including generic companies, to develop off-patent medicines for children. |
| --- | --- |

(21)

An application for a Paediatric Use Marketing Authorisation should include the submission of data concerning use of the product in the paediatric population, collected in accordance with an agreed paediatric investigation plan. These data may be derived from the published literature or from new studies. An application for a Paediatric Use Marketing Authorisation should also be able to refer to data contained in the dossier of a medicinal product which is or has been authorised in the Community. That is intended to provide an additional incentive to attract small and medium-sized enterprises, including generic companies, to develop off-patent medicines for children.

| (22) | This Regulation should include measures to maximise access of the Community population to new medicinal products tested and adapted for paediatric use, and minimise the chance of Communitywide rewards and incentives being granted without sections of the Community paediatric population benefiting from the availability of a newly authorised medicine. An application for a marketing authorisation, including an application for a Paediatric Use Marketing Authorisation, which contains the results of studies conducted in compliance with an agreed paediatric investigation plan should be eligible for the Community centralised procedure set out in Articles 5 to 15 of Regulation (EC) No 726/2004. |
| --- | --- |

(22)

This Regulation should include measures to maximise access of the Community population to new medicinal products tested and adapted for paediatric use, and minimise the chance of Communitywide rewards and incentives being granted without sections of the Community paediatric population benefiting from the availability of a newly authorised medicine. An application for a marketing authorisation, including an application for a Paediatric Use Marketing Authorisation, which contains the results of studies conducted in compliance with an agreed paediatric investigation plan should be eligible for the Community centralised procedure set out in Articles 5 to 15 of Regulation (EC) No 726/2004.

| (23) | When an agreed paediatric investigation plan has led to the authorisation of a paediatric indication for a product already marketed for other indications, the marketing authorisation holder should be obliged to place the product on the market taking into account the paediatric information within two years following the date of approval of the indication.
  The competent authorities should be able, in specific cases affected by administrative delays, or in exceptional circumstances, to grant derogations from this provision. Any such derogations should be justified on duly substantiated grounds. The marketing obligation
  should relate only to products already authorised, but not to medicines authorised via a Paediatric Use Marketing Authorisation. |
| --- | --- |

(23)

When an agreed paediatric investigation plan has led to the authorisation of a paediatric indication for a product already marketed for other indications, the marketing authorisation holder should be obliged to place the product on the market taking into account the paediatric information within two years following the date of approval of the indication.
  The competent authorities should be able, in specific cases affected by administrative delays, or in exceptional circumstances, to grant derogations from this provision. Any such derogations should be justified on duly substantiated grounds. The marketing obligation
  should relate only to products already authorised, but not to medicines authorised via a Paediatric Use Marketing Authorisation.

| (24) | An optional procedure should be established to make it possible to obtain a single Community-wide opinion for a nationally authorised medicinal product when data on children following an agreed paediatric investigation plan form part of the marketing authorisation application. To achieve this, the procedure set out in Articles 32 to 34 of Directive 2001/83/EC may be used. This will allow the adoption of a Community harmonised Decision on use of the medicinal product in children and its introduction in all national product information.
  In the meantime, it would be desirable for a European paediatric form to be drawn up to serve as a reference for the collection of all the data available in the various Member States on a pharmaceutical product desired to be marketed in the Union but at that moment placed on the market only at national level. |
| --- | --- |

(24)

An optional procedure should be established to make it possible to obtain a single Community-wide opinion for a nationally authorised medicinal product when data on children following an agreed paediatric investigation plan form part of the marketing authorisation application. To achieve this, the procedure set out in Articles 32 to 34 of Directive 2001/83/EC may be used. This will allow the adoption of a Community harmonised Decision on use of the medicinal product in children and its introduction in all national product information.
  In the meantime, it would be desirable for a European paediatric form to be drawn up to serve as a reference for the collection of all the data available in the various Member States on a pharmaceutical product desired to be marketed in the Union but at that moment placed on the market only at national level.

| (25) | It is essential to ensure that pharmacovigilance mechanisms are adapted to meet the specific challenges of collecting safety data in children, including data on possible long-term effects. Efficacy in children may also need additional study following authorisation. Therefore, an additional requirement for applying for a marketing authorisation that includes the results of studies conducted in compliance with an agreed paediatric investigation plan should be an obligation for the applicant to indicate how he proposes to ensure the long-term follow-up of possible adverse reactions to the use of the medicinal product and efficacy in the paediatric population. Additionally, where there is a particular cause for concern,
  it is necessary, under the responsibility of the Paediatric Committee, to require
  the applicant to submit and implement a risk management system and/or perform specific post-marketing studies as a condition of the marketing authorisation. |
| --- | --- |

(25)

It is essential to ensure that pharmacovigilance mechanisms are adapted to meet the specific challenges of collecting safety data in children, including data on possible long-term effects. Efficacy in children may also need additional study following authorisation. Therefore, an additional requirement for applying for a marketing authorisation that includes the results of studies conducted in compliance with an agreed paediatric investigation plan should be an obligation for the applicant to indicate how he proposes to ensure the long-term follow-up of possible adverse reactions to the use of the medicinal product and efficacy in the paediatric population. Additionally, where there is a particular cause for concern,
  it is necessary, under the responsibility of the Paediatric Committee, to require
  the applicant to submit and implement a risk management system and/or perform specific post-marketing studies as a condition of the marketing authorisation.

| (26) | For products falling within the scope of the requirement to submit paediatric data, if all the measures included in the agreed paediatric investigation plan are complied with, if
  marketing procedures are in progress in accordance with the provisions of Directive 2004/27/EC
  and if relevant information on the results of studies is included in product information, a reward should be granted in the form of a 6-month extension of the Supplementary Protection Certificate created by Council Regulation (EEC) No 1768/92 (6). |
| --- | --- |

(26)

For products falling within the scope of the requirement to submit paediatric data, if all the measures included in the agreed paediatric investigation plan are complied with, if
  marketing procedures are in progress in accordance with the provisions of Directive 2004/27/EC
  and if relevant information on the results of studies is included in product information, a reward should be granted in the form of a 6-month extension of the Supplementary Protection Certificate created by Council Regulation (EEC) No 1768/92 (6).

| (27) | Because the reward is for conducting studies in children and not for demonstrating that a product is safe and effective in children, the reward should be granted even when a paediatric indication is not authorised. However, to improve the information available on the use of medicines in the paediatric population, relevant information on use in paediatric populations should be included in authorised product information. |
| --- | --- |

(27)

Because the reward is for conducting studies in children and not for demonstrating that a product is safe and effective in children, the reward should be granted even when a paediatric indication is not authorised. However, to improve the information available on the use of medicines in the paediatric population, relevant information on use in paediatric populations should be included in authorised product information.

| (28) | Under Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (7), medicinal products designated as orphan medicinal products gain ten years of market exclusivity on the granting of a marketing authorisation for the orphan indication. As such products are frequently not patent-protected, the reward of Supplementary Protection Certificate extension cannot be applied and when they are patent-protected, such an extension would provide a double incentive. Therefore, for orphan medicinal products, instead of extension of the Supplementary Protection Certificate, the ten-year period of orphan market exclusivity should be extended to twelve years if the requirement for data on use in children is fully met. |
| --- | --- |

(28)

Under Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (7), medicinal products designated as orphan medicinal products gain ten years of market exclusivity on the granting of a marketing authorisation for the orphan indication. As such products are frequently not patent-protected, the reward of Supplementary Protection Certificate extension cannot be applied and when they are patent-protected, such an extension would provide a double incentive. Therefore, for orphan medicinal products, instead of extension of the Supplementary Protection Certificate, the ten-year period of orphan market exclusivity should be extended to twelve years if the requirement for data on use in children is fully met.

| (29) | The measures provided for in this Regulation should not preclude the operation of other incentives or rewards. To ensure transparency on the different measures available at Community and Member State levels, the Commission should draw up a detailed list of all the incentives available, on the basis of information provided by the Member States. The measures set out in this Regulation, including the agreement of paediatric investigation plans, should not be grounds for obtaining any other Community incentives to support research, such as the funding of research projects under the multi-annual Community Framework Programmes for Research, Technological Development and Demonstration Activities. |
| --- | --- |

(29)

The measures provided for in this Regulation should not preclude the operation of other incentives or rewards. To ensure transparency on the different measures available at Community and Member State levels, the Commission should draw up a detailed list of all the incentives available, on the basis of information provided by the Member States. The measures set out in this Regulation, including the agreement of paediatric investigation plans, should not be grounds for obtaining any other Community incentives to support research, such as the funding of research projects under the multi-annual Community Framework Programmes for Research, Technological Development and Demonstration Activities.

| (30) | In order to increase the availability of information on the use of medicines in children, and to avoid the repetition of studies in children which do not add to the collective knowledge, the European database provided for in Article 11 of Directive 2001/20/EC should include
  a European register of clinical trials of medicinal products for paediatric use comprising
  all ongoing, prematurely terminated, and completed paediatric studies conducted both in the Community and in third countries.
  Such studies should also be entered in the databases of clinical investigations currently in operation at national level. Studies in children already performed in third countries should not be repeated. However, if unavoidable, control studies should be possible. |
| --- | --- |

(30)

In order to increase the availability of information on the use of medicines in children, and to avoid the repetition of studies in children which do not add to the collective knowledge, the European database provided for in Article 11 of Directive 2001/20/EC should include
  a European register of clinical trials of medicinal products for paediatric use comprising
  all ongoing, prematurely terminated, and completed paediatric studies conducted both in the Community and in third countries.
  Such studies should also be entered in the databases of clinical investigations currently in operation at national level. Studies in children already performed in third countries should not be repeated. However, if unavoidable, control studies should be possible.

| (31) | Clinical
  trials in the paediatric population may require specific expertise, specific methodology and, in some cases, specific facilities and should be carried out by appropriately trained investigators. A network linking together existing national and European initiatives and study centres
  and taking account of international data
  in order to build up the necessary competences at a European level, would help facilitating co-operation and avoiding duplication of studies. This network should contribute to the work of strengthening the foundations of the European Research Area in the context of Community Framework Programmes for Research, Technological Development and Demonstration Activities, benefit the paediatric population and provide a source of information and expertise for industry. |
| --- | --- |

(31)

Clinical
  trials in the paediatric population may require specific expertise, specific methodology and, in some cases, specific facilities and should be carried out by appropriately trained investigators. A network linking together existing national and European initiatives and study centres
  and taking account of international data
  in order to build up the necessary competences at a European level, would help facilitating co-operation and avoiding duplication of studies. This network should contribute to the work of strengthening the foundations of the European Research Area in the context of Community Framework Programmes for Research, Technological Development and Demonstration Activities, benefit the paediatric population and provide a source of information and expertise for industry.

| (32) | For certain authorised products, pharmaceutical companies may already hold data on safety or efficacy in children. To improve the information available on the use of medicines in the paediatric populations, companies holding such data should be required to submit them to all competent authorities where the product is authorised. In this way the data can be assessed and, if appropriate, information should be included in the authorised product information aimed at healthcare professionals and patients. |
| --- | --- |

(32)

For certain authorised products, pharmaceutical companies may already hold data on safety or efficacy in children. To improve the information available on the use of medicines in the paediatric populations, companies holding such data should be required to submit them to all competent authorities where the product is authorised. In this way the data can be assessed and, if appropriate, information should be included in the authorised product information aimed at healthcare professionals and patients.

| (33) | Community funding should be envisaged to cover the work of the Paediatric Committee and of the Agency resulting from the implementation of this Regulation, such as the assessment of paediatric investigation plans, fee waivers for scientific advice, and information and transparency measures, including the database of paediatric studies and the network. |
| --- | --- |

(33)

Community funding should be envisaged to cover the work of the Paediatric Committee and of the Agency resulting from the implementation of this Regulation, such as the assessment of paediatric investigation plans, fee waivers for scientific advice, and information and transparency measures, including the database of paediatric studies and the network.

| (34) | The measures necessary for the implementation of this Regulation should be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (8). |
| --- | --- |

(34)

The measures necessary for the implementation of this Regulation should be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (8).

| (35) | Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 should therefore be amended accordingly, |
| --- | --- |

(35)

Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 should therefore be amended accordingly,

HAVE ADOPTED THIS REGULATION:

TITLE I

INTRODUCTORY PROVISIONS

Chapter 1

Subject-matter and definitions

Article 1

This Regulation lays down rules concerning the development of medicinal products for human use in order to meet the specific therapeutic needs of the paediatric population, without subjecting children to unnecessary clinical
  or other
  trials
  (particularly in the case of medicinal products which are already used by children suffering from rare congenital conditions)
  and in compliance with Directive 2001/20/EC.

Article 2

In addition to the definitions laid down in Article 1 of Directive 2001/83/EC, the following definitions shall apply for the purposes of this Regulation:

| 1. | ‘paediatric population’ means that part of the population aged between birth and 18 years; |
| --- | --- |

1.

‘paediatric population’ means that part of the population aged between birth and 18 years;

| 2. | ‘paediatric investigation plan’ means a research and development programme aimed at ensuring that the necessary data are generated determining the conditions in which a medicinal product may be authorised to treat the paediatric population. |
| --- | --- |

2.

‘paediatric investigation plan’ means a research and development programme aimed at ensuring that the necessary data are generated determining the conditions in which a medicinal product may be authorised to treat the paediatric population.

| 3. | ‘medicinal product authorised for a paediatric indication’ means a medicinal product which is authorised for use in part or all of the paediatric population and in respect of which the details of the authorised indication are specified in the summary of the product characteristics drawn up in accordance with Article 11 of Directive 2001/83/EC. |
| --- | --- |

3.

‘medicinal product authorised for a paediatric indication’ means a medicinal product which is authorised for use in part or all of the paediatric population and in respect of which the details of the authorised indication are specified in the summary of the product characteristics drawn up in accordance with Article 11 of Directive 2001/83/EC.

Chapter 2

Identification of needs

Article 3

The Member States shall collect all available data on all existing and necessary uses of medicinal products and shall draw up an inventory of the needs which are not covered in the paediatric population. They shall forward those data to the Agency in the course of the year following the entry into force of this Regulation.

The Paediatric Committee set up under Article 7 shall provide guidance on the content and the format of the data to be collected.

Article 4

On the basis of the information referred to in Article 3 and after consulting the Commission, the Member States and the interested parties, the Paediatric Committee shall draw up a specific inventory of paediatric medicinal product needs.

In establishing the inventory of therapeutic needs, account shall be taken of the prevalence of the conditions in the paediatric population, the seriousness of the conditions to be treated, the availability and suitability of alternative treatments for the conditions in the paediatric population, including the efficacy and the adverse reaction profile of those treatments, and any unique paediatric safety issues.

The Agency shall publish the inventory within two years of the entry into force of this Regulation and shall update it regularly, including the data from trials carried out in third countries. This inventory shall also be aimed at establishing research priorities.

Article 5

The Agency shall, with the scientific support of the Paediatric Committee, develop a European network of existing national and European networks, investigators and centres with specific expertise in the performance of studies in the paediatric population.

The objectives of the European network shall be, inter alia, to coordinate studies relating to paediatric medicinal products, to build up the necessary scientific and administrative competences at European level, and to avoid duplication of studies and testing in children.

Within one year of the entry into force of this Regulation, the Management Board of the Agency shall, on a proposal from the Executive Director and following consultation with the Commission, the Member States and interested parties, adopt an implementing strategy for the launching and operation of the European network. This network must, where appropriate, be compatible with the work of strengthening the foundations of the European Research Area in the context of the Community Framework Programmes for Research, Technological Development and Demonstration Activities.

Article 6

Within one year of the entry into force of this Regulation, the Commission and the Member States shall establish a European paediatrics research programme under which studies into the use of medicinal products (in particular ones which are not covered by patents or supplementary certificates) shall be financed.

The programme shall take into account the priorities referred to in the third paragraph of Article 4.

Chapter 3

Paediatric Committee

Article 7

1.   
  Not later than 6 months after the entry into force of this Regulation,
  a Paediatric Committee
  shall be
  established within the Agency.

The Agency shall act as the secretariat of the Paediatric Committee and shall provide it with technical and scientific support.

2.   Save where otherwise provided in this Regulation, Regulation (EC) No 726/2004 shall apply to the Paediatric Committee.

3.   The Executive Director of the Agency shall ensure appropriate co-ordination between the Paediatric Committee and the Committee for Medicinal Products for Human Use, the Committee for Orphan Medicinal Products, their working parties and any other scientific advisory groups.

The Agency shall draw up specific procedures for possible consultations between them.

Article 8

1.   The Paediatric Committee shall be composed of the following members:

| (a) | five members of the Committee for Medicinal Products for Human Use, appointed by the latter; |
| --- | --- |

(a)

five members of the Committee for Medicinal Products for Human Use, appointed by the latter;

| (b) | one person appointed by each Member State whose national competent authority is not represented through the members appointed by the Committee for Medicinal Products for Human Use; |
| --- | --- |

(b)

one person appointed by each Member State whose national competent authority is not represented through the members appointed by the Committee for Medicinal Products for Human Use;

| (c) | ten
  persons appointed by the Commission,
  after consulting the European Parliament
  , on the basis of a public call for expressions of interest, in order to represent paediatricians
  , other physicians specialising in the treatment of children, general practitioners, pharmacists, pharmacovigilance and public-health specialists and parents'
  associations. |
| --- | --- |

(c)

ten
  persons appointed by the Commission,
  after consulting the European Parliament
  , on the basis of a public call for expressions of interest, in order to represent paediatricians
  , other physicians specialising in the treatment of children, general practitioners, pharmacists, pharmacovigilance and public-health specialists and parents'
  associations.

For the purposes of point (b), the Member States shall cooperate, under the coordination of the Executive Director of the Agency, in order to ensure that the final composition of the Paediatric Committee covers the scientific areas relevant to paediatric medicinal products, and including at least: pharmaceutical development, paediatric medicine, paediatric pharmacy, paediatric pharmacology, paediatric research, pharmacovigilance and ethics.

2.   The members of the Paediatric Committee shall be appointed for a renewable period of three years. At meetings of the Paediatric Committee, they may be accompanied by experts.

3.   The Paediatric Committee shall elect its Chairman from among its members for a term of three years renewable once.

4.   The names and scientific qualifications of the members shall be published by the Agency.

Article 9

1.   When preparing its opinions, the Paediatric Committee shall use its best endeavours to reach a scientific consensus. If such a consensus cannot be reached, the opinion shall
  be the one adopted by
  the majority of members
  . The opinion shall mention the
  divergent positions, with the grounds on which they are based.

The opinion shall be made public immediately.

2.   The Paediatric Committee shall draw up its own rules of procedure for the implementation of its tasks. The rules of procedure shall enter into force after receiving a favourable opinion from the Management Board of the Agency and, subsequently, from the Commission.

3.   All meetings of the Paediatric Committee may be attended by
  two
  representatives of the Commission, the Executive Director of the Agency or his
  representative
  .

Article 10

Members of the Paediatric Committee and its experts shall undertake to act in the public interest and in an independent manner. They shall not have financial or other interests in the pharmaceutical industry that could affect their impartiality.

All
  direct or
  indirect interests that could relate to the pharmaceutical industry shall be entered in a register held by the Agency which the public may consult. The register shall be updated annually.

Members of the Paediatric Committee and its experts shall declare at each meeting any specific interests which could be considered to be prejudicial to their independence with respect to the points on the agenda.

Members of the Paediatric Committee and its experts shall be required, even after their duties have ceased, not to disclose any information of the kind covered by the obligation of professional secrecy.

Article 11

1.   The tasks of the Paediatric Committee shall include the following:

| (a) | to assess the content of any paediatric investigation plan for a medicinal product submitted to it in accordance with this Regulation, and formulate an opinion thereon; |
| --- | --- |

(a)

to assess the content of any paediatric investigation plan for a medicinal product submitted to it in accordance with this Regulation, and formulate an opinion thereon;

| (b) | to assess waivers and deferrals, and formulate an opinion thereon; |
| --- | --- |

(b)

to assess waivers and deferrals, and formulate an opinion thereon;

| (c) | at the request of the Committee for Medicinal Products for Human Use, a competent authority or the applicant, to assess compliance of the application for a marketing authorisation with the relevant agreed paediatric investigation plan, and formulate an opinion thereon; |
| --- | --- |

(c)

at the request of the Committee for Medicinal Products for Human Use, a competent authority or the applicant, to assess compliance of the application for a marketing authorisation with the relevant agreed paediatric investigation plan, and formulate an opinion thereon;

| (d) | at the request of the Committee for Medicinal Products for Human Use or a competent authority, to assess any data generated in accordance with an agreed paediatric investigation plan, and formulate an opinion on the quality, safety or efficacy of the medicinal product for use in the paediatric population; |
| --- | --- |

(d)

at the request of the Committee for Medicinal Products for Human Use or a competent authority, to assess any data generated in accordance with an agreed paediatric investigation plan, and formulate an opinion on the quality, safety or efficacy of the medicinal product for use in the paediatric population;

| (e) | to advise on the content and format of data to be collected for the survey referred to in Article 3 and to adopt an inventory of therapeutic needs as referred to in Article 4; |
| --- | --- |

(e)

to advise on the content and format of data to be collected for the survey referred to in Article 3 and to adopt an inventory of therapeutic needs as referred to in Article 4;

| (f) | to support and advise the Agency on establishing the European network referred to in Article 5; |
| --- | --- |

(f)

to support and advise the Agency on establishing the European network referred to in Article 5;

| (g) | to
  provide scientific assistance, free of charge,
  in the elaboration of any documents related to the fulfilment of the objectives of this Regulation; |
| --- | --- |

(g)

to
  provide scientific assistance, free of charge,
  in the elaboration of any documents related to the fulfilment of the objectives of this Regulation;

| (h) | to provide advice on any question related to medicinal products for paediatric use, at the request of the Executive Director of the Agency or the Commission; |
| --- | --- |

(h)

to provide advice on any question related to medicinal products for paediatric use, at the request of the Executive Director of the Agency or the Commission;

| (i) | to establish a specific inventory of paediatric medicinal product needs, update it on a regular basis and make it available to interested parties (professionals, enterprises, patients, etc); |
| --- | --- |

(i)

to establish a specific inventory of paediatric medicinal product needs, update it on a regular basis and make it available to interested parties (professionals, enterprises, patients, etc);

| (j) | to promote information campaigns on the role of the Committee and the arrangements available for the conducting of paediatric pharmaceuticals trials. |
| --- | --- |

(j)

to promote information campaigns on the role of the Committee and the arrangements available for the conducting of paediatric pharmaceuticals trials.

2.   When carrying out its tasks, the Paediatric Committee shall consider whether or not any proposed studies can be expected to be of significant therapeutic benefit to the paediatric population.
  It shall also take into account, inter alia, any opinions, decisions or advice issued by the competent authorities of third countries.

TITLE II

MARKETING AUTHORISATION REQUIREMENTS

Chapter 1

General authorisation requirements

Article 12

1.   An application for marketing authorisation under Article 6 of Directive 2001/83/EC in respect of a medicinal product for human use which is not authorised in the Community at the time of entry into force of this Regulation shall be regarded as valid only if it includes, in addition to the particulars and documents referred to in Article 8(3) of Directive 2001/83/EC, one of the following:

| (a) | the results of all studies performed and details of all information collected in compliance with an agreed paediatric investigation plan; |
| --- | --- |

(a)

the results of all studies performed and details of all information collected in compliance with an agreed paediatric investigation plan;

| (b) | a decision of the Agency granting a product-specific waiver; |
| --- | --- |

(b)

a decision of the Agency granting a product-specific waiver;

| (c) | a decision of the Agency granting a class waiver; |
| --- | --- |

(c)

a decision of the Agency granting a class waiver;

| (d) | a decision of the Agency granting a deferral; |
| --- | --- |

(d)

a decision of the Agency granting a deferral;

| (e) | ongoing paediatric studies on the product, the scheduled date for completion of the studies and the Agency's opinion on these points. |
| --- | --- |

(e)

ongoing paediatric studies on the product, the scheduled date for completion of the studies and the Agency's opinion on these points.

For the purposes of point (a), the decision of the Agency agreeing the paediatric investigation plan concerned shall also be included in the application.

2.   The documents submitted pursuant to paragraph 1 shall, cumulatively, cover all subsets of the paediatric population.

Article 13

In the case of authorised medicinal products which are protected either by a supplementary protection certificate under Regulation (EEC) No 1768/92, or by a patent which qualifies for the granting of the supplementary protection certificate, Article 12 of this Regulation shall apply to applications for authorisation of new indications, including paediatric indications, new pharmaceutical forms and new routes of administration.

Where appropriate, Commission Regulation (EC) No 1085/2003 of 3 June 2003
  concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products falling within the scope of Council Regulation (EEC) No 2309/93 (9)

  shall apply.

The first paragraph shall also apply where the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical innovation in accordance with the provisions of Regulation (EC) No 726/2004 and, in particular, Article 3(2)(b) thereof.

Article 14

Articles 12 and 13 shall not apply to products authorised under Articles 10, 10a, 13 to 16 or 16a to 16i of Directive 2001/83/EC.

Article 15

In consultation with the Member States, the Agency and other interested parties, the Commission shall draw up the modalities concerning the format and content which applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals must follow in order to be considered valid.

Chapter 2

Waivers

Article 16

1.   Production of the information referred to in point (a) of Article 12(1) shall be waived for specific medicinal products or for classes of medicinal products, if there is evidence showing any of the following:

| (a) | that the specific medicinal product or class of medicinal products is likely to be ineffective or unsafe in part or all of the paediatric population; |
| --- | --- |

(a)

that the specific medicinal product or class of medicinal products is likely to be ineffective or unsafe in part or all of the paediatric population;

| (b) | that the disease or condition for which the specific medicinal product or class is intended occurs only in adult populations; |
| --- | --- |

(b)

that the disease or condition for which the specific medicinal product or class is intended occurs only in adult populations;

| (c) | that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients. |
| --- | --- |

(c)

that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.   The waiver provided for in paragraph 1 may be issued with reference only to one or more specified subsets of the paediatric population, with reference only to one or more specified therapeutic indications, or with reference to a combination of both.

Article 17

The Paediatric Committee may of its own motion adopt an opinion, on the grounds set out in Article 16(1), to the effect that a class or a product-specific waiver, as referred to in Article 16(1), should be granted.

As soon as the Paediatric Committee adopts an opinion, the procedure laid down in Chapter 4 shall apply. In the case of a class waiver, only Article 30(4) shall apply.

Article 18

1.   The applicant may, on the grounds set out in Article 16(1), apply to the Agency for a product-specific waiver.

2.   
  Following
  receipt of the application, the Paediatric Committee shall
  appoint a rapporteur and shall within a maximum period of 60 days
  adopt an opinion as to whether or not a product-specific waiver should be granted.

Either the applicant or the Paediatric Committee may request a meeting during that 60-day period.

Whenever appropriate, the Paediatric Committee may request the applicant to supplement the particulars and documents submitted. Where the Paediatric Committee avails itself of this option, the 60-day time-limit shall be suspended until such time as the supplementary information requested has been provided.

3.   As soon as the Paediatric Committee adopts an opinion, the procedure laid down in Chapter 4 shall apply. The Agency shall inform the applicant accordingly
  within no more than seven working days
  . The applicant shall be informed of the reasons for the conclusion reached.

Article 19

1.   The Agency shall maintain a list of all waivers.
  The list shall be updated regularly (at least every six months) and made available to the public.

2.   The Paediatric Committee may, at any time, adopt an opinion advocating the review of a granted waiver.

In the case of a change affecting a product-specific waiver, the procedure laid down in Chapter 4 shall apply.

In the case of a change affecting a class waiver, Article 30(5) shall apply.

3.   If a particular product-specific or class waiver is revoked, the requirement set out in Articles 12 and 13 shall not apply for 36 months from the date of its removal from the list of waivers.

Chapter 3

Paediatric investigation plan

Section 1

Requests for agreement

Article 20

1.   Where the intention is to apply in accordance with points (a) or (d) of Article 12(1), a paediatric investigation plan shall be drawn up and submitted to the Agency with a request for agreement.

2.   The paediatric investigation plan shall specify the timing and the measures proposed to assess the quality, safety and efficacy of the medicinal product in all subsets of the paediatric population that may be concerned. In addition, it shall describe any measures to adapt the formulation of the medicinal product so as to make its use more acceptable, easier, safer or more effective for different subsets of the paediatric population.

Article 21

1.   In the case of applications as referred to in Articles 12 and 13, the paediatric investigation plan
  including a summary report may
  be submitted with a request for agreement,
  at the earliest after
  completion of
  phase II of
  the human pharmaco-kinetic studies in
  adults, so
  as to ensure that
  investigation plans can be formulated in specific terms and hence meet requirements in the field of clinical studies involving children
  .

Should an application not be submitted upon completion of the human pharmaco-kinetic studies, the applicant shall supply the ongoing paediatric studies and the scheduled date for their completion. The competent authority shall follow up these points with the applicant.

2.   Within
  10
  days of receiving the request referred to in paragraph 1, the Agency shall verify the validity of the
  request
  .

3.   Whenever appropriate, the Agency may ask the applicant to submit additional particulars and documents, in which case the time-limit of
  10
  days shall be suspended until such time as the supplementary information requested has been provided.

Article 22

1.   
  Following receipt of
  a proposed paediatric investigation plan which is valid, the Paediatric Committee shall
  appoint a rapporteur and shall within a maximum period of 60 days
  adopt an opinion as to whether or not the proposed studies will ensure the generation of the necessary data determining the conditions in which the medicinal product may be used to treat the paediatric population or subsets thereof, and as to whether or not the expected therapeutic benefits justify the studies proposed.

Within the same period, either the applicant or the Paediatric Committee may request a meeting.

2.   Within the 60-day period referred to in paragraph 1, the Paediatric Committee may request the applicant to propose modifications to the plan, in which case the time-limit referred to in paragraph 1 for the adoption of the final opinion shall be extended for a maximum of 60 days. In such cases, the applicant or the Paediatric Committee may request an additional meeting during this period. The time-limit shall be suspended until such time as the modifications requested have been made.

Article 23

As soon as the Paediatric Committee adopts an opinion, whether positive or negative, the procedure laid down in Chapter 4 shall apply.

Article 24

If, having considered a paediatric investigation plan, the Paediatric Committee concludes that Article 16(1)(a), (b) or (c) applies to the medicinal product concerned, it shall adopt a negative opinion under Article 22(1).

In such cases, the Paediatric Committee shall adopt an opinion in favour of a waiver under Article 17, whereupon the procedure laid down in Chapter 4 shall apply.

Section 2

Deferrals

Article 25

1.   At the same time as the paediatric investigation plan is submitted under Article 21(1), a request may be made for deferral of the initiation or completion of some or all of the measures set out in that plan. Such deferral shall be justified on scientific and technical grounds or on grounds related to public health.

In any case, a deferral shall be granted when it is appropriate to conduct studies in adults prior to initiating studies in the paediatric population or when studies in the paediatric population will take longer to conduct than studies in adults.

2.   On the basis of the experience acquired as a result of the operation of this Article, the Commission may adopt provisions in accordance with the procedure referred to in Article 54(2) to define further the grounds for granting a deferral.

Article 26

1.   At the same time as the Paediatric Committee adopts a positive opinion under Article 22(1), it shall, of its own motion or following a request submitted by the applicant under Article 25, adopt an opinion, if the conditions specified in Article 25 are met, in favour of deferring the initiation or completion of some or all of the measures in the paediatric investigation plan.

An opinion in favour of a deferral shall specify the time-limits for initiating or completing the measures concerned.

2.   As soon as the Paediatric Committee adopts an opinion in favour of deferral, as referred to in paragraph 1, the procedure laid down in Chapter 4 shall apply.

Section 3

Modification of a paediatric investigation plan

Article 27

If, after the decision agreeing the paediatric investigation plan, the applicant encounters difficulties with its implementation such as to render the plan unworkable or no longer appropriate, the applicant may propose changes or request a deferral or a waiver, based on detailed grounds, to the Paediatric Committee.
  Within 60 days
  , the Paediatric Committee shall review these changes
  or the request for a deferral or a waiver
  and adopt an opinion proposing their refusal or acceptance
  and, wherever possible, propose a deadline for submission by the applicant of an amended paediatric investigation plan
  . As soon as the Paediatric Committee adopts an opinion, whether positive or negative, the procedure laid down in Chapter 4 shall apply.

Section 4

Compliance with the paediatric investigation plan

Article 28

The Paediatric Committee may, in the following cases, be requested to give its opinion as to whether studies conducted by the applicant are in compliance with the agreed paediatric investigation plan:

| (a) | by the applicant, prior to submitting an application for marketing authorisation or variation as referred to in Articles 12 and 13, respectively; |
| --- | --- |

(a)

by the applicant, prior to submitting an application for marketing authorisation or variation as referred to in Articles 12 and 13, respectively;

| (b) | by the Agency, or the competent authority, when validating an application, as referred to in point (a), which does not include an opinion concerning compliance adopted following a request under point (a); |
| --- | --- |

(b)

by the Agency, or the competent authority, when validating an application, as referred to in point (a), which does not include an opinion concerning compliance adopted following a request under point (a);

| (c) | by the Committee for Medicinal Products for Human Use, or the competent authority, when assessing an application, as referred to in point (a), where there is doubt concerning compliance and an opinion has not been given already following a request under points (a) or (b). |
| --- | --- |

(c)

by the Committee for Medicinal Products for Human Use, or the competent authority, when assessing an application, as referred to in point (a), where there is doubt concerning compliance and an opinion has not been given already following a request under points (a) or (b).

Member States shall take account of such an opinion.

If the Paediatric Committee is asked to give an opinion under the first paragraph, it must do so within 60 days of receiving the request.

Article 29

If, when conducting the scientific assessment of a valid application, the competent authority concludes that the studies are not compliant with the agreed paediatric investigation plan, the product shall not be eligible for the rewards provided for in Articles 40 and 41.

Chapter 4

Procedure

Article 30

1.   Within 30 days of receiving the opinion of the Paediatric Committee, the applicant may submit to the Agency a written request, on detailed grounds, for a re-examination of the opinion.

2.   Within 30 days of receiving a request for re-examination pursuant to paragraph 1, the Paediatric Committee, having appointed a new rapporteur,
  who shall be able to question the applicant directly,
  shall issue a new opinion confirming or revising its previous opinion.
  The applicant may also offer to be questioned. The rapporteur shall inform the Paediatric Committee without delay in writing about the details of contacts with the applicant.
  The opinion shall be duly reasoned and a statement of reasons for the conclusion reached shall be annexed to the new opinion, which shall become definitive.

3.   If, within the 30-day period referred to in paragraph 1, the applicant does not request re-examination, the opinion of the Paediatric Committee shall become definitive.

4.   The Agency shall adopt a decision
  within a period not exceeding 15 days following receipt of the Paediatric Committee's definitive opinion
  . This decision shall be communicated to the applicant
  in writing, with detailed grounds
  .

5.   In the case of a class waiver as referred to in Article 17, the Agency shall adopt a decision, which shall be published.

Chapter 5

Miscellaneous provisions

Article 31

The sponsor of a medicinal product intended for paediatric use may, prior to the submission of a paediatric investigation plan and during its implementation, request advice from the Agency on the design and conduct of the various tests and studies necessary to demonstrate the quality, safety and efficacy of the medicinal product in the paediatric population in accordance with Article 57(1)(n) of Regulation (EC) No 726/2004.

In addition, the sponsor may request advice on the design and conduct of pharmacovigilance and risk management systems as referred to in Article 39.

The Agency shall provide advice under this Article free of charge.

TITLE III

MARKETING AUTHORISATION PROCEDURES

Article 32

Save where otherwise provided in this Title, marketing authorisation procedures for the marketing authorisations covered by this Title shall be governed by the provisions laid down in Regulation (EC) No 726/2004 or in Directive 2001/83/EC.

Chapter 1

Marketing authorisation procedures for applications falling within the scope of Articles 12 and 13

Article 33

1.   Applications may be submitted in accordance with the procedure laid down in Articles 5 to 15 of Regulation (EC) No 726/2004 for a marketing authorisation as referred to in Article 12(1) of this Regulation which includes one or more paediatric indications selected on the basis of studies conducted in compliance with an agreed paediatric investigation plan.

Where authorisation is granted,
  all
  the results of those studies shall be included in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product,
  provided that the competent authority deems the information to be of use to patients,
  whether or not all the paediatric indications concerned were approved.
  In such cases, the information shall be set out in such a way as to distinguish clearly between the paediatric indications that have been approved and those that have not.

2.   Where a marketing authorisation is granted or varied, any waiver or deferral which has been granted pursuant to this Regulation shall be recorded in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned.

3.   If the application complies with all the measures contained in the agreed completed paediatric investigation plan and if the summary of product characteristics reflects the results of studies conducted in compliance with that agreed paediatric investigation plan, the competent authority shall include within the marketing authorisation a statement indicating compliance of the application with the agreed completed paediatric investigation plan.

Article 34

In the case of medicinal products authorised under Directive 2001/83/EC, an application as referred to in Article 13 of this Regulation may be submitted, in accordance with the procedure laid down in Articles 32, 33 and 34 of Directive 2001/83/EC, for authorisation of a new indication, including the extension of an authorisation for use in the paediatric population, a new pharmaceutical form or a new route of administration.

That application shall comply with the requirement laid down in point (a) of Article 12(1).

The procedure shall be limited to the assessment of the specific sections of the summary of product characteristics to be varied.

Chapter 2

Paediatric use marketing authorisation

Article 35

1.   For the purposes of this Regulation, a paediatric use marketing authorisation shall mean a marketing authorisation granted in respect of a medicinal product for human use which is not protected by a supplementary protection certificate under Regulation (EEC) No 1768/92 or by a patent which qualifies for the granting of the supplementary protection certificate, covering exclusively therapeutic indications which are relevant for use in the paediatric population, or subsets thereof, including the appropriate strength, pharmaceutical form or route of administration for that product.

2.   Submission of an application for a paediatric use marketing authorisation shall in no way preclude the right to apply for a marketing authorisation for other indications.

3.   An application for a paediatric use marketing authorisation shall be accompanied by the particulars and documents necessary to establish safety, quality and efficacy in children, including any specific data needed to support an appropriate strength, pharmaceutical form or route of administration of the product, in accordance with an agreed paediatric investigation plan.

The application shall also include the decision of the Agency agreeing the paediatric investigation plan concerned.

4.   Where a medicinal product is or has been authorised in a Member State or in the Community, data contained in the dossier on that product may, where appropriate, be referred to, in accordance with Article 14(11) of Regulation (EC) No 726/2004 or Article 10 of Directive 2001/83/EC, in an application for a paediatric use marketing authorisation.

5.   The medicinal product in respect of which a paediatric use marketing authorisation is granted may retain the name of any medicinal product which contains the same active substance and in respect of which the same holder has been granted authorisation for use in adults.

Article 36

Without prejudice to Article 3(2) of Regulation (EC) No 726/2004, an application for a paediatric use marketing authorisation may be made in accordance with the procedure laid down in Articles 5 to 15 of that Regulation.

Chapter 3

Identification

Article 37

Where a medicinal product is granted a marketing authorisation for a paediatric indication based on the results of studies conducted in compliance with an agreed paediatric investigation plan, the label shall display the name of the medicinal product
  and, below it, the European logo
  for any paediatric presentation.

That logo shall be selected following a design competition for children. The logo shall symbolically represent the contribution by the medicinal product to health.

The organisational arrangements for the competition shall be a matter for the Agency.

The first paragraph shall apply whether the name of the medicinal product is an invented name or a common name as referred to in Article 1(20) and (21), respectively, of Directive 2001/83/EC.

The provisions of this Article shall also apply to medicinal products authorised prior to the entry into force of this Regulation and covering paediatric indications only.

TITLE IV

POST-AUTHORISATION REQUIREMENTS

Article 38

Where medicinal products are authorised for a paediatric indication following completion of an agreed paediatric investigation plan and those products have already been marketed with other indications, the marketing authorisation holder shall,
  wherever possible within one year and no later than
  within two years of the date on which the paediatric indication is authorised, place the product on the market taking into account the paediatric indication.
  A publicly accessible register shall be set up by the competent authorities in order to indicate these deadlines.

The competent authorities may, in specific cases affected by administrative delays, grant derogations from this provision. Any such derogations shall be justified on duly substantiated grounds...

Article 39

1.   In the following cases, the applicant shall detail, in addition to the normal requirements for postmarketing monitoring, the measures to ensure the follow-up of efficacy and of possible adverse reactions to the paediatric use of the medicinal product:

| (a) | applications for a marketing authorisation that includes a paediatric indication; |
| --- | --- |

(a)

applications for a marketing authorisation that includes a paediatric indication;

| (b) | applications to include a paediatric indication in an existing marketing authorisation; |
| --- | --- |

(b)

applications to include a paediatric indication in an existing marketing authorisation;

| (c) | applications for a paediatric use marketing authorisation. |
| --- | --- |

(c)

applications for a paediatric use marketing authorisation.

2.   
  Granting marketing authorisation for a paediatric indication shall be subject to the setting up of a risk management system by the firm concerned. If necessary, the competent authority may also require specific studies to be performed.
  The risk management system shall comprise a set of activities and interventions designed to prevent or minimise risks relating to medicinal products, including the assessment of the effectiveness of those interventions.

Assessment of the effectiveness of any risk management system and the results of any studies performed shall be included in the periodic safety update reports referred to in Article 104(6) of Directive 2001/83/EC and Article 24(3) of Regulation (EC) No 726/2004.

In addition, the competent authority may request submission of additional reports assessing the effectiveness of any risk minimisation system and the results of any such studies performed.

The holder of the marketing authorisation may not communicate information on pharmacovigilance matters to the public without the Agency's consent.

3.
     
  Pharmacovigilance data on adverse reactions reported before and after marketing shall be collated in a register that is made publicly available.

4.   In the case of a deferral, the marketing authorisation holder shall submit an annual report to the Agency providing an update on progress with paediatric studies in accordance with the decision of the Agency agreeing the paediatric investigation plan and granting a deferral.

The Agency shall inform the competent authority if it is found that the marketing authorisation holder has failed to comply with the decision of Agency agreeing the paediatric investigation plan and granting a deferral.

5.   The Agency shall draw up detailed guidelines relating to the application of this Article.

6.
     
  With a view to ensuring total independence, public funding commensurate with the tasks assigned to competent authorities shall be provided for pharmacovigilance activities.

7.
     
  If, in cases where a medicinal product is authorised for a paediatric indication and the marketing authorisation holder has benefited from the provisions of Articles 40, 41 or 42, the marketing authorisation holder ceases to market the medicinal product, the marketing authorisation holder shall allow a third party to use the pharmaceutical, pre-clinical and clinical documentation contained in the file on the medicinal product on the basis of Article 10c of Directive 2001/83/EC. The marketing authorisation holder shall inform the Agency of its intention to cease marketing the product and the Agency will make this fact public.

TITLE V

REWARDS AND INCENTIVES

Article 40

1.   Where an application under Articles 12 or 13 includes the results of all studies conducted in compliance with an agreed paediatric investigation plan, the holder of the patent or supplementary protection certificate shall be entitled to a six-month extension of the period referred to in Article 13(1) and (2) of Regulation (EEC) No 1768/92.

The first subparagraph shall also apply where completion of the agreed paediatric investigation plan fails to lead to the authorisation of a paediatric indication, but the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned.

2.   The inclusion in a marketing authorisation of the statement referred to in Article 33(3) shall be used for the purposes of applying paragraph 1 of this Article.

3.   Where the procedures laid down in Directive 2001/83/EC have been used, the six-month extension of the period referred to in paragraph 1 shall be
  granted in the
  Member States
  in which the product is authorised, or in which marketing procedures are in progress in accordance with the provisions of Directive 2004/27/EC
  .

4.   Paragraphs 1, 2 and 3 shall apply to products that are protected by a supplementary protection certificate under Regulation (EEC) No 1768/92, or under a patent which qualifies for the granting of the supplementary protection certificate. They shall not apply to medicinal products designated as orphan medicinal products pursuant to Regulation (EC) No 141/2000
  or to products whose active substance has already benefited from a patent covering the same paediatric use or formulation or has received any other form of data exclusivity or market exclusivity for the same paediatric use in the European Union.

5.
     
  The extension referred to in paragraph 1 shall be admissible only once per medicinal product.

Article 41

Where an application for a marketing authorisation is submitted in respect of a medicinal product designated as an orphan medicinal product pursuant to Regulation (EC) No 141/2000 and that application includes the results of all studies conducted in compliance with an agreed paediatric investigation plan, and the statement referred to in Article 33(3) of this Regulation is subsequently included in the marketing authorisation granted, the ten-year period referred to in Article 8(1) of Regulation (EC) No 141/2000 shall be extended to twelve years.

The first paragraph shall also apply where completion of the agreed paediatric investigation plan fails to lead to the authorisation of a paediatric indication, but the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned.
  Where it is ascertained that, in a specific paediatric subpopulation identified in accordance with criteria and modalities defined by the Paediatric Committee, the conditions for recourse to the procedure laid down for orphan medicinal products are fulfilled, the authorisation holder may have recourse to whichever of the two procedures he chooses.

Article 42

1.   Where a paediatric use marketing authorisation is granted in accordance with Articles 5 to 15 of Regulation (EC) No 726/2004, the data and marketing protection periods referred to in Article 14(11) of that Regulation shall apply.

2.   Where a paediatric use marketing authorisation is granted in accordance with the procedures laid down in Directive 2001/83/EC, the data and marketing protection periods referred to in Article 10(1) of that Directive shall apply.

Article 43

1.   In addition to the rewards and incentives provided for in Articles 40, 41 and 42, medicinal products for paediatric use may be eligible for incentives provided by the Community or by the Member States to support research into, and the development and availability of, medicinal products for paediatric use.

2.   Within one year of the entry into force of this Regulation, the Member States shall communicate to the Commission detailed information concerning any measures they have enacted to support research into, and the development and availability of, medicinal products for paediatric use. This information shall be updated regularly at the request of the Commission.

3.   Within 18 months of the entry into force of this Regulation, the Commission shall publish a detailed inventory of all incentives provided by the Community and Member States to support research into, and the development and availability of, medicinal products for paediatric use. This inventory shall be updated regularly
  and shall be accessible to the public
  .

Article 44

1.
     
  Within one year of the adoption of this Regulation, a specific European programme for research into medicinal products for children shall be established to provide support for studies relating to existing pharmaceutical products or existing active substances not covered by a patent or a supplementary protection certificate.

2.
     
  This Community programme shall be called MICE (Medicines Investigation for the Children of Europe).

3.
     
  On a proposal from the Commission, the European Parliament and the Council shall, acting under the conditions laid down in the Treaty, adopt financial rules governing the establishment and operation of the programme.

4.
     
  The programme shall be administered by the Agency which, acting under the authority of the Commission, shall issue specific calls for proposals. Calls for proposals shall, wherever possible, be based on a level of funding that will cover all, or at least a very large part of, the costs generated by the studies requested.

TITLE VI

COMMUNICATION AND COORDINATION

Article 45

1.   Appropriate details of trials that are contained within agreed paediatric investigation plans, including those that are carried out in third countries, shall be entered into the European database created by Article 11 of Directive 2001/20/EC.
  By way of derogation from the latter provision, the Agency shall arrange for part of this information to be accessible to the public.

Details of the results of all completed studies conducted in accordance with an agreed paediatric investigation plan, whether terminated prematurely or not, as well as details of the results of all studies funded by the Community and the Member States to support research into, and the development and availability of, medicinal products for paediatric use, including any studies funded by the MICE programme, shall be published by the Agency with, whenever applicable, all relevant conclusions for medicinal products in the same therapeutic class that cover the same proposed paediatric use.

2.   The Commission shall, on a proposal by the Agency and in consultation with Member States and interested parties, draw up guidance on the nature of the information referred to in paragraph 1 to be entered in the European database created by Article 11 of Directive 2001/20/EC,
  on the content of the information to be made accessible to the public in application of paragraph 1 and on the Agency's responsibilities and tasks in this connection.

Article 46

1.   Within one year of the entry into force of this Regulation, any paediatric studies already completed, by the date of entry into force, in respect of products authorised in the Community shall be submitted for assessment to the competent authority.

The competent authority shall, as appropriate, update the summary of product characteristics and package leaflet, and shall vary the marketing authorisation accordingly. Competent authorities shall exchange information regarding the studies submitted and their implications for any marketing authorisations concerned.

The Agency shall coordinate the exchange of information.

2.   All existing paediatric studies, as referred to in paragraph 1,
  and all paediatric studies initiated prior to the entry into force of this Regulation shall be eligible to be included in a paediatric investigation plan, and
  shall be taken into consideration by the Paediatric Committee when assessing applications
  for waivers
  and deferrals and by competent authorities when assessing applications submitted pursuant to Articles 12, 13 or 35.

3.   No paediatric studies, as referred to in paragraph 1, which have at the date of entry into force of this Regulation already been submitted for assessment in a third country, shall be taken into consideration for the rewards and incentives provided for in Articles 40, 41 and 42.

Article 47

Any other studies sponsored by the marketing authorisation holder which involve the use in the paediatric population of a medicinal product covered by a marketing authorisation, whether or not they are conducted in compliance with an agreed paediatric investigation plan, shall be submitted to the competent authority within six months of the completion of the studies concerned.

The first paragraph shall apply whether or not the marketing authorisation holder intends to apply for a paediatric indication.

The competent authority shall, as appropriate, update the summary of product characteristics and package leaflet, and shall vary the marketing authorisation accordingly.

Competent authorities shall exchange information regarding the studies submitted and their implications for any marketing authorisations concerned.

The Agency shall coordinate the exchange of information.

TITLE VII

GENERAL AND FINAL PROVISIONS

Chapter 1

General

Section 1

Fees, Community funding, penalties and reports

Article 48

1.   Where an application for a paediatric use marketing authorisation is submitted in accordance with the procedure laid down in Regulation (EC) No 726/2004, the amount of the reduced fees for the examination of the application and the maintenance of the marketing authorisation shall be fixed in accordance with Article 70 of that Regulation.

2.   Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products
   (10) shall apply.

3.   Assessments of the following by the Paediatric Committee shall be free of charge:

| (a) | applications for waiver; |
| --- | --- |

(a)

applications for waiver;

| (b) | applications for deferral; |
| --- | --- |

(b)

applications for deferral;

| (c) | paediatric investigation plans; |
| --- | --- |

(c)

paediatric investigation plans;

| (d) | compliance with the agreed paediatric investigation plan. |
| --- | --- |

(d)

compliance with the agreed paediatric investigation plan.

Article 49

The Community contribution provided for in Article 67 of Regulation (EC) No 726/2004 shall
  cover the
  work of the Paediatric Committee, including scientific support provided by experts, and of the Agency, including the assessment of paediatric investigation plans, scientific advice and any fee waivers provided for in this Regulation, and shall support the Agency's activities under Articles 5 and 45 of this Regulation.

In addition, a special paediatric study programme shall be established, using health policy resources, for research on off-patent medicines.

Article 50

The Community contribution will also support studies performed in the context of the MICE programme in which academic research will have a substantial role to play.

Article 51

1.   Without prejudice to the Protocol on the Privileges and Immunities of the European Communities, each Member State shall determine the penalties to be applied for infringement of the provisions of this Regulation or the implementing measures adopted pursuant to it in relation to medicinal products authorised through the procedures laid down in Directive 2001/83/EC and shall take all measures necessary for their implementation. The penalties shall be effective,
  proportionate, dissuasive and, wherever possible, harmonised
  .

Member States shall inform the Commission of these provisions no later than [...]. They shall notify any subsequent alterations as soon as possible.

2.   Member States shall inform the Commission immediately of any litigation instituted for infringement of this Regulation.

3.   At the Agency's request, the Commission may impose financial penalties for infringement of the provisions of this Regulation or the implementing measures adopted pursuant to it in relation to medicinal products authorised through the procedure laid down in Regulation (EC) No 726/2004. The maximum amounts as well as the conditions and methods for collection of these penalties shall be laid down in accordance with the procedure referred to in Article 54(2) of this Regulation.

4.   The Commission shall publish the names of the marketing authorisation holders involved
  , and also of anyone infringing the provisions of this Regulation or of any regulations adopted pursuant to it,
  and the amounts of and reasons for the financial penalties imposed.

Article 52

1.   On the basis of a report from the Agency and at least on an annual basis, the Commission shall publish a list of the companies that have benefited from any of the rewards and incentives in this Regulation and the companies that have failed to comply with any of the obligations in this Regulation. The Member States shall provide this information to the Agency.

2.   Within six years of the entry into force of this Regulation, the Commission shall publish a general report on experience acquired as a result of its application, including in particular a detailed inventory of all medicinal products authorised for paediatric use since its entry into force.
  The Commission shall, in particular, carry out an analysis of the incentive and reward operations under Articles 40 and 41, with a financial assessment relating to the research costs and profits resulting from such incentives. Should the analysis show the mechanism to be ill-suited to the results sought or achieved, an amendment of the aforementioned articles shall be proposed.

Section 2

Committee

Article 53

The Commission shall, after consulting the Agency, adopt appropriate provisions for the performance of the tasks of the Paediatric Committee referred to in Article 11 in the form of a Regulation in accordance with the procedure referred to in Article 54(2).

Article 54

1.   The Commission shall be assisted by the Standing Committee on Medicinal Products for Human Use set up by Article 121 of Directive 2001/83/EC.

2.   Where reference is made to this paragraph, Articles 5 and 7 of Decision 1999/468/EC shall apply, having regard to the provisions of Article 8 thereof.

The period laid down in Article 5(6) of Decision 1999/468/EC shall be set at three months.

Chapter 2

Amendments

Article 55

Regulation (EEC) No 1768/92 shall be amended as follows:

| (1) | In Article 7, the following paragraph 3 is added:
  ‘3.   The application for an extension of the duration of a certificate already granted in application of Article 13(3) of this Regulation and of Article 40 of Regulation (EC) No [.../2005 of the European Parliament and of the Council (Paediatric Regulation) (11)] shall be lodged not later than
  six months
  before the expiry of the certificate. |
| --- | --- |

(1)

In Article 7, the following paragraph 3 is added:

‘3.   The application for an extension of the duration of a certificate already granted in application of Article 13(3) of this Regulation and of Article 40 of Regulation (EC) No [.../2005 of the European Parliament and of the Council (Paediatric Regulation) (11)] shall be lodged not later than
  six months
  before the expiry of the certificate.

| (2) | Article 8 shall be amended as follows:






  (a) | in paragraph 1, the following point (d) is added:






  ‘(d) | where the application for a certificate includes a request for an extended duration in application of Article 13(3) of this Regulation and Article 40 of Regulation (EC) No [.../2005 (Paediatric Regulation)]:






  (i) | a copy of the statement indicating compliance with an agreed completed paediatric investigation plan as referred to in Article 40(3) of Regulation (EC) No [.../2005 (Paediatric Regulation)]; |
| --- | --- | --- | --- | --- |

(2)

Article 8 shall be amended as follows:

(a)

in paragraph 1, the following point (d) is added:

‘(d)

where the application for a certificate includes a request for an extended duration in application of Article 13(3) of this Regulation and Article 40 of Regulation (EC) No [.../2005 (Paediatric Regulation)]:

(i)

a copy of the statement indicating compliance with an agreed completed paediatric investigation plan as referred to in Article 40(3) of Regulation (EC) No [.../2005 (Paediatric Regulation)];

| (ii) | where necessary, in addition to the copy of the authorisations to place the product on the market as referred to in point (b), copies of the authorisations to place the product on the market of all other Member States, as referred to in Article 40(4) of Regulation (EC) No [.../2005 (Paediatric Regulation)].’ |
| --- | --- |

(ii)

where necessary, in addition to the copy of the authorisations to place the product on the market as referred to in point (b), copies of the authorisations to place the product on the market of all other Member States, as referred to in Article 40(4) of Regulation (EC) No [.../2005 (Paediatric Regulation)].’

| (b) | the following paragraph 1a is inserted:
  ‘1a.   The application for an extension of the duration of a certificate already granted shall contain:






  (a) | a copy of the certificate already granted; |
| --- | --- | --- |

(b)

the following paragraph 1a is inserted:

‘1a.   The application for an extension of the duration of a certificate already granted shall contain:

(a)

a copy of the certificate already granted;

| (b) | a copy of the statement indicating compliance with an agreed completed paediatric investigation plan as referred to in Article 40(3) of Regulation (EC) No [.../2005 (Paediatric Regulation)]; |
| --- | --- |

(b)

a copy of the statement indicating compliance with an agreed completed paediatric investigation plan as referred to in Article 40(3) of Regulation (EC) No [.../2005 (Paediatric Regulation)];

| (c) | copies of the authorisations to place the product on the market of all Member States.’ |
| --- | --- |

(c)

copies of the authorisations to place the product on the market of all Member States.’

| (c) | paragraph 2 is replaced by the following:
  ‘2.   Member States may provide that a fee is to be payable upon application for a certificate and upon application for the extension of the duration of a certificate.’ |
| --- | --- |

(c)

paragraph 2 is replaced by the following:

‘2.   Member States may provide that a fee is to be payable upon application for a certificate and upon application for the extension of the duration of a certificate.’

| (3) | Article 9 is amended as follows:






  (a) | in paragraph 1, the following subparagraph is added:
  ‘The application for an extension of the duration of a certificate already granted shall be lodged with the competent industrial property office of the Member State which granted the certificate.’ |
| --- | --- | --- |

(3)

Article 9 is amended as follows:

(a)

in paragraph 1, the following subparagraph is added:

‘The application for an extension of the duration of a certificate already granted shall be lodged with the competent industrial property office of the Member State which granted the certificate.’

| (b) | the following paragraph 3 is added:
  ‘3.   Paragraph 2 shall apply to the notification of the application for an extension of the duration of a certificate already granted. The notification shall additionally contain the request for an extended duration of the certificate in application of Article 40 of Regulation (EC) No [.../2005 (Paediatric Regulation)].’ |
| --- | --- |

(b)

the following paragraph 3 is added:

‘3.   Paragraph 2 shall apply to the notification of the application for an extension of the duration of a certificate already granted. The notification shall additionally contain the request for an extended duration of the certificate in application of Article 40 of Regulation (EC) No [.../2005 (Paediatric Regulation)].’

| (4) | In Article 11, the following paragraph 3 is added:
  ‘3.   Paragraphs 1 and 2 shall apply to the notification of the fact that an extension of the duration of a certificate already granted has been granted or rejected.’ |
| --- | --- |

(4)

In Article 11, the following paragraph 3 is added:

‘3.   Paragraphs 1 and 2 shall apply to the notification of the fact that an extension of the duration of a certificate already granted has been granted or rejected.’

| (5) | In Article 13, the following paragraph 3 is added:
  ‘3.   The periods laid down in paragraphs 1 and 2 shall be extended by six months in the case of application of Article 40 of Regulation (EC) No [.../2005 (Paediatric Regulation)]. In that case, the duration of the period laid down in paragraph 1 of this Article may be extended only once.’ |
| --- | --- |

(5)

In Article 13, the following paragraph 3 is added:

‘3.   The periods laid down in paragraphs 1 and 2 shall be extended by six months in the case of application of Article 40 of Regulation (EC) No [.../2005 (Paediatric Regulation)]. In that case, the duration of the period laid down in paragraph 1 of this Article may be extended only once.’

Article 56

In Article 6 of Directive 2001/83/EC, the first subparagraph of paragraph 1 is replaced by the following:

‘No medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State in accordance with this Directive or an authorisation has been granted in accordance with Regulation (EC) No 726/2004, read in conjunction with Regulation (EC) No [.../2005 of the European Parliament and of the Council (Paediatric Regulation) (12)].

Article 57

Article 57

Regulation (EC) No 726/2004 is amended as follows:

No

| (1) | Article 56(1) is replaced by the following:
  ‘1.   The Agency shall comprise:






  (a) | the Committee for Medicinal Products for Human Use, which shall be responsible for preparing the opinion of the Agency on any question relating to the evaluation of medicinal products for human use; |
| --- | --- | --- |

(1)

Article 56(1) is replaced by the following:

‘1.   The Agency shall comprise:

(a)

the Committee for Medicinal Products for Human Use, which shall be responsible for preparing the opinion of the Agency on any question relating to the evaluation of medicinal products for human use;

| (b) | the Committee for Medicinal Products for Veterinary Use, which shall be responsible for preparing the opinion of the Agency on any question relating to the evaluation of medicinal products for veterinary use; |
| --- | --- |

(b)

the Committee for Medicinal Products for Veterinary Use, which shall be responsible for preparing the opinion of the Agency on any question relating to the evaluation of medicinal products for veterinary use;

| (c) | the Committee on Orphan Medicinal Products; |
| --- | --- |

(c)

the Committee on Orphan Medicinal Products;

| (d) | the Committee on Herbal Medicinal Products; |
| --- | --- |

(d)

the Committee on Herbal Medicinal Products;

| (e) | the Paediatric Committee; |
| --- | --- |

(e)

the Paediatric Committee;

| (f) | a Secretariat, which shall provide technical, scientific and administrative support for the committees and ensure appropriate coordination between them; |
| --- | --- |

(f)

a Secretariat, which shall provide technical, scientific and administrative support for the committees and ensure appropriate coordination between them;

| (g) | an Executive Director, who shall exercise the responsibilities set out in Article 64; |
| --- | --- |

(g)

an Executive Director, who shall exercise the responsibilities set out in Article 64;

| (h) | a Management Board, which shall exercise the responsibilities set out in Articles 65, 66 and 67.’ |
| --- | --- |

(h)

a Management Board, which shall exercise the responsibilities set out in Articles 65, 66 and 67.’

| (2) | The following Article 73a is inserted:
  ‘Article 73a
  Decisions taken by the Agency under Regulation (EC) No [.../2005 of the European Parliament and of the Council (Paediatric Regulation)*] may form the subject of an action before the Court of Justice of the European Communities under the conditions laid down in Article 230 of the Treaty.






  (*) | OJ L ...’ |
| --- | --- | --- |

(2)

The following Article 73a is inserted:

‘Article 73a

Decisions taken by the Agency under Regulation (EC) No [.../2005 of the European Parliament and of the Council (Paediatric Regulation)*] may form the subject of an action before the Court of Justice of the European Communities under the conditions laid down in Article 230 of the Treaty.

2005

(*)

OJ L ...’

Chapter 3

Final provisions

Article 58

Article 58

1.
     The requirement laid down in Article 12(1) shall not apply to valid applications pending at the time of entry into force of this Regulation.

1.

Article 12

2.
     
  Paediatric studies initiated prior to the entry into force of this Regulation, and which have not been used for any other assessment, shall be eligible to be included in a paediatric investigation plan
  .

2.

Paediatric studies initiated prior to the entry into force of this Regulation, and which have not been used for any other assessment, shall be eligible to be included in a paediatric investigation plan

Article 59

Article 59

1.   This Regulation shall enter into force on the thirtieth day following that of its publication in the Official Journal of the European Union.

2.
     
  An application submitted pursuant to Articles 12 and 13 which contains findings from aggregate studies with agreed paediatric investigation plans and which has been submitted to the Agency before the entry into force of this Regulation shall be treated as an application under this Regulation and the resultant decision shall be applied from the date on which the Regulation enters into force.

2.

An application submitted pursuant to Articles 12 and 13 which contains findings from aggregate studies with agreed paediatric investigation plans and which has been submitted to the Agency before the entry into force of this Regulation shall be treated as an application under this Regulation and the resultant decision shall be applied from the date on which the Regulation enters into force.

3.   Article 12 shall apply from ... (13).

3.

Article 12

from

13

Article 13 shall apply from ... (14).

Article 13

from

14

Articles 35 and 36 shall apply from ... (15).

Articles 35 and 36

from

15

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at ..., on ...

For the European Parliament

The President

For the Council

The President

---

(1)  OJ C ...

1

(2)  Position of the European Parliament of 7 September 2005.

2

Position of the European Parliament of 7 September 2005

(3)  OJ L 121, 1.5.2001, p. 34.

3

(4)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).

4

(5)  OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC (OJ L 136, 30.4.2004, p. 34).

5

(6)  OJ L 182, 2.7.1992, p. 1. Regulation as last amended by the 2003 Act of Accession.

6

(7)  OJ L 18, 22.1.2000, p. 1.

7

(8)  OJ L 184, 17.7.1999, p. 23.

8

(9)  

  OJ L 159, 27.6.2003, p. 24.

9

OJ L 159, 27.6.2003, p. 24.

(10)  OJ L 35, 15.2.1995, p. 1. Regulation as last amended by Commission Regulation (EC) No 494/2003 (OJ L 73, 19.3.2003, p. 6).

10

Regulation as last amended by Commission Regulation (EC) No 494/2003 (OJ L 73, 19.3.2003, p. 6).

(11)  OJ L ...’

11

(12)  OJ L ...’

12

(13)  Twelve months following the date of entry into force of this Regulation.

13

Twelve months

(14)  Eighteen months following the date of entry into force of this Regulation.

14

Eighteen months

(15)  Six months following the date of entry into force of this Regulation.

15

P6_TA(2005)0332

VAT: Simplifying obligations *

European Parliament legislative resolution on the proposal for a Council directive amending Directive 77/388/EEC with a view to simplifying value added tax obligations (COM(2004)0728 — C6-0024/2005 — 2004/0261(CNS))

(Consultation procedure)

The European Parliament,

| — | having regard to the Commission proposal to the Council (COM(2004)0728) (1), |
| --- | --- |

—

having regard to the Commission proposal to the Council (COM(2004)0728) (1),

| — | having regard to Article 93 of the EC Treaty, pursuant to which the Council consulted Parliament (C6-0024/2005), |
| --- | --- |

—

having regard to Article 93 of the EC Treaty, pursuant to which the Council consulted Parliament (C6-0024/2005),

| — | having regard to Rule 51 of its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 51 of its Rules of Procedure,

| — | having regard to the report of the Committee on Economic and Monetary Affairs (A6-0228/2005), |
| --- | --- |

—

having regard to the report of the Committee on Economic and Monetary Affairs (A6-0228/2005),

| 1. | Approves the Commission proposal as amended; |
| --- | --- |

1.

Approves the Commission proposal as amended;

| 2. | Calls on the Commission to alter its proposal accordingly, pursuant to Article 250(2) of the EC Treaty; |
| --- | --- |

2.

Calls on the Commission to alter its proposal accordingly, pursuant to Article 250(2) of the EC Treaty;

| 3. | Calls on the Council to notify Parliament if it intends to depart from the text approved by Parliament; |
| --- | --- |

3.

Calls on the Council to notify Parliament if it intends to depart from the text approved by Parliament;

| 4. | Asks the Council to consult Parliament again if it intends to amend the Commission proposal substantially; |
| --- | --- |

4.

Asks the Council to consult Parliament again if it intends to amend the Commission proposal substantially;

| 5. | Instructs its President to forward its position to the Council and Commission. |
| --- | --- |

5.

Instructs its President to forward its position to the Council and Commission.

| TEXT PROPOSED BY THE COMMISSION | AMENDMENTS BY THE PARLIAMENT |
| --- | --- |
| Amendment 1 |
| ARTICLE 1, POINT 4
  Article 22b, point C, paragraph 1, subparagraph 2 (Directive 77/388/EEC) |
| The taxable person shall provide the information necessary for his registration under the one-stop scheme. He shall also state whether he is already identified for value added tax purposes in Member States where he is not established nor has a fixed establishment and, if so, indicate the identification number under which he is registered. | The taxable person shall provide the information necessary for his registration under the one-stop scheme
  in the language of the Member State of identification
  . He shall also state whether he is already identified for value added tax purposes in Member States where he is not established nor has a fixed establishment and, if so, indicate the identification number under which he is registered. |
| Amendment 2 |
| Article 1, point 4
  Article 22b, point C, paragraph 2, subparagraph 1 (Directive 77/388/EEC) |
| 2. The Member State of identification shall register the taxable person referred to in paragraph 1 within
  a reasonable period of time.
  For that purpose the Member State shall use the individual number already allocated to the taxable persons in respect of his obligations under the internal system. | 2. The Member State of identification shall register the taxable person referred to in paragraph 1 within
  20 days.
  For that purpose the Member State shall use the individual number already allocated to the taxable persons in respect of his obligations under the internal system. |
| Amendment 3 |
| Article 1, point 4
  Article 22b, point C, paragraph 3 (Directive 77/388/EEC) |
| 3. Every taxable person shall notify the Member State of identification of any modification of the registration data provided pursuant to paragraph 1. That notification shall be made by electronic means. | 3. Every taxable person shall notify the Member State of identification
  within 20 days
  of any modification of the registration data provided pursuant to paragraph 1. That notification shall be made by electronic means. |
| Amendment 4 |
| ARTICLE 1, POINT 4
  Article 22b, point C, paragraph 5, subparagraph 1 (Directive 77/388/EEC) |
| 5. The Member State of identification shall
  without delay
  strike from the identification register any taxable person who no longer meets the conditions necessary to qualify for the one-stop scheme. | 5. The Member State of identification shall
  within five days
  strike from the identification register any taxable person who no longer meets the conditions necessary to qualify for the onestop scheme
  and notify the Member States where he has already been identified for value added tax purposes
  . |
| Amendment 5 |
| Article 1, point 4
  Article 22b, point C, paragraph 5a (new) (Directive 77/388/EEC) |
| | 5a. Any documents and records relating to transactions shall be stored exclusively in the Member State of establishment. |
| Amendment 6 |
| ARTICLE 1, POINT 4
  Article 22b, point E, paragraph 1, subparagraph 2 (Directive 77/388/EEC) |
| The return, which shall be made by electronic means, shall be submitted within
  20 days
  following the end of the period to which it refers. | The return, which shall be made by electronic means, shall be submitted within
  40 days
  following the end of the period to which it refers. |
| Amendment 7 |
| Article 1, point 4
  Article 22b, point E, paragraph 3 (Directive 77/388/EEC) |
| 3. The return referred to in paragraph 1 shall be made in euro. The Member States of consumption which have not adopted the euro may require
  the part of
  the return concerning supplies of goods and services on their territory to be made in national currency. | 3. The return referred to in paragraph 1 shall be made in euro. The Member States of consumption which have not adopted the euro may require
  , in accordance with Article 22 (3)(b), fourth subparagraph, as amended by Article 28h,
  the return concerning supplies of goods and services on their territory to be made in national currency. |
| Amendment 8 |
| Article 1, point 4
  Article 22b, point F, paragraph 1 (Directive 77/388/EEC) |
| 1. The taxable person shall pay the value added tax when submitting the value added tax return. Payment shall be made directly on the bank account and in the currency of each Member State of consumption concerned. | 1. The taxable person shall pay the value added tax when submitting the value added tax return.
  In the case of VAT liability,
  payment shall be made directly on the bank account and in the currency of each Member State of consumption concerned
  . Where the taxable person is owed value added tax, the Member State of consumption shall pay the amount due to the taxable person's bank account in the Member State of establishment. |
| Amendment 9 |
| Article 1, POINT 5, POINT (A)
  Article 24, paragraph 2, subparagraph 1 (Directive 77/388/EEC) |
| 2. Member States may exempt taxable persons whose annual turnover does not exceed a threshold which may be set no higher than EUR 100 000 or the equivalent in national currency at the conversion rate on 1 July 2006. They may apply one or several thresholds, which may not in any case exceed EUR 100 000 or the equivalent in national currency on 1 July 2006. | 2. Member States may exempt taxable persons whose annual turnover does not exceed a threshold which may be set
  no lower than 50 000 EUR and
  no higher than EUR 100 000 or the equivalent in national currency at the conversion rate on 1 July 2006. They may apply one or several thresholds, which may not in any case
  be set lower than EUR 50 000 or
  exceed EUR 100 000 or the equivalent in national currency on 1 July 2006.
  The lower limit shall apply for the first three years of the activity of newly established SMEs. |
| Amendment 10 |
| Article 2, PARAGRAPH 2A (new) |
| | 2a. The Commission shall analyse the budgetary and economic implications of this Directive within four years after the entry into force thereof. In conducting that analysis, the Commission shall examine the possibility of excluding SMEs' exchange rate losses. |

TEXT PROPOSED BY THE COMMISSION

AMENDMENTS BY THE PARLIAMENT

Amendment 1

ARTICLE 1, POINT 4

Article 22b, point C, paragraph 1, subparagraph 2 (Directive 77/388/EEC)

The taxable person shall provide the information necessary for his registration under the one-stop scheme. He shall also state whether he is already identified for value added tax purposes in Member States where he is not established nor has a fixed establishment and, if so, indicate the identification number under which he is registered.

The taxable person shall provide the information necessary for his registration under the one-stop scheme
  in the language of the Member State of identification
  . He shall also state whether he is already identified for value added tax purposes in Member States where he is not established nor has a fixed establishment and, if so, indicate the identification number under which he is registered.

Amendment 2

Article 1, point 4

Article 22b, point C, paragraph 2, subparagraph 1 (Directive 77/388/EEC)

2. The Member State of identification shall register the taxable person referred to in paragraph 1 within
  a reasonable period of time.
  For that purpose the Member State shall use the individual number already allocated to the taxable persons in respect of his obligations under the internal system.

2. The Member State of identification shall register the taxable person referred to in paragraph 1 within
  20 days.
  For that purpose the Member State shall use the individual number already allocated to the taxable persons in respect of his obligations under the internal system.

Amendment 3

Article 1, point 4

Article 22b, point C, paragraph 3 (Directive 77/388/EEC)

3. Every taxable person shall notify the Member State of identification of any modification of the registration data provided pursuant to paragraph 1. That notification shall be made by electronic means.

3. Every taxable person shall notify the Member State of identification
  within 20 days
  of any modification of the registration data provided pursuant to paragraph 1. That notification shall be made by electronic means.

Amendment 4

ARTICLE 1, POINT 4

Article 22b, point C, paragraph 5, subparagraph 1 (Directive 77/388/EEC)

5. The Member State of identification shall
  without delay
  strike from the identification register any taxable person who no longer meets the conditions necessary to qualify for the one-stop scheme.

5. The Member State of identification shall
  within five days
  strike from the identification register any taxable person who no longer meets the conditions necessary to qualify for the onestop scheme
  and notify the Member States where he has already been identified for value added tax purposes
  .

Amendment 5

Article 1, point 4

Article 22b, point C, paragraph 5a (new) (Directive 77/388/EEC)

5a. Any documents and records relating to transactions shall be stored exclusively in the Member State of establishment.

Amendment 6

ARTICLE 1, POINT 4

Article 22b, point E, paragraph 1, subparagraph 2 (Directive 77/388/EEC)

The return, which shall be made by electronic means, shall be submitted within
  20 days
  following the end of the period to which it refers.

The return, which shall be made by electronic means, shall be submitted within
  40 days
  following the end of the period to which it refers.

Amendment 7

Article 1, point 4

Article 22b, point E, paragraph 3 (Directive 77/388/EEC)

3. The return referred to in paragraph 1 shall be made in euro. The Member States of consumption which have not adopted the euro may require
  the part of
  the return concerning supplies of goods and services on their territory to be made in national currency.

3. The return referred to in paragraph 1 shall be made in euro. The Member States of consumption which have not adopted the euro may require
  , in accordance with Article 22 (3)(b), fourth subparagraph, as amended by Article 28h,
  the return concerning supplies of goods and services on their territory to be made in national currency.

Amendment 8

Article 1, point 4

Article 22b, point F, paragraph 1 (Directive 77/388/EEC)

1. The taxable person shall pay the value added tax when submitting the value added tax return. Payment shall be made directly on the bank account and in the currency of each Member State of consumption concerned.

1. The taxable person shall pay the value added tax when submitting the value added tax return.
  In the case of VAT liability,
  payment shall be made directly on the bank account and in the currency of each Member State of consumption concerned
  . Where the taxable person is owed value added tax, the Member State of consumption shall pay the amount due to the taxable person's bank account in the Member State of establishment.

Amendment 9

Article 1, POINT 5, POINT (A)

Article 24, paragraph 2, subparagraph 1 (Directive 77/388/EEC)

2. Member States may exempt taxable persons whose annual turnover does not exceed a threshold which may be set no higher than EUR 100 000 or the equivalent in national currency at the conversion rate on 1 July 2006. They may apply one or several thresholds, which may not in any case exceed EUR 100 000 or the equivalent in national currency on 1 July 2006.

2. Member States may exempt taxable persons whose annual turnover does not exceed a threshold which may be set
  no lower than 50 000 EUR and
  no higher than EUR 100 000 or the equivalent in national currency at the conversion rate on 1 July 2006. They may apply one or several thresholds, which may not in any case
  be set lower than EUR 50 000 or
  exceed EUR 100 000 or the equivalent in national currency on 1 July 2006.
  The lower limit shall apply for the first three years of the activity of newly established SMEs.

Amendment 10

Article 2, PARAGRAPH 2A (new)

2a. The Commission shall analyse the budgetary and economic implications of this Directive within four years after the entry into force thereof. In conducting that analysis, the Commission shall examine the possibility of excluding SMEs' exchange rate losses.

---

(1)  Not yet published in OJ.

P6_TA(2005)0333

VAT: One-stop scheme *

European Parliament legislative resolution on the proposal for a Council regulation amending Regulation (EC) No 1798/2003 as regards the introduction of administrative cooperation arrangements in the context of the one-stop scheme and the refund procedure for value added tax (COM(2004)0728 — C6-0025/2005 — 2004/0262(CNS))

(Consultation procedure)

The European Parliament,

| — | having regard to the Commission proposal to the Council (COM(2004)0728) (1), |
| --- | --- |

—

having regard to the Commission proposal to the Council (COM(2004)0728) (1),

| — | having regard to Article 93 of the EC Treaty, pursuant to which the Council consulted Parliament (C6-0025/2005), |
| --- | --- |

—

having regard to Article 93 of the EC Treaty, pursuant to which the Council consulted Parliament (C6-0025/2005),

| — | having regard to Rule 51 of its Rules of Procedure, |
| --- | --- |

—

having regard to Rule 51 of its Rules of Procedure,

| — | having regard to the report of the Committee on Economic and Monetary Affairs (A6-0228/2005), |
| --- | --- |

—

having regard to the report of the Committee on Economic and Monetary Affairs (A6-0228/2005),

| 1. | Approves the Commission proposal; |
| --- | --- |

1.

Approves the Commission proposal;

| 2. | Calls on the Council to notify Parliament if it intends to depart from the text approved by Parliament; |
| --- | --- |

2.

Calls on the Council to notify Parliament if it intends to depart from the text approved by Parliament;

| 3. | Asks the Council to consult Parliament again if it intends to amend the Commission proposal substantially; |
| --- | --- |

3.

Asks the Council to consult Parliament again if it intends to amend the Commission proposal substantially;

| 4. | Instructs its President to forward its position to the Council and Commission. |
| --- | --- |

4.

Instructs its President to forward its position to the Council and Commission.

---

(1)  Not yet published in OJ.

---